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Abstract 
 
Morbidity due to chronic liver disease (CLD) is determined by fibrosis, which is graded 
from F0 (no fibrosis) to F4 (cirrhosis). Progression to cirrhosis is associated with the 
development of portal hypertension, end-organ hepatic dysfunction and hepatocellular 
carcinoma (HCC). Decompensated cirrhosis is characterised by cirrhosis-related 
complications (e.g. ascites, varices, variceal bleeding) and prognosis can be stratified 
according to these features of decompensation.  
 
Liver biopsy is the gold standard, but invasive diagnostic test in CLD. Non-invasive 
imaging or biomarker panels have been developed to stage fibrosis and to identify patients 
at greatest risk of cirrhosis-related complications. The current HCC biomarker, alpha-
fetoprotein (AFP), however, has poor diagnostic performance in early HCC and, in 
common with other non-invasive tools, provides no information about pathogenesis or 
therapeutic targets. 
 
MiRNAs are small, stable, quantifiable non-coding RNAs that regulate post-transcriptional 
events and cellular processes. Preliminary data describing differential miRNA expression 
in CLD and HCC exist but whether miRNAs could be developed as useful non-invasive 
biomarkers to assess disease severity and aid in improving patient morbidity and mortality 
in cirrhosis remains unknown.  
 
This thesis aimed to explore: 
i) differential circulating miRNA expression associated with CLD of different 
severities (including cirrhosis, decompensated cirrhosis and HCC);  
ii) whether miRNA panels can be used alone or in combination with current non-
invasive biomarkers to discriminate CLD of different severities; and 
iii) the functional roles and purported target genes of miRNAs differentially 
expressed during the HCC development. 
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The most significant results of this thesis include:  
i) The identification of 5 miRNA candidates (miRNA-122-5p, miRNA-142-3p, 
miRNA-151a-5p, miRNA-409-3p and miRNA-486-5p), differentially expressed 
according to disease severity in serum from 60 chronic Hepatitis C patients 
analysed in 3 equal cohorts of mild disease (F0-2), cirrhosis (F4) and cirrhosis 
complicated by HCC. Stepwise logistic regression assembled a miRNA panel for 
cirrhosis (miRNA-409-3p + miRNA-122-5p) which, when compared with F0-2, 
resulted in a ROC curve with an AUC=0.80 (95% CI 0.66=0.95, p<0.001). A 
miRNA panel for HCC (miRNA-122-5p, miRNA-142-3p + miRNA-486-5p) was 
also assembled which, when compared with F4, resulted in an AUC=0.94 (95% 
CI 0.87–1.00, p<0.001). Combining the cirrhosis miRNA panel with currently-
available non-invasive fibrosis indices, APRI and FIB-4, improved its diagnostic 
performance with AUCs of 0.87 (p<0.001) and 0.89 (p<0.001), respectively. 
Combining the HCC miRNA panel with the HCC biomarker AFP did not improve 
its diagnostic performance. 
ii) Following transfection of immortalised human hepatocyte (IHH) and human 
hepatoma (Huh7) cell lines with miRNA-151a-5p and miRNA-486-5p, pull-down 
assays identified: 
• For miRNA-151a-5p: 2320 (IHH) and 1041 (Huh7) putative target genes 
• For miRNA-486-5p: 2016 (IHH) and 468 (Huh7) putative target genes 
Putative target pathways identified via IPA included the EGF, ERK/MAPK, p53 and 
Molecular Mechanisms of Cancer pathways (for miRNA-151a-5p) and ERK5, Hif1α 
and Molecular Mechanisms of Cancer pathways (for miRNA-486-5p). Transient 
transfection of these miRNAs into normal hepatocyte or liver tumour cell lines had 
no demonstrable impact on cell proliferation or migration in vitro. 
iii) Identification of a single miRNA candidate (miRNA-451a), differentially 
expressed (AUC=0.66, 95% CI 0.54-0.78; p=0.009) in the serum of 25 cirrhotic 
patients with early HCC compared with 74 cirrhotic patients without HCC. 
Significant differential expression remained when all 37 patients with HCC 
(including those with indeterminate lesions that were subsequently diagnosed as 
HCC) were compared with those without HCC over clinical follow-up (AUC=0.63, 
95% CI 0.51–0.74; p=0.018). These miRNA performances improved when 
combined with AFP (AUCs of 0.68 and 0.69, respectively). 
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iv) Identification of 5 miRNA candidates (miRNA-10a-5p, miRNA-10b-5p, 
miRNA101-3p, miRNA 22-3p and miRNA-27b-3p) in the serum of 136 patients 
with cirrhosis that are differentially expressed according to disease severity in 
compensated cirrhosis (n=30), cirrhosis with varices (n=30), cirrhosis with 
ascites ± varices (n=60), and cirrhosis with variceal bleeding (n=16). MiRNA 
panels were assembled to distinguish patients with specific complications with 
the following diagnostic performance: 
• Varices panel (miRNA-10b-5p + miRNA-101-3p) with an AUC of 0.78 (95% CI 
0.66–0.90, p<0.001)  
• Ascites panel (miRNA-10a-5p + miRNA-146a-5p) with an AUC of 0.83 (95% CI 
0.75–0.92, p<0.001) 
• Variceal bleeding panel (miRNA-10a-5p) with an AUC of 0.80 (95% CI 0.65–
0.95, p<0.001) 
• Decompensation panel, grouping ascites and variceal bleeding patients 
(miRNA-10a-5p, miRNA-146a-5p + miRNA-423-3p) with an AUC of 0.78 (95% 
CI 0.70–0.86, p<0.001). 
Combining platelet count < 150 (x109/L)2 with the miRNA panels improved the 
performance of the Varices panel and the Ascites panel (with AUCs of 0.84 and 
AUC of 0.87, respectively).  
 
This thesis has identified several differentially-expressed miRNA candidates across a 
clinically relevant spectrum of CLD and assembled promising panels of miRNAs that 
warrant further investigation for their diagnostic potential. Preliminary efforts to explore 
the possible functional roles of 2 candidates in HCC were unrewarding but further 
studies can build on these findings by optimising experimental conditions, validating 
identified miRNA candidates, and testing the prognostic potential of validated miRNAs 
as clinically-useful non-invasive biomarkers. 
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Introduction and literature review …… 
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1.1 Introduction 
 
Chronic liver disease is an important cause of death worldwide, mostly via complications 
related to the development of cirrhosis.1 Ranked as the 20th leading cause of death 
worldwide, cirrhosis is especially prevalent in western countries.2  In the United States, for 
example, liver disease and cirrhosis affect 4.9 million people and accounted for 40,326 
deaths in 2015/2016.3, 4 In Europe, chronic liver disease was responsible for 151,513 of all 
deaths, with data collected in the years 2013 – 2015.5 Cirrhosis is estimated to affect 
hundreds of millions of people worldwide, based on autopsy studies, but it is difficult to 
determine its exact prevalence as liver disease is generally under-reported and deaths due 
to cirrhosis can be misclassified.1 
 
Although liver cancer is ranked as the 22nd leading causes of death worldwide,2 it is one 
of the most severe complications of liver disease. Indeed, in Australia, it is one of the few 
cancers with an increasing incidence rate. The total number of deaths for liver cancer in 
Australia exceeded 1700 in 2014 and are estimated to exceed 2000 in 2018.6 
Furthermore, while the mortality rate due to all cancers in Australia has fallen by almost a 
quarter from 1982 to 2017, the reported mortality rate due to liver cancer has almost tripled 
over the same period.6 Liver transplantation is a life-saving intervention, but the increasing 
number of transplants performed each year still remains low in comparison with the 
numbers of incident cancers. In 2017, for example, only 313 liver transplantations were 
performed in Australia.7 These statistics make the ongoing study of liver disease, and 
cirrhosis in particular, of vital importance within Australia and around the world. 
 
1.2 Chronic liver disease 
1.2.1 Natural history of chronic liver disease  
 
Chronic liver disease (CLD) encompasses a range of individual liver diseases, caused by 
various factors that are generally characterised by iterative liver injury in the form of 
chronic inflammation and subsequent hepatic fibrosis. The most common causes of 
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chronic liver injury in Western populations are non-alcoholic fatty liver disease (NAFLD) - 
which can lead to the more severe form of non-alcoholic steatohepatitis (NASH)8 - viral 
hepatitis, including Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) infections,9 and 
alcohol-related liver disease.5, 10 Other causes can include but are not limited to 
autoimmune hepatitis,11 primary biliary cirrhosis,12 primary sclerosing cholangitis13 and 
hereditary hemochromatosis.14 These diseases predominate the spectrum of CLD.  
 
Hepatic fibrosis is a complex wound healing process representing the liver’s response to 
acute or chronic liver injury. As progressive fibrosis can lead to cirrhosis, it is usually 
considered the most important determinant of morbidity due to any CLD.15, 16 Fibrosis itself 
is the accumulation of excessive connective tissue, or interstitial extracellular matrix 
(ECM), in the liver parenchyma. The ECM is predominantly composed of collagen fibres, 
produced principally by hepatic stellate cells (HSCs), but also portal fibroblasts in biliary 
disease, that become activated and transformed into myofibroblasts in the setting of liver 
injury.17-19 
 
Injury to the liver affects mostly epithelial cells, including hepatocytes (the most abundant 
cell type in the liver) and cholangiocytes. As a result of the injury, inflammatory cytokines 
and damage-associated molecular patterns (DAMPs) are released, initiating the 
inflammatory response cascade. Located in the space of Disse adjacent to heptaocytes, 
HSCs represent the major myofibroblast precursor population in the liver and are activated 
by the release of cell contents and reactive oxygen species upon hepatocyte death. With 
activation, HSCs transform from a vitamin A storing phenotype to an activated, proliferative 
fibrogenic phenotype. Activated HSCs express cytokines and chemokines triggering the 
extensive inflammatory response but are also responsible for the production of key 
components of the ECM, including type Ι and other collagens. 16-20 Hepatic fibrosis, as a 
response to injury, may represent a hepatocyte protective response. One study in mice 
showed that hepatocytes exposed to collagen are more resistant to hepatotoxins,21 while 
another, using a murine model of acetaminophen-induced liver injury, reported increased 
damage and reduced survival when activated HSCs were depleted.22 It is the excessive 
scar tissue accumulation, however, produced by chronic injury and the fibrogenic response 
that ultimately leads to clinical pathology in liver disease and the progression to cirrhosis.16 
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Histologically defined, cirrhosis is the presence of septum formation surrounding nodules 
of hepatocytes that is accompanied by a functional distortion of hepatic architecture.16, 23 
This accumulation of scar tissue is usually a slow process and therefore fibrogenesis can 
take years to reach the histological definition of cirrhosis. For example, the median time to 
develop cirrhosis caused by the hepatitis C virus is estimated to be 30 years,20 but this 
time course can be very variable. Fibrogenesis of the liver is also a dynamic process, 
meaning that reversal of fibrosis (i.e. resolution of liver disease) is usually possible in its 
early stages if the cause of continuing injury is removed.20, 24 In the setting of cirrhosis, 
however, fibrotic change is thought to be permanent although recent evidence suggests 
that some regression of disease is possible with an associated improvement in liver 
function (see Figure 1.1).25, 26 Despite continuing attempts to develop anti-fibrotic therapies 
that limit or reverse the progression of fibrosis, currently the only treatment to definitely 
prevent liver failure in advanced stages of fibrosis remains liver transplantation.20, 27 
 
Any cause of hepatic fibrosis can eventually lead to cirrhosis, and its associated 
complications, and the presence of cofactors (such as alcohol consumption, diabetes 
mellitus/insulin resistance or obesity) can accelerate disease progression. Worsening liver 
synthetic and metabolic dysfunction and acute-on-chronic liver failure are associated with 
the progression of fibrosis to cirrhosis and portal hypertension. These are variably 
manifested as the development of complications such as hepatic encephalopathy, the 
accumulation of ascites, cirrhosis-related renal impairment (with hepatorenal syndrome 
being of utmost importance in cirrhosis), and variceal haemorrhage.28 Finally, architectural 
distortion and associated dysplastic hepatocyte regeneration can lead to malignancy in the 
liver, with primary hepatocellular carcinoma (HCC) representing arguably the most lethal 
complication of cirrhosis.9, 20, 29 
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Figure 1.1. Natural history of chronic liver disease. The inflammatory damage and 
accumulation of scar tissue caused by chronic liver injury is usually a slow process and 
therefore fibrogenesis can take years to reach the histological definition of cirrhosis. 
Fibrogenesis of the liver is also a dynamic process, meaning that reversal of fibrosis (i.e. 
resolution of liver disease) is possible in its early stages if the cause of continuing injury is 
removed. In the setting of cirrhosis, however, fibrotic change is thought to be permanent 
although recent evidence suggests that some regression of disease is possible with an 
associated improvement in liver function. Finally, architectural distortion can lead to 
complications of cirrhosis such as decompensating events (ascites, variceal bleeding) or 
malignancy in the liver, with primary hepatocellular carcinoma. (Abbreviations: HCC, 
hepatocellular carcinoma). Adapted from Pellicoro et al.20 
 
1.2.2 Staging disease progression 
 
The severity of CLD is conventionally graded according to staging systems that evaluate 
various histological features, including fibrosis. There are multiple histological staging 
systems (e.g. Knodel Histology Activity Index,30 Ishak Score,31 Scheuer system32) but a 
commonly used index is the METAVIR approach,33 which grades liver injury along a 
spectrum from normal liver to cirrhosis. The METAVIR Score evaluates fibrosis stage (F) 
progression using the following criteria: normal connective tissue (F0), expansion of the 
portal tract only without septa formation (F1), expansion of the portal tract with sporadic 
septa formation (F2), expansion of the portal tract with numerous septa formation (F3), 
and cirrhosis (F4).33 
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Staging disease progression is important to identify patients with advanced fibrosis (F3) as 
these patients are at a highest risk of progression to cirrhosis. Although therapeutics with a 
primary anti-fibrotic function are not currently available, lifestyle changes can be 
implemented to slow disease progression and treatment should be prescribed in patients 
with viral hepatitis. Monitoring of these patients is therefore important to identify early 
onset of cirrhosis and the development of associated complications. The extent of fibrosis 
can therefore be categorised clinically into mild disease (F0-2), with no or mild-moderate 
fibrosis, and advanced disease (F3-4) with advanced fibrosis (F3) and cirrhosis (F4). The 
differentiation between intermediate stages of liver disease (i.e. F2 versus F3), however, 
can be difficult and staging fibrosis reliably in patients with moderate-advanced disease is 
affected by significant inter- and intra-observer variation.34, 35 In addition, the categorical 
nature of all histological staging systems does not reflect the true dynamic nature of liver 
injury with fibrosis progressing along a continuous spectrum.36 
 
Finally, once the state of cirrhosis (F4) is reached, there is no further histological 
classification of disease, which raises additional issues. Clinically, cirrhosis can be 
classified as compensated and decompensated cirrhosis, with compensated cirrhosis 
being mostly characterised as an asymptomatic phase whereas decompensated cirrhosis 
is associated with hepatic metabolic/synthetic dysfunction, and the development of portal 
hypertension and disease-specific complications (outlined above).37 
 
1.2.3 Liver biopsy to stage disease 
 
Liver biopsy has been widely used as the gold standard technique to evaluate disease 
status by classifying histological changes of fibrosis (in addition to disease activity-related 
and other diagnostic features). Liver tissue can also be used for immunohistochemical 
analysis to explore and define disease pathogenesis.35, 38 Liver biopsy, however, does 
have a number of limitations. As an invasive technique, liver biopsy not only causes 
discomfort to patients but it is also prone to rare but serious complications. Although this 
risk has decreased with the improvement of equipment and imaging techniques, the risk of 
severe complications, such as severe sub-capsular bleeding, pneumothorax, 
hemoperitoneum or biliary peritonitis, is still estimated to be approximately 0.3–0.5%. 
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Milder complications, such as moderate-severe pain requiring analgesia ± hospitalisation, 
are more frequent.38-40 
 
In addition to the invasive nature of liver biopsy, other major drawbacks are reduced 
availability, the occurrence of sampling errors and subjective variability in interpretation of 
histological changes. The heterogeneous nature of evolving fibrosis can also lead to 
significant diagnostic differences between samples obtained from the right and left lobes. 
In fact, a study of sampling error showed that the diagnosis of fibrosis typically differs by 
approximately one fibrosis stage on average between biopsies, which can be clinically 
significant. Even a liver biopsy specimen of 2.5 cm length can be affected by variability of 
up to 25% for fibrosis staging.35 Sampling error is estimated to be responsible for the 
underdiagnosis of cirrhosis in 14.5% of patients.34 
 
1.2.4 Imaging and transient elastography 
 
Imaging techniques have traditionally been used to detect lesions within the liver or 
alterations of liver parenchyma. Ultrasound (US) has the advantage of detecting fatty 
infiltration in the liver as increased echogenicity, but the clinical utility of ultrasound can be 
limited by patient factors, such as obesity and overlying luminal gas. Parenchymal 
changes are also relatively non-specific for different stages of fibrosis and US cannot 
distinguish low level steatosis in the early stages of NAFLD. On the other hand, doppler 
US can be used to evaluate changes associated with portal hypertension and ultrasound is 
a very sensitive modality at detecting the presence of ascites. New techniques have been 
developed, however, such as the contrast enhanced ultrasound (CEUS) which assesses 
fibrosis stages based on the intrahepatic behaviour of intrahepatic microbubbles as 
contrast reagent. Contrast reagent specific imaging can also be performed on the 
vascular-phase or Kupffer-phase. With the latter technique, Kupffer cells take up the 
contrast reagent resulting in homogenous enhancement to demonstrate functioning liver 
parenchyma.41-43 The place of CEUS, however, in routine assessment of CLD is still 
somewhat controversial.41 Other imaging modalities, such as magnetic resonance imaging 
(MRI) have also been investigated for aetiology-focused liver disease related imaging, 
such as FerriScan® (Resonance Health Analysis Services PTY Limited) to report liver iron 
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concentrations, or the proton density fat fraction measurement, which quantifies steatosis 
within the liver and can provide additional data for NAFLD disease management.44, 45  
Another approach is the use of “elastography” to assess fibrosis. Elastography relies on 
the correlation between hepatic parenchymal pathology and measured liver stiffness to 
generate an assessment of fibrosis. Examples of technologies employing liver stiffness 
measurement (LSM) are vibration controlled transient elastography (TE), and acoustic 
radiation force imaging (ARFI),36, 46 while FibroScan® (EchosensTM, Paris, France) has 
perhaps been most widely adopted in the non-invasive assessment of liver fibrosis. Use of 
FibroScan®, traditionally called “FibroScan” in clinical practice, involves the propagation of 
a 50 MHz shear wave within the liver through the application of an ultrasound transducer 
against the patient’s skin. Measurement of shear wave velocity through repeated 
measurements generates a median TE score that is proportional to the liver stiffness. 
FibroScan has been validated in multiple studies and shows good diagnostic accuracy for 
different fibrosis stages, particularly at either ends of the fibrosis spectrum.47, 48 
 
Patient factors, such as ascites or obesity, can lead to invalid readings, however, and the 
median TE score can also be falsely elevated in the setting of cholestasis and significant 
parenchymal inflammation.36 More recently, elastography measurement has also been 
combined with MRI measurements, called magnetic resonance elastography (MRE), and 
has been shown to outperform other traditional TE modalities.49 Although now generally 
regarded as the most accurate non-invasive fibrosis assessment method, the application 
of MRE in clinical practice remains limited due to its availability and expense. 
 
1.2.5 Biochemical markers of disease severity 
 
Conventional blood tests represent serum biomarkers that reflect liver injury, although only 
some are specific to the liver. The most important of these are alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST), which reflect hepatocellular damage, and 
alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT), which reflect 
cholestasis. Bilirubin is an important breakdown product that is excreted by the liver and 
elevated levels (particularly of conjugated bilirubin) can reflect severe hepatic metabolic 
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dysfunction in both acute and chronic liver injury. Once again, it can be non-specific, with 
obstruction of biliary outflow (e.g. in choledocholithiasis or pancreatic cancer) causing 
potentially severe hyperbilirubinaemia in the absence of any significant hepatic 
dysfunction. As a general rule, however, the levels of these biomarkers and the basic “liver 
function tests” are used to assess the extent of damage or severity of the insult, although 
these rarely correlate directly with the extent of fibrosis or the chronicity of liver disease.50 
 
Routinely available serum biomarkers that are used to assess the severity of CLD include 
creatinine, albumin and the platelet count, which reflect progression of liver disease to an 
advanced stage where associated renal impairment, synthetic dysfunction and portal 
hypertension, respectively, can occur. In fact, these biomarkers (along with bilirubin) are 
most commonly used to assess overall liver function and prognosis in the setting of 
cirrhosis and are incorporated in commonly-used scoring systems (e.g. the Child-Turcotte-
Pugh (CTP) score and the Model for End-stage Liver Disease (MELD) score).51-57 Other 
scoring systems have also been developed (e.g. aminotransferase to platelet ratio index, 
or APRI, and Fibrosis 4, or FIB-4,58-60 that use combinations of routine tests to facilitate 
bedside assessments of liver disease across the spectrum of fibrosis from F0 to F4. 
Occasionally, other patient factors and comorbidities, such as age, degree of obesity, and 
the presence of diabetes mellitus/insulin resistance, are included in scores to reflect their 
importance to disease progression (e.g. the NAFLD Score).61 Non-invasive scores, such 
as the APRI, FIB-4 and NAFLD scores, are useful as they are readily available in routine 
patient assessment. Like FibroScan, however, they share a common problem of being 
reasonably accurate at distinguishing the presence/absence of significant disease at either 
end of the fibrosis spectrum (i.e. “ruling in” F0-1, “ruling out” F4) but are relatively 
inaccurate at discriminating more intermediate stages of fibrosis (with significant overlap of 
scores at more intermediate stages of fibrosis and even early cirrhosis).50, 58, 60, 62 
 
Other circulating biomarkers that reflect the process of fibrosis itself have been identified, 
although these tests are not as widely available. A number of scoring systems or 
biomarker panels have been developed that combine the levels of a range of metabolic 
substances (e.g. tissue inhibitor of metalloproteinases 1, amino-terminal propeptide of type 
III procollagen, hyaluronic acid, alpha-2-macroglobulin, haptoglobin, apolipoprotein A1) 
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that are involved in, or are breakdown products of, fibrosis to estimate the severity of 
hepatic fibrosis. A potential complicating factor in the use of these scores is the presence 
of extra-hepatic fibrosis, as fibrosis-associated biomarkers are rarely specific to the liver. 
Examples of these panels include the Original European Liver Fibrosis panel (OELF),63 the 
Enhanced Liver Fibrosis panel (ELF),64 HepaScore®,65 FibroMeter®,66 and FibroTest®.67 
The accuracy of these scoring systems has been improved through the combination of 
biomarkers levels with patient factors (e.g. age, gender) to assess the stage of liver 
disease.65, 68, 69 Non-invasive panels are generally validated against liver biopsy as the 
gold standard and display good but not perfect accuracy in staging CLD. For example, one 
prospective study by Leroy et al assessed the performance of FibroTest®, FibroMeter® 
and HepaScore® in staging fibrosis with areas under the ROC curve ranging from of 0.75 
to 0.87.70 Criticisms generally mirror other non-invasive fibrosis assessment modalities, 
including access to specific biochemical tests and reduced accuracy with intermediate 
stages of disease. One attraction, however, remains the fact that patient serum is a 
readily-available resource and patient acceptance of blood tests as being relatively non-
invasive. Whether novel biomarkers of disease severity can be identified, and whether 
these could be combined with existing blood-based non-invasive panels, remains the 
focus of ongoing research. 
 
1.2.6 Cirrhosis and its complications 
 
Compensated cirrhosis is generally an asymptomatic phase of disease, with patients 
mostly complaining of non-specific fatigue. Decompensated cirrhosis, however, is 
associated with the development of portal hypertension and liver dysfunction. Transition 
rates from compensated cirrhosis to decompensated cirrhosis are estimated to be 
approximately 5–7% per year.37 The median survival of patients with decompensated 
cirrhosis also falls dramatically from more than 12 years (for compensated patients) to  
approximately 2 years (in decompensated disease).37 D’Amico and colleagues proposed 
the categorisation of compensated versus decompensated cirrhosis be further stratified 
into 4 to better reflect clinical features and patient prognosis. The first stage represents 
truly compensated cirrhosis, without varices or ascites, and a low yearly mortality rate of 
approximately 1%. Patients in the second stage have a slightly increased, but still 
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relatively low, mortality rate of approximately 3-4% per year and have clinically 
compensated disease with only the presence of non-bleeding oesophageal varices. The 
third stage represents the onset of decompensation and includes patients with ascites (± 
non-bleeding oesophageal varices), carrying an estimated annual mortality of around 20%. 
The final stage is characterised by gastrointestinal bleeding (± ascites). The median 
survival of patients in this stage is less than 12 months (annual mortality 57%), with 
significant mortality within 6 weeks of gastrointestinal bleeding.37 
 
Portal hypertension (PHT), reflecting increased pressure within the portal circulation, is a 
direct consequence of intrahepatic changes associated with cirrhosis. There is increased 
resistance to portal flow as a result of architectural changes within the liver and increased 
accumulation of fibrous tissue. Hepatic vasoconstriction also actively contributes to 
increasing PHT.71 While the development of PHT represents a major transition point in 
terms of disease severity and prognosis, a number of other vascular changes in cirrhosis 
also contribute to the incidence of cirrhosis-related complications. As reviewed in detail by 
Iwakiri et al, the enhanced endothelial production of nitric oxide, carbon monoxide and 
other vasoactive molecules triggers a range of mechanisms increasing vasodilation.72 This 
increased vasodilation induces organ hypoperfusion, most notably in the kidneys, which 
activate compensatory vasoconstriction mechanisms, including sodium and water 
retention, via the renin-angiotensin-aldosterone system (RAAS), and the onset of a 
hypervolaemic state. As a direct consequence of sodium and water retention due to this 
cascade, one can see the accumulation of ascites as well as multi-organ dysfunction, with 
renal impairment, the onset of hepatorenal syndrome and significant cardiac dysfunction in 
advanced cirrhosis.73 
 
Ascites is the accumulation of fluid in the abdominal cavity and can be graded as mild, 
moderate or severe/gross ascites. The onset of ascites is a hallmark of decompensation 
as it is associated with increased patient mortality and significant morbidity. Depending on 
the degree of fluid accumulation, ascites is demonstrable clinically (as shifting dullness on 
clinical exam) or visible using imaging (such as ultrasound). The treatment of ascites 
depends on its severity and usually comprises the use of diuretics and restriction of 
sodium intake. Ascites can also be managed with large-volume paracentesis or, in 
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refractory cases, placement of a transjugular intrahepatic portosystemic shunt (TIPS), or 
ultimately liver transplantation.73 The use of these interventions, however, can be subject 
to complications, with renal impairment and electrolyte disturbances, infection and 
peritonitis, and hepatic encephalopathy and hepatic decompensation, respectively. Finally, 
the presence of ascites in patients with cirrhosis can itself be complicated by life-
threatening infection in the form of spontaneous bacterial peritonitis (SBP).37, 73 
 
Another further complication of PHT in cirrhosis is the occurrence of gastroesophageal 
varices. To compensate for increased pressure in the portal circulation, portosystemic 
collateral vessels form and/or enlarge, with gastroesophageal varices being the collateral 
vascular bed of highest clinical relevance in cirrhosis. Gastroesophageal varices, 
commonly collectively referred to simply as “varices” in clinical practice, are a common 
source of upper gastrointestinal haemorrhage in patients with PHT. Variceal bleeding 
carries a high risk of mortality with a short-term (6-week) mortality of 15-25% and is 
particularly lethal when the bleeding episode is complicated by acute kidney injury or 
bacterial infection.73 Varices can be graded from small (grade 1) to large (grade 3), with 
the risk of rupture ranging from 5-15% depending on variceal size.71 The risk of 
haemorrhage is principally determined by transmural pressure but also appears to be 
increased in association with more severe liver dysfunction; i.e. Child-Pugh ‘C’ status.73 
Although endoscopy remains the gold standard for the diagnosis of varices, it has been 
shown that assessment of portal pressure (HVPG > 10 mmHg) is predictive for the 
development of varices.74, 75 Although both methods are accurate, access to these is 
variable and healthcare resources are limited. A novel, non-invasive approach to identify 
patients at very low risk of clinically-significant varices is use of the Baveno VI criteria, 
which combined a platelet count of above 150 (x109/L)2 with a LSM measurement of < 20 
kPa to identify those at very low risk of varices requiring treatment (i.e. Grade 2 and 
above).76 This scoring system has since been validated with a 98% negative predictive 
value77 and a meta-analysis reports that using the Baveno VI criteria has a 4.3 fold risk 
reduction in having varices, thus reducing the number of unnecessary endoscopy 
procedures.78  
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Other examples of cirrhosis-related complications are the hepato-pulmonary syndrome, 
hepatic hydrothorax, hepatorenal syndrome, renal impairment, (either acute kidney injury 
or chronic kidney disease), and hepatic encephalopathy.73 Current treatment approaches 
focus on the definitive treatment of the underlying liver disease (e.g. HCV eradication or 
HBV suppression) and the specific management of individual complications as they arise. 
To date most work has been done on attempting to identify patients at risk of cirrhosis-
related complications, such as HCC, after cause of liver disease has been addressed.79-82 
Currently, the only curative treatment available for cirrhosis-related complication is liver 
transplantation.  
 
1.2.7 Hepatocellular carcinoma 
 
Another serious complication of cirrhosis is the development of primary liver cancer, 
dominated by HCC which accounts for approximately 85% of primary liver cancers.83-86 
The GLOBOCAN study in 2012 reported that HCC is the sixth most common cancer 
worldwide, with an estimated 782,000 new cases diagnosed in the year 2012 alone.87 
Astoundingly, HCC was also reported as the second most common cancer death with an 
estimated 745,000 deaths globally, only surpassed by lung cancer. While HCC accounts 
for the majority of liver cancers, cholangiocarcinoma accounts for 10-15%.29, 86, 88 with 
intrahepatic mixed cell-type carcinomas (such as mixed hepatocellular-cholangiocellular 
carcinoma) having been recently described and acknowledged as a sub-type of 
cholangiocarcinoma.89 
 
The major risk factor for HCC, among patients with CLD caused by viral hepatitis or 
NAFLD, is cirrhosis, although individual risk factors can vary from region to region. Across 
all aetiologies, approximately 3% of all cirrhotic patients develop HCC per year.29, 37, 86, 88, 90 
A study by Valery et al. examined HCC rates in several countries and predicted an 
increase in rates of primary liver cancer of up to 35% from study baseline in 2005 to 
2030.29 This increase is attributed to an overall ageing and growing population in 
combination with changing patterns of the aetiologies of liver disease causing HCC. 
Interestingly, whereas HBV and HCV are major risk factors for HCC development 
currently, there appears to be a shift in the primary aetiologies causing development of 
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HCC towards non-viral causes. Due to the uptake of anti-viral therapies (and vaccinations 
efforts in HBV),29, 90-92 the prevalence of viral hepatitis is expected to decline whereas 
metabolic disorders increasingly contribute to HCC development.29, 93 
 
Cirrhosis is known to be the predominant risk factor for HCC development in Western 
populations. Chronic alterations within the liver architecture in response to hepatic injury 
play a role with hepatocyte nodules of cellular proliferation arising in response to areas of 
liver injury, apoptosis and/or altered circulation. Regenerative nodules typically occur in the 
cirrhotic liver surrounded by fibrous septa but can occur in the non-cirrhotic liver, where 
they are surrounded by normal parenchyma. These nodules are mainly benign 
regenerative nodules, however some can progress to become dysplastic nodules and 
HCC. Dysplastic nodules are pre-malignant lesions that do not completely satisfy the 
criteria for malignant lesions and, once again, can appear in non-cirrhotic livers. 
Depending on the degree of dysplasia and the presence of cytological and architectural 
changes, dysplastic nodules can be classified as low-grade or high-grade dysplastic 
nodules. While low-grade dysplastic nodules are difficult to distinguish histologically from 
regenerative nodules, the high-dysplasia nodules show marked cellular changes (such as 
cellular density or increasingly disorganised architecture).94 Dysplastic nodules are found 
in ~15-25% of cirrhotic livers,95, 96 with high-grade dysplastic nodules being considered 
HCC precursors and at high risk of progression to HCC.97, 98 
 
HCCs are malignant neoplasms with a hepatocyte origin. They can be categorised as 
nodular or well differentiated HCCs with distinct margins, large or massive HCCs that 
exceed the size of nodular HCCs, and diffuse or poorly differentiated HCCs that often are 
characterised as an infiltrating tumour.94 With the onset of the hepatocarcinogenic process, 
several cellular pathways are altered and changes in angiogenesis appear to be 
particularly common with the progression of non-malignant to malignant nodules.94, 99, 100 
While perfusion of regenerative nodules and low-grade dysplastic nodules are mainly 
venous, high-grade dysplastic nodules and HCC are mainly supplied via arterial 
neovascularisation. The increased activation of angiogenic pathways leads to new vessel 
formation and increased density of unpaired arteries and capillary units. The most 
significant alterations occur in the switch from a low-grade to a high-grade dysplastic 
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nodule.94, 101, 102 In addition to alterations in arterial supply with continuous progression 
from dysplastic nodule to early HCC through to progressed HCC, venous drainage 
changes from hepatic vein to hepatic sinusoids and then to portal vein.103 Other changes 
related to altered angiogenesis include the accumulation of fat in high-grade-dysplastic 
nodules and HCCs less than 1.5 cm in size.94, 104 This is believed to occur due to localised 
intra-tumoural ischaemia through insufficient arterialisation of early tumours and, indeed, 
the presence of fat is now considered a specific marker of malignancy in dysplastic 
nodules that have progressed to small HCCs.104 Similarly, iron is increasingly accumulated 
in dysplastic nodules before it decreases in progression to HCC.105 Changes in peptide 
transporters occur, with reduced expression of the organic anion transporting polypeptide 
(OATP) in hepatocarcinogenesis. The concentrations of OATP are relatively higher in low-
dysplastic nodules compared with high-grade dysplastic nodules, highlighting molecular 
events occurring in precancerous nodules.106, 107 Changes can also be observed in Kupffer 
cell density, with reductions in Kupffer cells with progression to HCC, especially poorly 
differentiated HCCs.94 This change in cell density is particularly visible as Kupffer cells 
accumulate particulate agents through phagocytosis. 
 
1.2.7.1 Diagnosis and treatment of hepatocellular carcinoma 
 
Cellular alterations associated with hepatocarcinogenesis can be seen as part of imaging-
based diagnosis of HCC. As a result of changes of angiogenesis and venous drainage, the 
perfusion of HCC is altered, with its blood supply mostly deriving from the hepatic artery. 
This perfusion is detected on contrast-enhanced imaging and is known as arterial 
hyperenhancement.108 Arterial hyperenhancement is one of the key diagnostic radiologic 
features that have become incorporated as the Liver Imaging Reporting and Data System 
(LI-RADS) for HCC, developed by the American College of Radiology (Reston, Virginia, 
United States) to improve consistency of evaluating and reporting liver imaging. Given the 
continuous changes that characterise the progression from dysplastic nodule to HCC, 
significant variability in diagnostic reporting became apparent. The LI-RADS classification 
includes features of hepatocarcinogenesis to characterise suspicious lesions in patients 
with cirrhosis at risk of HCC. These features, supported by both the American Association 
for the Study of Liver Diseases (AASLD) and European Association for the Study of the 
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Liver (EASL),109-111 include arterial hyperenhancement and washout of contrast agent, 
lesion size, interval growth and the presence of a capsule to determine the likelihood of 
HCC (see Figure 1.2). The LI-RADS classification stratifies lesions as lesions that are 
definitely benign (LI-Rad 1) or probably benign (LI-Rad 2), those with an intermediate 
probability of being HCC (LI-Rad 3), and those that are probably (Li-Rad 4) or definitely 
HCC (LI-Rad 5).112 
 
 
 
Figure 1.2. The version 2017 Liver Imaging Reporting and Data System (LI-RADS). 
The LI-RADS v2017 outlining the diagnostic algorithm used with CT/MRI-based diagnosis 
of lesions suspicious for HCC. (Abbreviations: AASLD, American Association for the Study 
of the Liver; OPTN, Organ Procurement and Transplantation Network). Adapted from LI-
RADS-v2017; https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-
RADS/CT-MRI-LI-RADS-v2017 
 
The implementation of LI-RADS also highlights the importance of imaging for the diagnosis 
of HCC. Routine HCC surveillance in cirrhotic patients consists of 6-monthly ultrasound 
scans.90, 91 Ultrasound has been shown to have a sensitivity of 94% for the detection of 
HCC across all stages, however, the sensitivity decreases to 63% for the detection of early 
HCC.113 Once a lesion is identified on ultrasound, dynamic scanning (CT/MRI) is employed 
to further characterise suspicious lesions also using the LI-RADS categorisation to 
determine the likelihood of HCC. If the diagnosis remains indeterminate, ongoing imaging 
is recommended until interval growth or other features confirm a diagnosis.109, 114 The only 
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HCC tumour biomarker currently accepted is alpha-fetoprotein (AFP), which generally has 
suboptimal sensitivity and specificity for surveillance and diagnosis in most cases.113, 115 
Although it has an overall ROC curve performance with an AUC of 0.80, the overall 
sensitivity reaches only 66% in early HCC.116. Liver biopsy can be used for the diagnosis 
of HCC, however, it is associated with risks such as bleeding and track seeding or 
sampling error.114, 117 
 
Treatment of HCC can either be curative using resection, ablation, or liver transplant, or 
palliative. Palliative treatments vary in their efficacy with repeated transarterial 
chemoembolization (TACE) providing a median survival of 23.7 months118 and Sorafenib, 
which is currently the only rebatable systemic treatment available in Australia, conferring a 
median survival of 14.5 months compared to best supportive care with a median 11.4 
months.52 Other systemic therapies that are in late stage development/release and will 
likely form part of the treatment algorithm within months to years include regorafenib, 
lenvatinib and cabozantinib. The allocation of the appropriate treatment depends heavily 
on tumour stage (including number, size and spread), as well as the degree of liver 
function impairment and overall patient status. The Barcelona Clinic Liver Cancer (BCLC) 
classification divides patients across 5 stages and allocates treatment recommendations 
and prognostic information based upon the available evidence. This system highlights the 
need for early identification of HCC, as potentially curative treatment is only recommended 
for patients with stage 0 or A (i.e. very early or early stage) disease. In practice, this 
corresponds to tumours less than 3 cm in size. Large multinodular tumours and/or portal 
vein invasion are usually treated with palliative systemic therapies, patients with advanced 
decompensation or poor performance status receive no active treatment apart from 
supportive care.52, 119 Currently, the overall 5 year survival for compensated cirrhosis 
patients with a single HCC is around 68%, whereas cirrhotic patients (CTP ‘B’) with 
multiple HCCs have a 5 year survival of only 19%.120 
 
1.2.7.2 Molecular pathogenesis of hepatocellular carcinoma 
 
Several molecular pathways are involved in the development of HCC. An extensive study, 
examining the molecular heterogeneity of HCC showed that some mutations are present in 
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large numbers of patients (mutations on chromosome 1 and 17), while others only apply to 
smaller subsets of patients.121 Overall, amplifications are more common than 
chromosomal deletions and the development of HCC is associated with deregulation of 
hundreds of protein-coding genes.121, 122 Interestingly, this study also identified reduced 
transcriptional efficiency of genes linked to drug catabolism and increased transcriptional 
efficiency linked to inflammatory responses and cell proliferation in HCC.121  
 
As reviewed in great detail by Whittaker et al, several molecular pathways are altered in 
HCC.123 As highlighted earlier, HCC tumour development is highly dependent on 
angiogenesis and, as such, several angiogenesis pathways involving growth factors are 
involved in disease development. Examples of angiogenesis-related growth factors that 
are implicated in HCC development are vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF), insulin-like growth factor (IGF) and the hepatocyte growth 
factor (HGF/c-MET). Targeting of these growth factors through their receptors, such as the 
EGF receptor (EGFR) or IGF receptor (IGF-1R), has been undertaken in HCC as a 
potential therapeutic approach. Specific growth factors can also signal through several 
downstream pathways. One important example is the MAP kinase family related pathway 
consisting of mitogen-activated protein kinase (MAPK), also known as the ERK/MAPK 
pathway, which can also be regulated by the EGF receptor. This pathway is a signal 
transducing pathway and important for cellular processes such as proliferation, 
angiogenesis and/or differentiation. The pathway, consisting of Phosphatidylinositol-3 
kinase (PI3K), kinase AKT and mammalian target of rapamycin (mTOR), also called 
PI3K/AKT/mTOR pathway, is also a downstream pathway targeted by growth factors and 
is strongly linked to cell growth and survival.123 Other signalling pathways are involved 
through their key components, such as the WNT/β-catenin pathway. The altered 
expression of the transcription factor β-catenin is a key component of HCC development, 
mainly through its downstream targets which regulate cell proliferation and epithelial to 
mesenchymal transition (EMT), or those known to be involved in the formation of 
extracellular matrix.123, 124 The interaction of growth factors with several pathways or 
interaction with several targets within the same pathway highlights the complexity of 
hepatocarcinogenesis.  
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Currently the only systemic drug treatment available for HCC is Sorafenib, a multi-kinase 
inhibitor targeting the RAF/ERK/MAPK pathway and VEGF, as well as the PI3K/AKT 
pathway through targeting of myeloid leukemia cell differentiation protein (Mcl-1).123, 125 
The success of Sorafenib in targeting several pathways simultaneously highlights how a 
better understanding of altered gene expression in HCC could provide viable targets for 
future therapeutic approaches. Indeed, altered expression of several potential tumour 
suppressors and oncogenes has been identified. For example, HCC-associated gene 
expression changes have been observed for well-known oncogenes, including MET and 
EGF, as well as established tumour suppressors, including phosphatase and tensin 
homolog (PTEN) and tumour protein P53 (TP53).121, 126 While these genes have been 
validated in vivo, newer functional genomics approaches have now identified several other 
tumour suppressor genes and oncogenes, such as exportin 4 (XPO4), DEAD Box helicase 
(DDX) (tumour suppressor genes) as well as yes associated protein (YAP) and E2 
ubiquitin conjugating enzyme H (UBE2H) (oncogenes) 121, 126 Finally, there has been 
considerable interest in recent years in the area of molecular profiling of HCC in an effort 
to individualise cancer therapy. To briefly summarise the enormous amount of work done 
to date, it is fair to say that the current systems of molecular/genetic signatures of HCC 
have provided a lot if useful information about pathogenesis and the natural history of 
different tumour types. Considerable heterogeneity in HCC (both inter-tumoral and intra-
tumoral), however, have limited the clinical application of this new understanding to 
improved anti-cancer therapies.127, 128 Furthermore, complex cell-cell interactions and 
signalling within the tumour microenvironment, with considerable redundancy and 
variability, have not allowed these exciting findings to be translated into prognostic or 
therapy-guiding  biomarkers that can be used in a prospective fashion in the clinic. 
 
1.3 MiRNAs 
 
MicroRNAs (miRNAs, miRs) are small non-coding RNAs that are highly conserved across 
different animal species.129 Since their discovery by Ambros and colleagues,130 miRNAs 
have been increasingly investigated. In 2000, the identification of miRNA let-7a as a 
regulatory RNA and description of its involvement in gene expression led to extensive 
miRNA research.131 The discovery of miRNAs across all species has prompted the 
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development of a registry to name newly identified RNAs.132 To date, this registry has 
evolved to become the largest miRNA database, called miRBase, with the latest release 
(version 22) including 2654 mature miRNA entries for Homo sapiens alone.133-136 
 
1.3.1 MiRNA biogenesis 
 
MiRNAs have been described as a highly abundant class of non-coding RNAs with for 
example, up to 50 000 copies per cell in neonatal mouse liver.137 Mature miRNAs are 
single stranded RNAs approximately 22 nucleotides in length.  
 
The biogenesis of miRNAs starts with the transcription of miRNA coding genes by RNA 
Polymerase ΙΙ into primary miRNAs (pri-miRNAs).138 Pri-miRNAs are double-stranded; 
containing one or more hairpins as well as cap and poly-A tail structures.139, 140 The 
maturation process of the pri-miRNA is mediated by a microprocessor complex, consisting 
of Drosha (RNase ΙΙΙ endonuclease) which interacts with DGCR8 (a RNA-binding 
protein).141, 142  Drosha is the core nuclease initiating pri-miRNA processing which results 
in the ~ 70 nucleotide precursor miRNA (pre-miRNA). The processing from pri-miRNA to 
pre-miRNA is compartmentalised to the nucleus.138, 143, 144 It is followed by the export of 
pre-miRNA, mediated by Exportin 5, into the cytoplasm and processing into the mature 
miRNA.138, 145, 146 Dicer is responsible for the cleavage of pre-miRNA into mature 
miRNA147, 148 Recognition of the pre-miRNA by Dicer is mediated by the 3’ nucleotide 
overhang at the base of the pre-miRNA.149-152 
 
Following Dicer mediated cleavage, the mature miRNA, is formed by a guide strand and a 
passenger strand. This miRNA duplex is then incorporated into the RNA-induced silencing 
complex (RISC), by directly binding to a member of the Argonaute protein family.153-158 
Importantly, central or seed mismatches within the miRNA duplex are promoting RISC 
loading and unwinding, respectively.159-162 The RISC assembly happens in two steps. First, 
the miRNA duplex is loaded into the Argonaute proteins. In the second step the miRNA 
duplex is un-winded and both strands are separated. The single-strand mature miRNA part 
of the RISC complex is protected from nucleases. The passenger strand is released and 
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often degraded in the cytoplasm.163 The miRNA and mRNA binding within the mature 
RISC complex is subject to Watson-Crick base pairing of the miRNA seed region. The 
miRNA seed region is at the nucleotide 2-7 from 5’ miRNA end and contains a minimum of 
6 base pairs (bp).164-168 
 
1.3.2 MiRNAs and regulation of post-transcriptional events 
 
MiRNAs can alter translation and post-transcriptional events through the repression of 
translation and/or degradation of mRNA targets. The mechanisms by which miRNAs alter 
translation are the subject of intensive investigation. Although currently the subject of 
ongoing research to examine these in more detail, several modes of action have been 
described to date.169 
 
One distinct mechanism of translational repression involves a number of possible 
pathways, such as the 5’ to 3’ decay pathway. This pathway describes how the miRNA-
mRNA pairing results in mRNA degradation, via stimulation of CCR4-NOT deadenylase 
and subsequent recruitment of the CDP1:DCP2 decapping complex.169-173 Degradation of 
mRNA can also occur through the recruitment of processing bodies (P-bodies), which are 
cytoplasmic foci and recruited through the interaction of miRNA and Argonaute interaction. 
The Argonaute protein forms the central core of the RNA-induced silencing complex 
(RISC) which, after binding with miRNA, target mRNAs and deliver them to P-bodies for 
degradation. P-bodies have been shown to contain untranslated mRNAs.174-180  
 
MiRNAs can also directly inhibit mRNA translation. One example is the targeting of cap-
independent mRNA whereby miRNA binds directly to the internal ribosome entry site 
(IRES), usually located at the 5’ end of the mRNA.181, 182 Another example, although rarer, 
is the ribosome drop-off model. Here, the miRNA binds to the 3’ untranslated region (UTR) 
of the mRNA, once again via an interaction with the RISC, to directly inhibit translation by 
inducing dissociation of ribosome and mRNA binding.169, 181, 183 Interestingly, miRNA have 
also been shown to be able to upregulate translation,184 although this effect is rare. 
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The effects of miRNA-mediated post-transcriptional regulation show that one miRNA can 
alter the expression levels of large numbers of mRNAs.185 In fact, decreased mRNA levels 
due to miRNA regulatory interactions can account for up to 80 % of decreased protein 
production, highlighting the impact of miRNAs on protein-coding genes.186 It is important to 
note that the effects of miRNAs on protein expression levels have been described as “fine-
tuning” protein synthesis, rather than “shutting down” the translation completely.187, 188 The 
magnitude of translational repression does, however, vary between one miRNA and its 
targets. This can be explained by reduced target site availability with mutations impairing 
miRNA binding.189 RNA binding proteins can also modulate miRNA repression, by 
promoting dissociation of the miRNA-RISC complex, for example.190, 191 Translational 
efficiency, characterised by the mRNA coding sequence and 5’ and 3’ untranslated regions 
(UTR), has been shown to directly correlate with miRNA mediated translational 
repression.192 In fact, 3’ UTR isoforms can vary between cell types and can modulate 
miRNA binding sites. This can account for 10% of all miRNA targets, highlighting the 
complexity of predicting specific miRNA targets and effects.193 
 
1.3.3 MiRNAs and disease 
 
Since their discovery, miRNAs have been strongly linked to cellular processes such as cell 
cycle regulation, proliferation or apoptosis.194-197 Additionally, there is an emerging role for 
miRNAs in multiple diseases, including inflammatory diseases (e.g. example sepsis198 or 
ulcerative colitis),199 chronic diseases (e.g. diabetes mellitus,200 coronary heart disease201 
or chronic pain conditions),202 and infectious viral diseases (e.g. influenza203 and HIV).204 
 
The expression of miRNAs can be tissue specific, such as miRNA-122 in liver tissue, 
miRNA-124 in the nervous system, or miRNA-375 in endocrine glands. More commonly, 
miRNAs are expressed in multiple cell types at various expression levels.205 In fact, a 
strong cellular context of miRNA expression has been shown. For example, miRNA-125b 
either functions as a pro-oncogenic or tumour suppressor miRNA depending on the 
cellular environment.206 MiRNAs have been described in various cancers, with differential 
expression shown most prominently in breast cancer, lung cancer or gastric cancer. In 
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malignancy, they have been linked to cancer pathogenesis such as tumour growth, 
progression and metastasis.207-210 
 
MiRNAs have also been extensively studied in liver disease and their roles reviewed in 
detail elsewhere.211, 212 To summarise, differential hepatic miRNA expression in animal213 
and human studies214-216 has been shown in various liver disease aetiologies including 
viral hepatitis, fatty liver disease and alcoholic liver disease. MiRNAs appear to regulate 
gene expression in critical areas, including processes involved in hepatic fibrogenesis. 
Murakami et al identified miRNA-199a, miRNA-200a and miRNA-200b to be associated 
with pro-fibrotic events,217 whereas miRNA-29 was shown to be associated with anti-
fibrotic effects.218 MiRNAs have been shown to regulate other processes involved in the 
progression of CLD, including the activation and proliferation of hepatic stellate cells.211, 
219-221 
 
As miRNAs are involved in key cellular processes, it is therefore unsurprising that miRNAs 
appear to be aberrantly expressed in HCC, shown both in animal studies and humans.211   
Several differentially-expressed miRNAs, such as decreased levels of miRNA-199a and 
miRNA-199b, have been described to date in human HCC tissue.222 Studies correlating 
miRNA expression with patient characteristics have shown that reduced expression of 
these miRNAs correlates with a poor survival in HCC. Further, miRNA-199a/b was shown 
to target the HCC related pathway MEK/ERK.222 Reduced expression of miRNA-188 has 
also been demonstrated in HCC tissue and is associated with HCC proliferation and 
metastasis.223 For other miRNAs, such as miRNA-9, miRNA-21 and miRNA-224, 
increased HCC tissue expression has been reported and their increased expression levels 
are associated with HCC invasiveness.224 Identifying miRNAs related to HCC has 
therefore become an area of great interest and many studies have now reported 
differentially expressed miRNAs in HCC tissue or in vitro.211, 225, 226 Unfortunately, however, 
most studies lack reproducibility or miRNA candidates of interest lack validation. 
Nevertheless, these preliminary studies have generated a number of potential candidates 
and the roles of individual miRNA in HCC are the subject of ongoing investigation. For 
example, miRNA-7, which purported to have an inhibitory effect on tumour growth and 
metastasis,227 has now been shown to be a very potent HCC growth inhibitor in vitro and in 
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vivo and restores sensitivity to Sorafenib in treatment-resistant HCC cells. Functional 
investigations show that miRNA-7 targets several HCC pathways such as EGF/EGFR and 
PI3-Kinase/AKT pathway and has therefore great therapeutic potential.228 
 
1.3.4 Circulating miRNAs and disease 
 
Research investigating associations between miRNAs and liver disease has not only 
highlighted potential roles in the pathogenesis of disease but has also raised their profile 
as possible therapeutic targets. Additionally, the presence of miRNAs in multiple body 
fluids, such as blood (serum, plasma),229 saliva,230 urine231 and semen,232 also highlights 
their potential as diagnostic biomarkers. These extracellular miRNAs, also called 
circulating miRNAs, are very stable in the circulation and therefore represent very 
accessible biomarkers. The stability of circulating miRNAs has been linked to how they are 
released into the bloodstream. Circulating miRNAs can be found in extracellular vesicles 
(EVs), such as exosomes (or microvesicles) that are actively released from the donor cell 
into body fluids. It has been shown that the content of EVs is actively selected and 
functions as a paracrine or endocrine pathway of cellular communication.233-235 
Interestingly, miRNAs and other RNAs can be actively packaged into EVs and exported 
from tumour cells, representing a tumour-specific miRNA expression profile, as shown in 
ovarian cancer.236 MiRNAs can also be released into the circulation as a result of 
apoptosis. Although these are released in a non-selective manner, they can interact with 
circulating proteins, such as Argonaute proteins, thus increasing their stability in the 
circulation.235, 237  
 
Circulating miRNAs have been increasingly investigated as non-invasive biomarkers of 
disease, including liver disease. Increased expression of miRNA-122, the most abundant 
miRNA in liver, has been shown in multiple liver disease aetiologies, including CHB and 
CHC, and therefore could represent a circulating biomarker of liver injury.211, 238, 239 Several 
other circulating miRNAs have also been suggested as biomarkers in CLD, such as 
miRNA-34a (which increases with the progression from steatosis to steatohepatitis and 
correlates with liver enzymes,240 miRNA-571 (which increases with fibrosis stage and has 
been suggested as a biomarker for cirrhosis),241 and miRNA-155 and miRNA-125b (which 
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are upregulated in HCV patients with expression levels correlating with ALT and AST 
levels).242 In HCC, circulating miRNAs have also been investigated as possible non-
invasive biomarkers. Several studies report various miRNA candidates, such as miRNA-21 
and miRNA-223 (which have been shown with an increased expression in HCC),243 or 
describe expression profiles of several miRNAs in HCC, including miRNA-27a, miRNA-
18a, miRNA-222, miRNA-223 and miRNA-26a within one combined miRNA panel.244 
Although circulating miRNAs therefore have great potential to function as non-invasive 
biomarkers, the preliminary results reported in these studies are yet to be validated and 
ongoing studies are investigating potential diagnostic combinations with no reproducible 
and/or highly accurate diagnostic panels reported to date.  
 
1.4 Clinical limitations and challenges in patient assessment  
 
As outlined earlier, traditional assessments of disease severity and associated 
complications do not ideally meet the clinical requirements of patient assessment in CLD. 
Categorical histological staging does not accommodate uncertainty or sampling error, nor 
does it reflect the continuous spectrum of disease (including, and perhaps most 
importantly, the diverse patient subpopulation spanning incomplete cirrhosis through to 
advanced, decompensated disease). In HCC, the currently-accepted biomarker, AFP, 
lacks sensitivity and specificity, especially in early, treatable cancer. Non-invasive 
technologies, such as transient elastography, have become widely utilised and have the 
advantage of generating a continuous measure of fibrosis that better reflects the 
continuous spectrum of liver disease. This assessment modality has also now started to 
find a role in stratifying risk of complications, such as clinically-significant varices and 
HCC. Fibrosis assessment, however, does not yield any information on mechanisms of 
disease nor does it provide any potential targets for future therapies. Finally, many newer, 
non-invasive modalities are potentially limited in their accessibility and blood-based 
biomarkers may therefore offer an advantage. 
 
MiRNAs are small non-coding RNAs that have been shown to regulate post-transcriptional 
events. Altered miRNA expression has now been demonstrated in several diseases, 
including CLD and HCC, and several studies have investigated the potential of miRNAs as 
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therapeutic targets. Additionally miRNAs are released into the circulation, are stable and 
quantifiable using existing laboratory assays, and have become increasingly attractive 
candidates as potential non-invasive biomarkers of disease.  
  
In summary, therefore, there is a clinical need for better diagnostic and potentially 
predictive tools for the assessment of disease severity, accurate identification of cirrhosis, 
and identification of patients at highest risk of cirrhosis-related complications, including 
HCC. Furthermore, there are promising preliminary results to suggest that circulating 
miRNA could be exploited here and developed as non-invasive biomarkers of disease but 
this research is in its early stages and much is still to be learned about miRNAs in CLD. In 
the context of a disease that affects millions worldwide and is associated with lethal 
complications and, in the case of HCC, increasing mortality rates, it is arguable that further 
research into the potential of miRNAs as non-invasive biomarkers in cirrhosis and HCC 
has become a clinical imperative. 
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1.5 Overall hypotheses and aims 
 
In light of what is currently known about miRNAs and their purported roles in CLD, it is 
hypothesised that some circulating miRNAs exhibit differential expression across the 
spectrum of CLD, and that a distinct miRNA expression profile, or “signature”, exists that is 
associated with disease severity. It is further hypothesised that miRNA expression levels 
could be quantified in circulating blood and potentially investigated as a non-invasive 
means to diagnose cirrhosis, cirrhosis-associated complications and HCC. Based on this, 
it is also hypothesized that combinations of miRNA candidates could outperform, or be 
used to improve the performance of, currently-accepted non-invasive biomarkers to 
improve diagnostic performance. Finally, it is the hypothesis that differentially-expressed 
miRNAs identified in association with the development of HCC target the expression of 
specific hepatocyte genes that could be further investigated in relation to understanding 
the pathways of carcinogenesis. 
 
The specific aims for this thesis, therefore, are as follows: 
 
1.A.  To identify differentially-expressed serum miRNAs in patients with differing 
severities of HCV-related CLD and to identify candidate miRNAs that could be used as 
non-invasive biomarkers to distinguish (i) mild disease (i.e. no fibrosis to moderate fibrosis) 
from cirrhosis, and (ii) cirrhosis complicated by HCC from cirrhosis alone; and  
1.B.  to design serum miRNA panels and assess their performance in distinguishing 
disease stages alone and/or in combination with the aminotransferase to platelet ratio 
(APRI) and Fibrosis 4 (Fib-4) biomarker panel and the tumour marker alpha-fetoprotein 
(AFP). 
 
2. To characterise the functional roles and purported target genes of differentially-
expressed miRNAs identified in Aim 1 in the pathogenesis of HCC progression. 
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3.A. To identify circulating miRNAs whose expression profile is associated with early 
HCC; and  
3.B. to identify miRNAs that are differentially expressed in patients with atypical or 
indeterminate liver lesions that are ultimately diagnosed as HCC. 
 
4. To identify circulating miRNA biomarkers that are associated with the appearance 
of cirrhosis-related complications such as ascites, varices and/or variceal bleeding, with a 
view to identifying specific miRNAs that exhibit dynamic expression across the spectrum of 
disease severity (and could potentially predict the incidence of cirrhosis-related 
complications in patients with cirrhosis). 
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CHAPTER 2                                                                
Material and methods…… 
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2.1 Patient recruitment and characteristics 
 
This study was approved by the Human Research and Ethics Committees of, the Royal 
Brisbane and Women’s Hospital (RBWH; Herston, QLD, 4029 Australia) Ethics No. 
HREC/13/QRBW/308, the QIMR Berghofer Medical Research Institute (QIMR Berghofer 
MRI; Brisbane, Australia) Ethics No. P1509 and the Sir Charles Gairdner Hospital (SCGH; 
Nedlands, WA, 6009, Australia) Ethics No. 2009-101.Informed consent was obtained from 
all study participants. Patients with chronic liver disease of any aetiology were enrolled 
through the course of routine outpatient or inpatient care. A serum bank was curated to 
store peripheral blood samples collected at enrolment and during follow-up (where 
possible). Contemporary patient demographic data (comprising age, gender and body 
mass index; BMI) and clinical data (comprising details of disease aetiology and severity, 
routine laboratory biochemical test results, and medical imaging and liver biopsy/resection 
results) were obtained via a review of the patients’ hospital records. Data for all study 
participants were collated via a dedicated study database. 
 
Following enrolment, patients were retrospectively allocated to relevant study cohorts, 
based on the severity of liver disease and/or the presence of liver disease-related 
complications, according to the aims of the thesis. For the first aim, patients with confirmed 
chronic HCV infection were divided among 3 cohorts based on the presence of mild 
disease (F0-2), cirrhosis (F4) or cirrhosis complicated by the presence of HCC. Fibrosis 
staging was performed based on the METAVIR staging system (F0-4) as described in 
detail in Chapter 1. Typically, liver biopsy was not routinely employed and therefore 
fibrosis staging was performed using transient elastography in combination with 
biochemistry, imaging and clinical assessment according to current professional 
guidelines.245-247 Clinical assessment, with FibroScan, can reliably stage patients 
according to the presence of mild disease (F0-2) and cirrhosis (F4) – and traditionally 
cannot precisely distinguish between consecutive stages of fibrosis (i.e., F1 vs. F2, F2 vs. 
F3, F3 vs. F4) – so these clinically-relevant cohorts were chosen for further analysis. 
Patients in the F4 cohort had clinical features of cirrhosis (e.g. splenomegaly or other 
imaging features of portal hypertension, thrombocytopenia, inversion of the usual ALT:AST 
ratio, history of hepatic decompensation, etc) and high median liver stiffness 
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measurements (average 19.2 kPa). Conversely, patients in the F0-2 cohort had none of 
these clinical features of advanced fibrosis/cirrhosis and all had low median liver stiffness 
measurements (average 6.1 kPa). For the third aim, 4 cohorts were assembled comprising 
patients with cirrhosis, cirrhosis with small HCC (≤ 2.5 cm in maximal diameter), and 
cirrhosis complicated by possible HCC (i.e. indeterminate lesions). This latter cohort of 
possible HCC was then sub-divided into 2 further cohorts of patients with indeterminate 
lesions based on the ultimate diagnosis (i.e. those that were subsequently diagnosed as 
HCCs, and those that were subsequently diagnosed as benign lesions). For the fourth aim, 
a cohort of patients with cirrhosis of various severities was also assembled and sub-
divided according to the presence of different cirrhosis-related complications; namely, 
varices, ascites and incident variceal bleeding. If patients presented with multiple 
complications, they were allocated to the more advanced disease cohort. As such, the 
cohort of cirrhotic patients with ascites may have included patients with varices, and the 
cohort of patients with an episode of variceal bleeding may have included patients with 
ascites. All study cohort allocations were based upon expert clinical assessment, including 
the evaluation of biochemistry and other routine laboratory test results, transient 
elastography liver stiffness measurement (using FibroScanTM), and/or other medical 
imaging (ultrasound, CT and/or MRI to diagnose liver lesions or other disease-related 
complications) or investigations (i.e. upper endoscopy to confirm the presence of varices 
and variceal bleeding). Patients were not included in the study cohorts if the required 
clinical work-up substantiating any particular diagnosis was incomplete, critical data were 
missing, or a contemporaneously obtained serum sample was not provided to be matched 
with corresponding clinical data. 
 
Relevant biochemical data were collected for all patients at enrolment, including routine 
laboratory blood tests; namely, sodium, creatinine, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), platelet count (Plt), bilirubin, and albumin. Additional 
disease-specific laboratory tests were also collected, including international normalized 
ratio (INR) and alpha-fetoprotein (AFP). Where relevant, non-invasive biomarker panels to 
evaluate disease severity were calculated, including the AST to Platelet Ratio Index 
(APRI), Fibrosis-4 (FIB-4) score, Child-Turcotte-Pugh (CTP) score and model for end-
stage liver disease (MELD) score. All scores were calculated using blood tests that were 
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collected contemporaneously with the collection of patient serum samples. The methods 
for calculating each non-invasive score is described in detail in Table 2.1. 
 
A diagnosis of HCC was established according to currently accepted professional 
guidelines.109, 110, 114, 248 Briefly, HCC was diagnosed based upon expert specialist clinical 
assessment of its imaging characteristics (interval growth and/or typical appearances on 
contrast-enhanced, multi-phase CT/MRI scanning) ± elevated AFP level ± histological 
sampling. All HCCs were stratified using the Barcelona clinic liver cancer (BCLC) criteria, 
as summarised by Forner et al.52 The imaging basis for a diagnosis of HCC was 
standardised according to the 2017 Liver Imaging and Reporting Data System (LI-RADS, 
American College of Radiology, Reston, VA, United States)249 and verified with a single 
radiologist. 
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Table 2.1. Non-invasive biomarker panel calculations. 
Scoring 
system 
Calculations Ref 
APRI 
 
(
𝐴𝑆𝑇
𝑈𝑝𝑝𝑒𝑟 𝑙𝑖𝑚𝑖𝑡 𝑜𝑓 𝑛𝑜𝑟𝑚𝑎𝑙 𝐴𝑆𝑇 )x 100
𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝐶𝑜𝑢𝑛𝑡 (109/𝐿)
 
 
58 
FIB-4 𝐴𝑔𝑒 (𝑦𝑒𝑎𝑟𝑠)x 𝐴𝑆𝑇 (𝑈/𝐿)
𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝐶𝑜𝑢𝑛𝑡 (109/𝐿) x (√𝐴𝐿𝑇(𝑈/𝐿)
 
 
60, 250 
MELD 〈0.957 ln  (𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 [
𝑚𝑔
𝑑𝐿
]) + 0.378 ln (𝑏𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 [
𝑚𝑔
𝑑𝐿
]) + 1.12 ln[𝐼𝑁𝑅]
+ 0.643〉  x 10 
 
53-55 
CTP 
(Graded 
based on 
total points 
score: 
‘A’ = 5-6,  
‘B’ = 7-9, 
‘C’ = 10-15  
Score Albumin Bilirubin INR Ascites Hepatic 
Encephalopathy 
51, 52 
1  
point 
> 35g/L < 2mg/dL < 1.7 absent none 
2 
points 
28–35 g/L 2-3mg/dL 1.7–2.3 mild mild (grade I–II) 
3 
points 
< 28 g/L > 3 mg/dL > 2.3 moderate 
to severe 
Marked (grade 
III–IV) 
(Abbreviations: ALT, alanine aminotransferase; APRI, AST to Platelet Ratio Index; AST, 
aspartate transaminase; CTP, Child-Turcotte-Pugh score; FIB-4, Fibrosis-4 score; INR, 
international normalized ratio; MELD, model for end-stage liver disease score; Ref, 
References). 
 
2.2 Clinical samples 
 
Serum samples were obtained using routine clinical phlebotomy services at Pathology 
Queensland (RBWH) and PathWest (SCGH) collection centres. Blood draws were 
performed into VACUETTE® serum collection tubes (Greiner-Bio One, Kremsmünster, 
Austria) or BD Vacutainer® Serum Tubes (Becton Dickinson, Franklin Lakes, New Jersey, 
United States). Samples were centrifuged at 2000 revolutions per minute (rpm) for 10 
minutes (mins) at room temperature for the purposes of serum collection. All samples were 
34 
 
processed within 12 hours of blood draw and serum stored at minus 80 degrees Celsius 
(˚C).  
 
2.3 In vitro studies 
2.3.1 Cell lines  
 
Established human cell lines were selected for all in vitro studies. Immortalised human 
hepatocytes (IHH) were selected as a control hepatocyte cell line and Huh7 cells were 
selected as a human hepatoma-derived cell line. IHH cells are a non-commercially 
available cell line and were kindly provided by Prof. Didier Trono (Ecole Polytechnique 
Fédérale de Lausanne, Lausanne, Switzerland). These cells are albumin positive and AFP 
negative hepatocytes and have been characterised in detail by Nguyen et al.251 The Huh7 
cell line252 was provided by Dr Manuel A. Fernandez-Rojo (Madrid Institute for Advanced 
Studies, Madrid, Spain). Both cell lines were cultured at 37 ˚C and 5% carbon dioxide in an 
humidified environment. Cells were passaged after reaching 70-80% confluence, using 
Accutase enzyme mix (Sigma-Aldrich, St. Louis, Missouri, United States) to detach cells 
from the vessel surface. IHH cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) / Nutrient Mixture F-12 Ham (Sigma-Aldrich), supplemented with 10% foetal 
bovine serum (FBS, Gibco by Thermo Fisher Scientific, Carlsbad, California, United 
States), 1% L-Glutamine (Life Technologies, Carlsbad, California, United States) and 1X 
Insulin-transferrin-sodium selenite media supplement (Sigma-Aldrich) containing 5 mg/L 
insulin, 5 mg/L transferrin and 5 µg/L selenium. Huh7 cells were cultured in DMEM with 
4500 mg/L glucose (Sigma-Aldrich) supplemented with 10% FBS (Gibco by Thermo Fisher 
Scientific) and 1% L-Glutamine (Life Technologies). 
 
Experimental work was performed in a Class II biohazard hood within a physical 
containment level 2 (PC2) certified laboratory. In vitro work was performed using sterile, 
cell culture grade reagents. The Huh7 cell line and the human origin of IHH were 
authenticated by short tandem repeats (STR) profiling before experiments commenced. 
Cell lines were tested and confirmed mycoplasma negative before and after experiments. 
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Cell line authentication and mycoplasma testing were provided as in house services 
through QIMR Berghofer MRI (Herston, Queensland, Australia). 
 
2.3.2 MiRNA transfections 
 
Transient transfection of selected miRNAs in the respective cell lines was performed in 6-
well plates (Greiner Bio-One) or 10 cm tissue culture dishes (Corning Inc., New York, 
United States). All transfections were performed with the miRNA of interest and the 
respective negative control in parallel. Commercially available miRNA mimics used are 
described in detail in Table 2.2. 
 
For miRNA transient transfection of IHH and Huh7 cells in a 6-well tissue culture plate 
(Greiner Bio-One), a cell density of 200 000 cells per well was used for both cell lines. 
After 24 hours the cells were transfected at a confluence of 70-80%. The transfection mix 
consisted of 495.5 µL Opti-MEM (Life technologies, Carlsbad, California, United States), 
2.5 µL Lipofectamine2000 (Invitrogen by Thermo Fisher Scientific) and 2 µL of the miRNA 
mimic at a concentration of 10 µM (to ensure a final amount per well of 20 pmol). The 
transfection mix was thoroughly vortexed for 15 seconds and incubated for 15 minutes at 
room temperature. In the meantime, cells were washed twice with phosphate buffered 
saline (PBS) and 1.5 mL of fresh cell line specific media was added. Following incubation, 
500 µL transfection mix was added per well of cells, dropwise and evenly distributed 
across the well. Transfection efficiency was assessed using fluorescein-labelled miRNA 
mimic negative control (Bioneer Corporation, Daedeok-gu, Daejeon, Republic of Korea). 
Uptake of miRNA was assessed 24 hours post-transfection, with cell counting performed 
on an EVOS fluorescence microscope (Advanced Microscopy Group by Thermo Fisher 
Scientific, Carlsbad, California, United States). 
 
Transient transfection in 10 cm tissue culture dishes (Corning Inc.) was performed with a 
cell concentration of 720,000 cells for the IHH cell line and 1,345,000 cells for the Huh7 
cell line. The migration assay protocol used a cell concentration of 1,000,000 cells for the 
IHH cell line and 1,500,000 for the Huh7 cell line. After 24 hours, cells were transfected at 
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a confluence of 70-80% for pull-down and proliferation assays and a minimum confluence 
of 80% for migration assays. The transient transfection mix consisted of the following: 1 ml 
Opti-MEM (Life technologies), 40 µL Lipofectamine2000 (Invitrogen by Thermo Fisher 
Scientific) and 5 µL of miRNA mimic at a concentration of 10 µM concentration (to ensure 
a final amount per well of 50 pmol). The transfection mix was thoroughly vortexed for 15 
seconds and incubated for 15 minutes at room temperature. In the interim, the cells were 
washed twice with PBS and 5 mL of fresh cell line specific media was added. The 
complete transfection mix was added dropwise and distributed evenly across one 10 cm 
tissue culture dish.  
 
Table 2.2. MiRNA mimics used with transient transfections. 
No miRNA name Description Product No Supplier 
1 Negative control AccuTargetTM Fluorescein-
labelled microRNA Mimic 
Negative Control 1 
SMC-4002 Bioneer 
Corporation  
2 Negative control Mission® microRNA Mimic, 
human, Negative control 2 
HMC0003 Sigma-Aldrich 
3 Hsa-miR-151a-5p Mission® microRNA Mimic, 
hsa-miR-151-5p 
HMI0244 Sigma-Aldrich 
4 Hsa-miR-486-5p Mission® microRNA Mimic, 
hsa-miR-486-5p 
HMI0596 Sigma-Aldrich 
5 Negative control miScript Inhibitor Negative 
Control 
1027271 Qiagen 
6 Hsa-miR-151a-5p miScript microRNA Mimic – 
hsa-miR-151a-5p 
MSY0004697 Qiagen 
7 Hsa-miR-486-5p miScript microRNA Mimic – 
hsa-miR-486-5p 
MSY0002177 Qiagen 
Overview of commercial miRNA mimics used for transient transfections in vitro. All miRNA 
mimics were transfected at a concentration of 10 µM. Suppliers of selected miRNAs are 
Bioneer Corporation (Daedeok-gu, Daejeon, Republic of Korea), Sigma-Aldrich (St. Louis, 
Missouri, United States) and Qiagen (Qiagen; Hilden, Germany). (Abbreviations: hsa, 
Homo sapiens; miR, microRNA; No, Number). 
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2.3.3 Pull-down assay 
 
To profile mRNA-miRNA interactions a pull-down assay was performed using a detailed 
protocol described by Wani et al.253 In brief, both cell lines (IHH and Huh7) were seeded 
into 10 cm tissue culture dishes (Corning Inc using a concentration of 720,000 cells for the 
IHH cell line and 1,345,000 cells for the Huh7 cell line in 5 mL of cell line specific media. 
As per the pull-down protocol, 4 x 10 cm tissue culture dishes were used for one pull-down 
in Huh7 cells, whereas the pull-down for IHH cells was optimised using 16 x 10cm plates 
for one pull-down assay. The cells were transfected at 70-80% confluence using 
Lipofectamine2000 (see Section 2.3.2), with pull-down specific biotinylated miRNA 
duplexes at 20 pmol/dish. As described by Wani et al,253 these miRNA duplexes are 
designed to include biotin labelling at the 3’OH group via C6 linker of the mature strand, a 
2 nucleotide overhang of each strand and 2 base pair mismatches in the passenger strand 
(see Table 2.3). Self-designed miRNA duplexes were synthesised by Integrated DNA 
technologies (Coralville, Iowa, United States). Following transfection and 24 hours prior to 
each pull-down experiment, MyOne Streptavidin C1 Dynabeads (Invitrogen by Thermo 
Fisher Scientific) were washed and blocked overnight. On the following day, cells were 
harvested with freshly prepared lysis buffer. For this step, all plates (4 for Huh7 and 16 for 
IHH) were pooled into one reaction tube. Importantly, after this step, one aliquot of total 
lysate was set aside and was used as total lysate control, while the remainder of the cell 
lysate was combined with pre-washed Dynabeads. The cell lysate and Dynabead mix was 
incubated to capture target mRNA to Dynabeads. In the next step, Dynabeads-mRNA 
complexes were washed repeatedly to remove any non-specifically bound products. 
Purification of mRNA targets captured by Dynabeads and control lysate was performed 
using the RNeasy Kit following the manufacturer’s RNA clean-up protocol (Qiagen; Hilden, 
Germany). RNA purification was followed by a filtration step to remove any contaminants 
in each sample. The final quality and concentration of purified mRNA was assessed using 
the Bioanalyzer (see Section 2.5.2) before proceeding to next generation sequencing 
(NGS) (see Section 2.6.7). All pull-down reactions consisted of a total RNA control sample 
and an enriched mRNA pull-down sample. Pull-down analyses were performed using 3 
independent biological replicates per miRNA.  
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Table 2.3. MiRNA duplex for pull-down assay. 
miRNA  Mature sequence  
(5’ – 3’) 
miRNA Duplex 
miRNA-151a-
5p 
UCGAGGAGCUCACAGU
CUAGU 
5’-3’: PO4-UCGAGGAGCUCACAGUCUAGU AG-
OH-C6-Biotin 
  3’-5’:OH-GAAUCUCCUCGAGUGUUAGAUCA-PO4 
miRNA-486-
5p 
UCCUGUACUGAGCUGC
CCCGAG 
5’-3’: PO4- UCCUGUACUGAGCUGCCCCGAG AG-
OH-C6-Biotin   
  3’-5’:OH-GAACGACAUGACUCGACGGCGCUC -
PO4 
MiRNA duplex designed for pull-down assay including a biotin labelling at the 3’OH group 
via C6 linker of the mature strand, 2 nucleotide overhang of each strand (green) and 2 
base pair mismatches in the passenger strand (blue). All miRNA duplexes were 
transfected at an amount of 20 pmol. Duplex design following protocol by Wani et al.253 
and produced by Integrated DNA technologies (Coralville, Iowa, United States) 
(Abbreviations: C6, 6-carbon amino linker; miRNA, microRNA; PO4, phosphate; OH, 
hydroxyl group). 
 
2.3.4 Proliferation assay 
 
Cell proliferation was measured using the IncuCyte Zoom live cell analysis system (Essen 
Bioscience, Ann Arbor, Michigan, United States). Cells were seeded into 10 cm tissue 
culture dishes (Corning Inc.) using a concentration of 720,000 cells for the IHH cell line 
and 1,345,000 cells for the Huh7 cell line and transfected as described in Section 2.3.2. At 
24 hours post-transfection with the selected miRNA mimic or negative control, 
respectively, cells were re-seeded into a 24 well tissue culture plate (Corning Inc., New 
York, United States) using 2 mL of the respective media and the following concentrations: 
IHH cells with 15,000 cells per well and Huh7 cells with 50,000 cells per well. MiRNA 
negative control and miRNA mimic transfected cells were seeded with 4 replicates each. 
Cells were then incubated in the Zoom analysis system following the manufacturer’s set-
up instructions. The cell growth was measured every 3 hours for up to 5 days and data 
collected using the IncuCyte software. Of note, the remainder of the transfected cells were 
centrifuged at 1000 g for 3 minutes and the derived cell pellet re-suspended in 300 µL RLT 
buffer (Qiagen). The cell pellet was then stored at minus 20 ˚C prior to RNA purification. 
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2.3.5 Migration assay 
 
Cell migration was measured using the IncuCyte Zoom live cell analysis system (Essen 
Bioscience). Both cell lines were seeded into 10cm plate (Corning Inc.) using a 
concentration of 1000 000 cells for IHH cells and 1 500 000 for Huh7 cells. Transfection of 
cell lines followed the protocol described in Section 2.3.2. At 6 hours post-transfection with 
the selected miRNA mimic or negative control, respectively, cells were re-seeded into a 96 
well Image Lock Plate (Essen Bioscience). Both cell lines, IHH and Huh7, were seeded at 
a density of 60,000 cells per well with 100 µL of the cell line specific media. MiRNA mimic 
and control transfected cells were both seeded using 12 replicates each. In parallel, the 
remainder of transfected cells were seeded into a 6-well tissue culture plate (Greiner Bio-
One) at a cell density of 200,000 cells per well for each cell line.  
 
At 18 hours post re-seeding, the cells were scratched using the Scratch Wound Maker 
(Essen Bioscience) following the manufacturer’s instructions. Cells were incubated in the 
Zoom analysis system following the manufacturer’s set-up instructions. Cell migration was 
measured every hour for 24 hours in total. In parallel, the remainder of the transfected 
cells in the 6-well tissue culture plate (Greiner Bio-One) were harvested and centrifuged at 
1000 g for 3 minutes. The derived cell pellet was then re-suspended in 300 µL RLT buffer 
(Qiagen) and stored at minus 20 ˚C for RNA purification. Cell migration data were 
collected using the IncuCyte software. Of note, only wells with successful (clean defined 
edges) scratch wounds, confirmed using IncuCyte imaging (Essen Bioscience), were 
selected for cell migration analysis.  
 
2.4 Nucleic acid purification 
2.4.1 RNA isolation from cells 
 
The mRNA from cells was extracted using the RNeasy® Mini Kit (Qiagen) following the 
manufacturer’s instructions (Protocol Part 1) using the following specifications: Cells were 
harvested as cell pellet and lysed using 350 µL RLT buffer. The optional centrifugation 
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step to dry the RNeasy column was performed as per protocol. RNA elution was 
performed with a total volume of 40 µL of nuclease-free water. Following the protocol’s 
suggestion for low yield samples the elution step was repeated using the eluate from the 
previous step. 
 
2.4.2 Total RNA isolation (containing miRNA) from cells 
 
The isolation of RNA containing miRNA from cells was performed using a modified 
protocol of the RNeasy® Mini Kit (Qiagen). Following the Qiagen supplementary protocol, 
the RNeasy Protocol included the following modifications: Cells were harvested as cell 
pellet and lysed using 350 µL RLT. Following this, 1.5 volumes of ethanol was added to 
the lysate prior to proceeding with the manufacturer’s protocol. During the washing steps 
the RW1 buffer was replaced by the RWT buffer supplied separately (Qiagen). The 
optional centrifugation step to dry the RNeasy column and repeated elution step using the 
same eluate was performed as per the manufacturer’s suggestion. RNA was eluted in a 
final volume of 40 µL nuclease-free water.  
 
2.4.3 Phenol based miRNA isolation from serum samples 
 
RNA was extracted from 200 µL of serum using the miRNeasy Serum/Plasma Kit 
(Qiagen). Isolations were performed according to manufacturer’s instructions with minor 
modifications to optimise results. Following the phenol-chloroform phase separation, the 
interphase and organic layers were rehydrated with nuclease free water equal to the 
volume removed during the aqueous phase collection.254 Thus, a second aqueous phase 
was obtained maximizing RNA recovery. Both aqueous phases were combined into one 
RNeasy MiniElute spin column and RNA isolation was continued.254 Following RNA 
elution, a second elution with identical settings was performed using 14 µL nuclease-free 
water in a new collection tube. 
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2.4.4 Phenol-free miRNA isolation from serum samples 
 
RNA was extracted from 200 µL serum using the Plasma/Serum RNA Purification Mini Kit 
(Norgen Biotek Corp; Thorold, Ontario, Canada) following the manufacturer’s instructions 
with minor modifications. Prior to transferring the sample onto the Micro Spin Column, the 
mixture was passed through a syringe with a 26 gauge (G) needle to break down lysis 
debris and prevent column clogging. RNA was eluted in 15 µL of nuclease free water and 
assessed on a NanodropTM. 
 
2.5 Nucleic Acid quantification 
2.5.1 NanodropTM spectrophotometer 
 
Serum haemolysis was assessed by the measurement of the optical density at 414 nm 
using the NanodropTM 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, United States). Prior to haemolysis quantification, a reference spectrum 
was measured using ultrapure Milli-Q water (Merck Millipore, Burlington, Massachusetts, 
United States). RNA concentrations were measured using a reference spectrum of 
nuclease-free water absorbance measurements at 260 nm and 280 nm. All measurements 
used a sample volume of 1 µL and a default baseline normalisation of 340 nm. All 
measurements were performed following the manufacturer’s instructions. 
 
2.5.2 Bioanalyzer microfluidics-based electrophoresis 
 
RNA quality was assessed and quantified using the Agilent Bioanalyzer 2100 
microfluidics-based electrophoresis platform (Agilent Technologies, Santa Clara, 
California, United States). The RNA 6000 Pico Kit was used to assess sample quality and 
quantity for total RNA samples, whereas the Small RNA Kit was used for miRNA 
assessments. The measurements were performed following the manufacturer’s 
instructions with one minor modification. Prior to analysis, all samples were diluted 5-fold 
before loading 1 µL onto the respective RNA chip. RNA concentrations were measured 
42 
 
using a reference ladder for total RNA or small RNA, respectively, supplied by the 
manufacturer (Agilent Technologies). Total RNA quality was reported as RNA Integrity 
Number (RIN) score and RNA concentration in pg/µL A RIN quality cut-off of ≥ 7 was used 
to assure high sample quality. Small RNA was reported as miRNA/small RNA ratio with 
miRNA concentration given as pg/µL. 
 
2.6 Reverse transcription and RNA expression analysis 
2.6.1 Reverse Transcription of phenol based and phenol-free miRNA isolation from 
serum samples or total RNA isolation from cells 
 
Serum-extracted RNA was reverse transcribed (RT) using the miScript II RT Kit (Qiagen) 
following the manufacturer’s instructions. RNA was quantified using the NanodropTM 
spectrophotometer (Thermo Fisher Scientific) to calculate RT reactions using 250 ng RNA 
for all miScript miRNA PCR Arrays. Individual primer-based serum miRNA quantitative real 
time-polymerase chain reactions (qRT-PCR) used a fixed volume of 4 µL. All 
complementary DNA (cDNA) products were diluted 10-fold before proceeding to PCR use. 
Cell line derived miRNAs were reverse transcribed using 250 ng RNA input in each 
reaction. Resulting cDNA products were diluted 10 fold before qRT-PCR.  
 
2.6.2 Reverse transcription of phenol-free miRNA isolation from serum samples  
 
Extracted RNA was reversed transcribed using the miRCURY LNATM universal RT 
microRNA PCR Kit (Exiqon, Vedbaek, Denmark) following manufacturer’s instructions. All 
reverse transcription reactions used a fixed RNA volume input of 4 µL (at the 
manufacturer’s suggestion) due to limitations in quantifying circulatory miRNAs. cDNA 
products were diluted 1:40 prior to qRT-PCR use. 
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2.6.3 Reverse transcription of mRNA isolation from cells 
 
Total RNA was reverse transcribed using the SensiFASTTM cDNA Synthesis Kit (Bioline, 
Luckenwalde, Germany) following the manufacturer’s instructions. RNA input for all 
reverse transcription reactions was 500 ng. RT products were diluted 1:5 prior to qRT-PCR 
use.  
 
2.6.4 Quantitative real-time polymerase chain reaction of phenol based and phenol-
free miRNA isolation from serum samples or total RNA isolation from cells 
 
The Human Liver miFinder miScript miRNA PCR Array (MIHS-3116ZG; Qiagen) is a qRT-
PCR based microarray, measuring the expression of 372 liver-related miRNAs 
simultaneously. All reactions were set-up following the manufacturer’s instructions and the 
following qRT-PCR was performed using the Lightcycler 480 (Roche Holding AG, Basel, 
Switzerland) using the cycling conditions as recommended by Qiagen.  
 
The miScript SYBR® Green PCR Kit (Qiagen) was used to perform qRT-PCR reactions 
with the miRNA primers detailed in Table 2.4 and the commercially available RNU6-2 
primer (Hs-RNU6-2_11, catalogue number MS00033740, Qiagen). The reaction set-up 
was performed according to manufacturer’s instructions with minor modifications. All 
primers described in Table 2.4 were designed using miRPrimer v2.0255 and manufactured 
by Integrated DNA Technologies. Each qRT-PCR reaction used a primer concentration of 
0.5 µM in the final reaction volume and 2 µL of template cDNA (see Section 2.6.1). All 
qRT-PCRs were performed on the CFX384 Touch™ Real-Time PCR Detection System 
(Bio-Rad Laboratories, Hercules, California, United States) using the cycling conditions as 
recommended by Qiagen. All samples were assessed for valid melt temperature reading 
to exclude false positive signals based on primer dimer or non-specific target amplification. 
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Table 2.4. MiRNA primer used with miScript miRNA PCR system. 
miRNA Name miRNA Sequence (5’ to 3’) miRNA Primer (5’ to 3’) 
hsa-let-7a-3p CUAUACAAUCUACUGUCUUUC CGCAGCTATACAATCTACTGTC 
hsa-let-7c-5p UGAGGUAGUAGGUUGUAUGGUU GCAGTGAGGTAGTAGGTTGT 
hsa-let-7f-5p UGAGGUAGUAGAUUGUAUAGUU CGCAGTGAGGTAGTAGATTG 
hsa-let-7i-5p UGAGGUAGUAGUUUGUGCUGUU GCAGTGAGGTAGTAGTTTGTG 
hsa-miRNA-101-3p UACAGUACUGUGAUAACUGAA GCGCAGTACAGTACTGTG 
hsa-miRNA-10a-5p UACCCUGUAGAUCCGAAUUUGU
G 
GCAGTACCCTGTAGATCCGA 
hsa-miRNA-10b-5p UACCCUGUAGAACCGAAUUUGU
G 
CAGTACCCTGTAGAACCGA 
hsa-miRNA-127-3p UCGGAUCCGUCUGAGCUUGGCU GGATCCGTCTGAGCTTG 
hsa-miRNA-144-3p UACAGUAUAGAUGAUGUACU AGCGCAGTACAGTATAGATGA 
hsa-miRNA-146a-5p UGAGAACUGAAUUCCAUGGGUU GCAGTGAGAACTGAATTCCA 
hsa-miRNA-151a-5p UCGAGGAGCUCACAGUCUAGU AGTCGAGGAGCTCACAG 
hsa-miRNA-223-5p CGUGUAUUUGACAAGCUGAGUU GCAGCGTGTATTTGACAAG 
hsa-miRNA-22-3p AAGCUGCCAGUUGAAGAACUGU GAAGCTGCCAGTTGAAGA 
hsa-miRNA-27b-3p UUCACAGUGGCUAAGUUCUGC GCAGTTCACAGTGGCTAAG 
hsa-miRNA-423-3p AGCUCGGUCUGAGGCCCCUCAG
U 
GCAGAGCTCGGTCTGAG 
hsa-miRNA-451a AAACCGUUACCAUUACUGAGUU CGCAGAAACCGTTACCA 
hsa-miRNA-486-5p UCCUGUACUGAGCUGCCCCGAG GCAGTCCTGTACTGAGCTG 
hsa-miRNA-493-3p UGAAGGUCUACUGUGUGCCAGG GCAGTGAAGGTCTACTGTGT 
hsa-miRNA-93-5p CAAAGUGCUGUUCGUGCAGGUA
G 
GCAAAGTGCTGTTCGTG 
(Abbreviations: hsa, Homo sapiens; miRNA, microRNA; PCR, polymerase chain reactions) 
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2.6.5 Quantitative real-time polymerase chain reaction of phenol-free miRNA 
isolation from serum samples 
 
Following cDNA preparation (see Section 2.6.2), qRT-PCR reactions were prepared using 
the miRCURY LNATM universal RT microRNA PCR system (Exiqon). Reactions have been 
set-up following the manufacturer’s instructions using primers as listed in Table 2.5. All 
qRT-PCRs were performed on the CFX384 Touch™ Real-Time PCR Detection System 
(Bio-Rad Laboratories) using Exiqon recommended cycling conditions. All samples were 
assessed for valid melt temperature reading to exclude false positive signals based on 
primer dimer or non-specific target amplification. 
 
2.6.6 Quantitative real-time polymerase chain reaction of mRNA isolation from cells 
 
Following cDNA preparation, as described in Section 2.6.3, the Platinum SYBR Green 
qPCR Super Mix-UDG (Thermo Fisher Scientific) was used for mRNA qRT-PCRs. All 
reactions were prepared following the manufacturer’s instructions with minor modifications. 
Reactions were performed in a total volume of 10 µL containing 5 µL Platinum SYBR 
Green, 2 µL nuclease-free water, 1 µL primer mix and 2 µL cDNA template. QuantiTect® 
Primer Assays (Qiagen) have been diluted following the manufacturer’s instructions and 
the final reaction used a concentration of 1x. The self-designed primer Hif1α (forward 
primer 5’GCAGCAACGACACAGAAACTGAT’3 and reverse primer 
5’AGCGGTGGGTAATGGAGACATT’3) used a concentration of 5 µM for each primer and 
was manufactured by Integrated DNA Technologies.  
 
PCRs were performed on the CFX384 Touch™ Real-Time PCR Detection System (Bio-
Rad Laboratories) using the following cycle conditions: 50˚C for 2 minutes, 95˚C for 2 
minutes, 40 cycles of 95˚C for 15 seconds and 60˚C for 30 seconds followed by a melt 
curve measurement. All samples were assessed for valid melt temperature reading to 
exclude false positive signals based on primer dimer or non-specific target amplification. 
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Table 2.5. MiRNA target sequences for commercially available miRCURY PCR 
primers. 
(Abbreviations: hsa, Homo sapiens; miRNA, microRNA; No, number; PCR, polymerase 
chain reaction). 
  
miRNA 
name 
Description Target Sequence (5’ to 3’) Product No. 
(Exiqon) 
let-7i-5p 
hsa-let-7i-5p LNA™ PCR 
primer set 
UGAGGUAGUAGUUUGUGCUGUU 204394 
miRNA-122-
5p 
hsa-miRNA-122-5p LNA™ 
PCR primer set 
UGGAGUGUGACAAUGGUGUUUG 205664 
miRNA-142-
3p 
hsa-miRNA-142-3p LNA™ 
PCR primer set 
UGUAGUGUUUCCUACUUUAUGGA 204291 
miRNA-149-
3p 
hsa-miRNA-149-3p LNA™ 
PCR primer set 
AGGGAGGGACGGGGGCUGUGC 204093 
miRNA-
151a-5p 
hsa-miRNA-151a-5p LNA™ 
PCR primer set 
UCGAGGAGCUCACAGUCUAGU 204007 
miRNA-19b-
3p 
hsa-miRNA-19b-3p LNA™ 
PCR primer set 
UGUGCAAAUCCAUGCAAAACUGA 204450 
miRNA-22-
3p 
hsa-miRNA-22-3p LNA™ 
PCR primer set 
AAGCUGCCAGUUGAAGAACUGU 204606 
miRNA-
2277-3p 
hsa-miRNA-2277-3p LNA™ 
PCR primer set 
UGACAGCGCCCUGCCUGGCUC 2E+06 
miRNA-23a-
3p 
hsa-miRNA-23a-3p LNA™ 
PCR primer set 
AUCACAUUGCCAGGGAUUUCC 204772 
miRNA-409-
3p 
hsa-miRNA-409-3p LNA™ 
PCR primer set, UniRT 
GAAUGUUGCUCGGUGAACCCCU 204358 
miRNA-
4758-3p 
hsa-miRNA-4758-3p LNA™ 
PCR primer set 
UGCCCCACCUGCUGACCACCCUC 2E+06 
miRNA-4767 
hsa-miRNA-4767 LNA™ 
PCR primer set 
CGCGGGCGCUCCUGGCCGCCGC
C 
2E+06 
miRNA-486-
5p 
hsa-miRNA-486-5p LNA™ 
PCR primer set 
UCCUGUACUGAGCUGCCCCGAG 204001 
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Table 2.6. Commercial primers for SYBR green PCRs. 
(Abbreviations: Hs, Homo sapiens; No, Number; PCR, polymerase chain reaction; SG, 
SYBR Green). 
 
 
Gene name Assay name Product No. Supplier 
ACTB Hs_ACTB_1_SG QT00095431 Qiagen 
EGFR Hs_EGFR_1_SG QT00085701 Qiagen 
ELK3 Hs_ELK3_1_SG QT00202293 Qiagen 
EP300 Hs_EP300_1_SG QT00094500 Qiagen 
ITGA2 Hs_ITGA2_1_SG QT00086695 Qiagen 
MAP2K5 
(MEK5) 
Hs_MAP2K5_1_SG QT00019082 Qiagen 
MET Hs_MET_1_SG QT00023408 Qiagen 
PTEN Hs_PTEN_1_SG QT00086933 Qiagen 
ROCK2 Hs_ROCK2_1_SG QT00011165 Qiagen  
UBE2H Hs_UBE2H_1_SG QT00048937 Qiagen 
XPO4 Hs_XPO4_1_SG QT00074662 Qiagen 
YAP1 Hs_YAP1_1_SG QT00080822 Qiagen 
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2.6.7 RNA library preparation and sequencing 
 
Double stranded RNA libraries were prepared using the TruSeq RNALibrary Prep Kit 
(Illumina, Inc., San Diego, California, United States) following the manufacturer’s 
instructions. All libraries used an input of 200 ng RNA. The sequencing itself was 
performed on the NextSeq500 (Illumina Inc.) using 2 x 75 base pair (bp) high output runs 
with set-up following the manufacturer’s instructions. 
 
Library preparation and sequencing was performed through the sequencing facility at the 
Institute for Molecular Biosciences (St Lucia, Queensland, Australia). 
 
2.6.8 Small RNA library preparation and sequencing 
 
Small RNA libraries were prepared using the NEBNext® Small RNA Library Prep Set (New 
England Biolabs, Ipswich, Massachusetts, United States) following the manufacturer’s 
instructions for Illumina platforms (i.e. multiplex compatible) with some modifications. 
Using circulating miRNAs isolated from serum samples, according to the protocol outlined 
in Section 2.4.4, generated low yield samples that were then used for library preparation. 
To address this, RNA input was set to a fixed volume of 6 µL per sample per library 
preparation. Dilutions within the protocol were performed using the dilution 
recommendations for low input RNA. PCR amplification was performed for 15 cycles in 
total, followed by sample clean-up using the Agencourt AMPure XP beads (Beckman 
Coulter Inc., Brea, California, United States) in a 2:1 ratio. Following size selection, 
samples were pooled for future multiplex application by pooling 12 samples at the time 
with equal volumes of 5 µL per sample. After pooling, size selection was repeated to 
remove high levels of adapter dimer. Of note, a gel cut was not performed as library yield 
was too low to be visualised.   
 
NGS was performed on the Illumina HiSeq2000 (Illumina, Inc.) platform, following the 
manufacturer’s instructions. The sequencing used the HiSeq SBS Kit V4 (Illumina Inc.) 
49 
 
and was performed on a single read flow cell. In total, 14 pM was loaded onto each 
sequencing lane and 10% PhiX was added to account for low sequencing diversity Data 
were generated using single-stranded reads of 50 bp sequencing length. 
 
Library preparation and sequencing was performed through the sequencing facility at the 
Queensland Brain Institute (St Lucia, Queensland, Australia). 
 
2.7 Bioinformatics 
2.7.1 Identification of endogenous reference miRNAs using distance metric 
 
Identification of endogenous reference miRNA within the miRNA microarray PCR used 
distance metric ranking, combining the P-values from the pairwise comparisons of 
comparing mild disease (F0-2) vs cirrhosis (F4) and comparing cirrhosis (F4) vs HCC. 
The resulting distance metric equation was as follows: 
 
𝑎𝑏𝑠(𝑙𝑜𝑔𝑝. 𝐻𝐶𝐶𝑣𝑠𝐹4) + 𝑎𝑏𝑠(𝑙𝑜𝑔𝑝. 𝐹4𝑣𝑠𝐹1.2) 
 
As shown in the equation above, the distance metric was calculated as the summation of 
the absolute value of the log transformed P-values, with “abs” defined as the absolute 
value of the log transformed P-value. 
 
2.7.2 Identification of endogenous reference miRNAs using NormFinder 
 
Within the NGS dataset, endogenous reference miRNA were determined using the 
NormFinder algorithm.256 The NormFinder add-in v0.953 for Microsoft Excel 2010 
(Microsoft, Redmond, Washington, United States) was used, following the NormFinder 
documentation v20 (MOMA, Department of Molecular Medicine, Aarhus University 
Hospital, Aarhus, Denmark). Potential endogenous reference miRNA were assessed 
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considering intra- and inter-group variation across study groups. This analysis resulted in a 
stability value for each potential reference miRNA, with the lowest stability value indicating 
most stable expression across the investigated dataset. 
 
2.7.3 Small RNA sequencing analysis 
 
The sequencing output was “de-multiplexed” using the bcl2fastq conversion software 
(Illumina Inc.), converting BCL files to FASTQ file formats. Overall sequencing quality was 
assessed using FASTQC version 0.11.7.257 Adapters and low quality reads were removed 
using trimmomatic.258  
 
Sequencing analysis was performed using the exceRpt small RNA sequencing pipeline 
version 4.6.2, developed by the Extracellular RNA Communication Consortium (ERC 
Consortium), implemented on the Genboree Workbench available under 
www.genboree.org/site/.259 Importantly, the exceRpt pipeline is designed to exclude 
possible contaminants such as ribosomal RNA through multiple layers of alignments and 
has been successfully applied to small RNA studies as shown by Freedman et al.260 
 
Novel miRNA identification was performed using the mirPRo pipeline version 1.1.4261 with 
human genome assembly from Genome Reference Consortium Build 38 Ensembl release 
92 and miRNA mature sequence/hairpin annotation from miRBase132-136 release 22. The 
complete mirPRo analysis was performed on Ubuntu 18.04 Linux using the following sub-
applications: Novoalign version 3.02.12 (Novocraft Technologies, Petaling Jaya, Selangor, 
Malaysia), RNAfold version 2.1.9262 and HTseq version 0.6.1p.263 MiRNA structure 
prediction was performed using RNAstructure version 6.0.1.264 Localisation of novel 
targets was performed using BLAST.265 
 
Sequencing analysis was performed with the assistance of Dr Derek Sarovich (University 
of the Sunshine Coast, Sippy Downs, Queensland, Australia) and Dr Michael Pearen 
(QIMR Berghofer MRI, Herston, Queensland, Australia). 
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2.7.4 RNA sequencing analysis  
 
The sequencing output was “de-multiplexed” using the bcl2fastq conversion software 
(Illumina Inc.), converting BCL files to FASTQ file format. Sequencing reads were adapter 
trimmed using Cutadapt (version 1.11)266 and aligned using STAR (version 2.5.2a)267 to 
the GRCh37 assembly with the gene, transcript and exon features of the Ensembl (release 
70) gene model. Quality control metrics were completed using RNA-SeQC (version 
1.1.8).268 Expression was estimated using RSEM version 1.2.30.269  
 
Sequencing analysis was performed with the assistance of Dr Stephen Kazakoff (QIMR 
Berghofer MRI, Herston, Queensland, Australia). 
 
2.7.5 Ingenuity Pathway Analysis and miRNA target prediction 
 
The differentially expressed miRNA targets identified through the pull-down assay and 
analysed in Sections 2.7.4 and 2.8.4, were uploaded into Ingenuity Pathway Analysis (IPA, 
Qiagen). Targets were selected with significance defined as p < 0.05 and fold change (FC) 
> 1.5. Each pull-down was analysed individually, assessing top canonical pathways and 
involvement of pathways of interest. 
 
MiRNA target prediction was performed for miRNA 151a-5p and miRNA-486-5p using the 
miRDB270, 271 and TargetScan167, 272-275 algorithms. The resulting mRNA targets were 
uploaded into IPA (Qiagen). To compare target prediction (via miRDB and TargetScan) to 
pull-down performance a comparison analysis was performed between the pull-down 
dataset and the miRDB and TargetScan target list, with subsequent lists merged together 
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2.8 Statistical analysis 
2.8.1 Statistical analysis of patient demographics 
 
Statistical analysis of patient demographics was undertaken using the chi-square test for 
categorical variables, and either an analysis of variance (ANOVA), Kruskal-Wallis test, 
unpaired t-test or Mann-Whitney test for continuous variables as informed by the 
D'Agostino & Pearson normality test. Significance was defined as a p < 0.05. All 
calculations were performed using GraphPad Prism v.7 (GraphPad Software, La Jolla, 
California, USA). 
 
2.8.2 Microarray power calculations, normalisation and differential expression 
analysis 
 
Power calculations for microarray assays are critical for appropriate study design and 
sample size determination.276 This study was designed using false-discovery rate based 
power calculations. Assuming that 5% of microRNAs are truly differentially expressed and 
accepting a false-discovery rate of 10%, only n=14 patients would be required in each 
group to detect a significant fold change in microRNA expression (2-fold) with 80% 
certainty.  
 
The microarray data were normalised using quantile normalisation.277-279 During the 
normalisation of the microarray data the highest CP (Crossing Point) value in the test 
distribution was normalised by replacing it with the mean of the highest values. Next, the 
second highest value on each array was replaced with the average of the second highest 
values. This continued iteratively until all quantiles were exhausted leaving a normalised 
data set. Differentially expressed miRNAs were identified by performing a modified t-test 
comparing the groups of interest. All calculations were performed using the limma package 
on R (version 3.3.3).280 
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2.8.3 PCR normalisation and differential expression analysis 
 
The qRT-PCR data of mRNA expression studies were analysed using the 2-ΔΔCP method, 
based on the Livak method,281 normalising the relative expression of all samples to an 
endogenous reference RNA and an internal control group. Analysis of miRNA expression 
data from qRT-PCR experiments was performed using a modified version of the Livak 
method (2ΔCP) using an endogenous reference miRNA. All self-designed primers were 
assessed for primer efficiency and differential expression of genes assessed with self-
designed primers was analysed using the Pfaffl method.282 
 
Statistical analysis of relative expression data was calculated using an unpaired t-test 
(comparison of two study groups), or a one-way ANOVA with Tukey’s post hoc pairwise 
comparison (comparison of three or more study groups). Statistical significance was 
defined as p < 0.05. Outlier testing was performed using the robust regression and outlier 
removal (ROUT) method.283 The statistical analysis was performed using GraphPad Prism 
v.7 (GraphPad Software). 
 
2.8.4 Sequencing power calculations and differential expression analysis 
 
Based on findings of Hart et al284 and assuming the sequencing has a depth of 20X, the 
sample size for sequencing based studies would need to be n=10 to ensure the detection 
of fold change of two or higher with a power of 80% and a significance of 0.05. These 
calculations used a coefficient of variation of less than 0.5.  
 
MiRNA differential expression analysis was performed using Degust, a web-based RNA-
sequencing visualisation software available under http://degust.erc.monash.edu/. 
Differential expression across all groups was analysed using the Voom/Limma method.285, 
286 Statistical significance was defined as false discovery rate adjusted P-value < 0.05 and 
a log fold change (logFC) ≥ 2. All selected comparisons use logFC relative to the study 
control group. 
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Differential expression analysis was performed using edgeR.287, 288 Visualisation was 
performed using gplots.289 Statistical significance defined as a false discovery rate 
adjusted P-value < 0.05 and a fold change > 1.5 or a log fold change (logFC) >0.6. The 
complete analysis was performed on R (version 3.3.3)280 
 
2.8.5 Panel design, ROC curves and k-fold cross-validation 
  
Stepwise logistic regression using forward selection and backward elimination was used to 
derive miRNA panels. Pairwise correlations between each of the miRNA were assessed to 
exclude any significant correlations within the models at the 5% level of significance. 
Model selection was based on the Akaike Information Criteria, the likelihood ratio test 
based on the change of the residual deviance, and by assessing the stability of the 
coefficient estimates. 
 
The resulting model equation was as follows: 
ln (
pᵢ
1-pᵢ
) = Intercept + ∑ Slopek x ∆CPmiRNAk
k
k=1
 
 
Where 𝑘 is the number of miRNAs in the panel and intercept is the 𝑦- Intercept value, 
Slopek is the slope of the regression corresponding to the 𝑘th miRNA (∆CPmiRNAk).  
 
To obtain the 𝑝𝑖 , the probability of the i
th subject having an outcome uses the following 
formula where function is the right-hand side of the equation in Function used: 
𝑝𝑖 =
1
1 +  exp  (−𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛)
 
 
The probability 𝑝𝑖 ranges from 0 to 1.  
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The Youden’s index is a technique used to determine the most appropriate cut-off value, 
which corresponds to a point on the ROC curve with the highest vertical distance from the 
45% diagonal line. At this point, the true positive rate and the false positive rate is at the 
maximum optimised.290 Using the Youden’s index a panel specific cut-point for 𝑝𝑖 was 
determined.  
 
K-fold cross-validation (5-fold), a statistical technique to evaluate a predictive model with a 
limited data sample, was used to assess the performance of the selected miRNA panels. 
Univariate and multivariable analyses were used to perform receiver operating 
characteristic (ROC) curve analyses resulting in an area under the curve (AUC) with a 
95% confidence interval (95% CI), sensitivity (Sens), specificity (Spec), positive predictive 
value (PPV), negative predictive value (NPV), and accuracy. All miRNA panel calculations 
were performed using the cvAUC and the ROCR package on R (version 3.3.3)280, whereas 
ROC curve analysis of individual miRNAs were performed on GraphPad Prism v.7 
(GraphPad Software). 
  
2.8.6 Statistical analysis of proliferation and migration assays. 
 
The raw dataset for proliferation and migration assays was exported from IncuCyte Zoom 
software (Essen Bioscience) and analysed in GraphPad Prism v.7 (GraphPad Software). 
The proliferation assay data was analysed performing baseline correction and nonlinear 
regression using one-phase association. In addition, the constraints Y0 = 0 and Plateau = 
100 were applied. Data output was selected to the rate constant (k) and standard error of 
the mean (SEM). Statistically significant differences in growth rates were determined using 
a ratio paired t-test with k of the miRNA of interest compared to k of control transfected 
cells. Proliferation was plotted as confluence percentage using mean and SEM of 
individual experiments. 
 
The migration data for 24 hours was evaluated in the IncuCyte Zoom software (Essen 
Bioscience) and only successful and consistently scratched replicates (n = 8) were 
exported into GraphPad Prism v.7 (GraphPad Software) for on-going analysis. The data 
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were then analysed using a normalisation with the following constraints: 0% defined as Y = 
0 and 100% defined as Y = 100 and nonlinear regression using one-phase association. 
Data output was selected to the rate constant (k) and standard error of the mean (SEM). 
Statistically significant difference in growth rates were determined using a ratio paired t-
test with k of the miRNA of interest compared to k of control transfected cells. Wound 
density was plotted using mean and SEM of individual experiments and was shown as a 
percentage. Both assays, proliferation and migration, used a minimum of n = 3 biological 
replicates and statistical significance was defined as P-value < 0.05.  
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CHAPTER 3                                                           
Identifying a microRNA signature in Hepatitis C-related 
cirrhosis and HCC……. 
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3.1 Introduction 
 
Chronic Hepatitis C (CHC) is an important cause of cirrhosis and contributes to the global 
burden of chronic liver disease worldwide. Cirrhosis and advanced (F3) fibrosis due to 
CHC are recognised as risk factors for the development of hepatocellular carcinoma 
(HCC), a cancer whose incidence and mortality is increasing.29 Chronic infection with the 
Hepatitis C virus (HCV) affects an estimated 80 million individuals worldwide.291 
 
New second-generation direct acting antivirals (DAA) are now available and have 
improved treatment of HCV by providing oral treatment options with excellent safety 
profiles and high sustained virological response (SVR) rates (reflective of complete viral 
eradication) with up to 98%.245 With the development of next-generation DAAs with pan-
genotypic activity, these outcomes are largely irrespective of patient or viral factors.292 The 
impact of these new treatments on the global burden of liver disease due to CHC, 
however, are critically dependent on when chronic infection is diagnosed (i.e. prior to the 
development of cirrhosis) and patient access to DAA therapy.293 As the CHC population 
ages, there is a higher probability of advanced fibrosis294 and cirrhosis, conferring an 
increased risk of incident HCC.295 Furthermore, despite DAA treatment, the burden of 
HCV-related HCC in most countries is still increasing and it is not expected to peak until 
the next decade.293, 294, 296 This raises some clinical imperatives; namely, to increase 
treatment and viral clearance rates, to accurately identify patients with cirrhosis, and to 
improve diagnostic tests for HCV-related HCC.  
 
With the advent of improved SVR rates, increasing data have emerged on the relationship 
between HCV viral eradication and improved patient outcomes. Achievement of an SVR 
has been shown to confer an all-cause mortality benefit for patients with CHC.245 Patients 
with cirrhosis also enjoy an improvement in liver synthetic function after treatment with 
DAAs, meaning that many patients can be de-listed from liver transplant waiting lists.245 
There are conflicting study results, however, on the incidence of HCC following DAA 
treatment. Initial studies from Italian and Spanish cohorts found an increased incidence of 
HCC following treatment with DAAs. 297-299 In contrast, a recent meta-analysis suggests no 
difference in HCC occurrence between previous interferon-based treatments and DAA.300 
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Indeed, it is now widely recommended that CHC treatment with DAAs generally reduces 
the overall risk of HCC in the CHC population.245 Nevertheless, whilst achieving a SVR 
has been shown to improve liver function in cirrhotic patients and overall survival, an 
absolute risk of complications like HCC remains.301 This highlights the importance of 
correctly identifying patients with cirrhosis prior to DAA treatment.  
 
The gold standard for the identification of cirrhosis for the purposes of HCC surveillance is 
liver biopsy but this is invasive and prone to sampling error.302 Indeed, despite being the 
gold standard, biopsy is now rarely used as a routine part of the assessment of most 
patients with CHC. Non-invasive tools, such as liver stiffness assessment (e.g. transient 
elastography, shearwave elastography) have been employed to screen CHC patients for 
cirrhosis but there is still a clinically-relevant indeterminate range that adversely affects 
test accuracy and reliability.62 Non-invasive biomarker panels, such as the APRI58 and 
FIB-460, 250 scores, provide good sensitivity and specificity within defined cut-offs58 but 
values falling short of these thresholds lack diagnostic accuracy. There are now a number 
of proprietary non-invasive serum biomarker panels that have also been validated in 
fibrosis staging across a range of chronic liver diseases, but these are similarly limited by a 
substantial indeterminate range that fails to reliably distinguish cirrhosis from moderate 
fibrosis.50, 58, 60, 70 Access to many of these non-invasive tools is also sometimes limited to 
specialist treatment, pathology or imaging facilities. 
 
The only currently-accepted HCC tumour biomarker, alpha-fetoprotein (AFP), generally 
has suboptimal sensitivity and specificity for surveillance and diagnosis in most cases.113, 
115 Routine HCC surveillance comprises 6-monthly ultrasound scans with dynamic 
scanning (CT/MRI) employed to further characterise suspicious lesions. This approach 
does not confirm the diagnosis for all tumours, particularly for early, small HCCs. This is 
the case for 14-23% of indeterminate lesions, where the imaging is inconclusive and 
diagnosis is delayed until interval growth consistent with malignancy can be demonstrated 
on follow-up imaging.114, 303 By definition, this impedes early access to definitive (and 
potentially curative) treatment. The literature suggests that, although the sensitivity and 
specificity of ultrasound-based diagnostic strategies exceeds 90% for detection of HCC 
across all stages, its sensitivity is only 63% for early HCC.113  
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Novel molecules, such as miRNAs, are being actively investigated for their diagnostic and 
prognostic potential as non-invasive biomarkers. As discussed in Section 1.3, miRNAs are 
small non-coding RNAs involved in the regulation of gene expression at a post-
transcriptional level. The stability of miRNAs in the circulation, as well as both healthy and 
diseased tissue, highlights their potential to function as biomarkers.235 Patient serum 
represents an especially attractive potential non-invasive biomarker source for the 
quantification of miRNA expression levels as sampling is minimally invasive and easily 
repeatable. While miRNAs have also been quantified in tissue specimens (from tumour 
and healthy tissue), the use of biopsy effectively limits the utility of tissue-based miRNA 
analysis as a routine diagnostic test. The involvement of miRNAs in chronic liver disease 
such as viral hepatitis, hepatic fibrosis and HCC has been discussed extensively 
elsewhere.211, 212, 215 In CHC and CHC-related HCC, preliminary studies of miRNAs have 
identified some promising candidates but these results require further validation.239, 240 To 
improve diagnostic accuracy, the development of panels of the most promising miRNA 
candidates are now being explored to differentiate disease severities and identify HCC. 
 
3.2 Aims and hypothesis 
 
It was hypothesized that serum miRNAs exhibit differential expression across the 
spectrum of CLD stages in chronic Hepatitis C (CHC) patients, including those with HCC. 
It was further hypothesized that a combination of miRNA candidates could outperform, or 
be used to improve the performance of, currently accepted non-invasive biomarkers to 
improve diagnostic performance. 
 
The first aim of this thesis, therefore, is: 
A.  To identify differentially-expressed serum miRNAs in patients with differing 
severities of HCV-related CLD and identify candidate miRNAs that could be used as non-
invasive biomarkers to distinguish (i) mild disease (i.e. no fibrosis to moderate fibrosis, F0-
2) from cirrhosis, and (ii) cirrhosis complicated by HCC from cirrhosis alone; and  
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B.  to design miRNA panels and assess their performance in distinguishing disease 
stages alone and/or in combination with APRI and Fib-4 biomarker panel and the tumour 
marker alpha-fetoprotein (AFP). 
 
3.3 Material and methods 
3.3.1 Patient recruitment and characteristics 
 
Sixty HCV-positive patients were retrospectively subdivided into 3 disease cohorts: mild 
disease without advanced fibrosis (F0-2; n = 20); cirrhosis (F4; n = 20); and cirrhosis with 
HCC (HCC; n = 20). Patient recruitment and staging criteria as well as data collection 
methods have been described in detail in Section 2.1. Briefly, enrolled patients were all 
existing patients of the Royal Brisbane and Women’s Hospital Liver Clinic whose disease 
severity and associated complications were diagnosed based on routine expert specialist 
assessment (Section 2.1) according to accepted professional guidelines. 
 
3.3.2 RNA extractions, reverse transcription, microarray and qRT-PCR. 
 
For the initial screening phase, miRNA was isolated using the miRNeasy Serum/Plasma 
Kit (Qiagen; see 2.4.3). Extracted miRNA was reverse transcribed using the miScript II RT 
Kit (Qiagen) and qRT-PCR performed using the miRNA PCR Array (Human Liver miFinder 
miScript miRNA PCR Array MIHS-3116ZG; Qiagen). The protocol has been described in 
detail in Sections 2.6.1 and 2.6.4. 
 
In the validation phase, miRNA was re-isolated using the matched samples from the same 
patients tested in the initial screening phase. Isolation of miRNA was performed using the 
Plasma/Serum RNA Purification Mini Kit (Norgen Biotek Corp). Extracted miRNA was 
reversed transcribed using the miRCURY LNATM universal RT miRNA PCR Kit (Exiqon). 
The RNA extraction protocol is described in detail in Section 2.4.4 and the reverse 
transcription, and qRT-PCR protocols are described in detail in Sections 2.6.2 and 2.6.5.  
62 
 
3.3.3 Data normalisation and statistical analysis 
 
Following the screening phase, microarray data were obtained for the serum expression 
levels of 372 miRNAs from the study cohort of 60 patients. As the study involved 
quantification of a large number of miRNAs from a large number of patients, microarray 
assays were performed in batches using the same protocol on each occasion. Data from 
each microarray assay were qualitatively compared using a heat map to identify bias 
related to the timing of the assay (i.e. a “batch effect”) and the data were processed to 
adjust for any identified batch effect. In brief, this was achieved by transforming raw data 
onto a normal distribution scale and removing the batch effect by generating a general 
linear model, with the experimental batch number functioning as a predictor and the 
miRNA measurement as the outcome. Batch effect removal is based on an empirical 
calculation using a numerical model and, in essence, the batch effect is first isolated and 
then numerically subtracted from the data leaving a data set that is not dependent on 
batch effects304. To achieve this, from each batch, an estimate of the batch effect is 
derived using a two-way ANOVA and the estimate for each batch (based on a linear 
model) is added or subtracted from the overall individual observations. This process 
results in performance of the expression analysis on the linear model’s “residuals”, with the 
residuals ideally being orthogonal to any batch effect.  
 
Any miRNAs lacking valid observations were excluded. The data were further cleaned by 
regarding CP readings of ≥ 40 as “not measured” (i.e. no expression) and eliminating 
miRNAs with less than 15% valid observations. The microarray data were then normalised 
using quantile normalisation and analysed using the modified t-test comparing groups of 
interest (limma package, R), as described in detail in Section 2.8.2.  
 
For the qRT-PCR-based validation study, data from each study cohort were analysed 
using the 2ΔCP method and expression values were normalised to the expression levels of 
the housekeeper miRNAs let-7i-5p and miRNA-23a-3p. These endogenous reference 
miRNAs were selected based on a distance metric ranking combining the P-values from 
the pairwise comparisons of mild disease (F0-2) vs cirrhosis (F4) and cirrhosis (F4) vs 
HCC, as described in detail in Section 2.7.1. Significant differential expression was 
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assessed using one-way ANOVA with Tukey’s post hoc pairwise comparison, as 
described in Section 2.8.3. 
 
3.3.4 Panel design, ROC curves and k-fold cross-validation 
 
Stepwise logistic regression was used to derive miRNA panels. Following the miRNA 
panel design, as described in Section 2.8.4, 𝑝𝑖 was determined using the following 
equations: 
 
Function A: F4 vs F0-2 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = 4.03 – (0.89 × ∆CP miR-122-5p) – (0.83 × ∆CP miR-409-3p) 
 
Function B: HCC vs F4 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = 3.59 + (1.78 × ∆CP miR-122-5p) – (1.99 × ∆CP miR-486-5p) + (2.32 × ∆CP 
miR-142-3p) 
 
The performance of the miRNA panel was then assessed using ROC curve analysis and 
k-fold cross-validation, as described in Section 2.8.4.  
 
3.4 Results 
3.4.1 Patient characteristics 
 
Serum samples from 60 CHC patients were analysed in this study. Detailed patient 
demographics and the clinical characteristics of each cohort are described in Table 3.1. 
Retrospective allocation of patients to their respective study groups allowed clinical follow-
up for a mean period of 16.7 months (SD 7.2 months) for mild disease (F0-2) and 21.2 
months (SD 6.7 months) for cirrhotic (F4) patients. No decompensation events were 
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observed during the follow-up period. Cirrhotic patients with HCC were followed until a 
treatment endpoint (being surgical resection, locoregional therapy, transplant listing, or 
referral for best supportive care). The mean follow-up for cirrhotic patients with HCC was 
3.3 months (SD 3.0 months) from sample collection to treatment endpoint. There were no 
significant differences amongst the groups according to HCV genotypes or treatment 
histories (p > 0.05).  
 
Serum samples for miRNA testing were paired with routine laboratory assessment of 
disease status, with 95% of each patients’ samples taken within 4 months of each other. 
As expected, traditional markers of disease severity (e.g. ALT, AST, sodium and platelet 
levels) were significantly different amongst the three study groups (p < 0.001, p < 0.001, p 
= 0.002 and p < 0.001, respectively), whereas no significant differences were observed 
with creatinine levels. Patient cohorts were assembled according to their qualifying 
characteristics (i.e. fibrosis stage and presence of HCC) and were not prospectively 
matched. Statistical analysis using ANOVA with post hoc analysis revealed significant 
differences in platelet counts when comparing F0-2 vs. F4 (p = 0.001) and F0-2 vs. HCC 
(p < 0.001). Markers of hepatic function (i.e. bilirubin, albumin and INR) were significantly 
worse in cirrhotic patients with HCC compared with those with cirrhosis alone (all p < 
0.001). Interestingly, the tumour marker AFP was not significantly different between the F4 
and HCC groups. 
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Table 3.1. Demographic and clinical characteristics of patients across all study 
groups. 
  
Mild fibrosis 
 (n=20) 
Cirrhosis 
(n=20) 
HCC 
(n=20) 
P- 
value 
Gender1 
    
0.045 
 
Male (n/%) 10 (50%) 17 (85%) 15 (75%) 
 
 
Female (n/%) 10 (50%) 3 (15%) 5 (25%) 
 
Age (years)2 49.6 (SD 10.1) 53.8 (SD 7.4) 58.3 (SD 5.3) 0.004 
BMI2 
 
26.3 (SD 6.0) 27.2 (SD 5.1) 27.1 (SD 5.2) 0.864 
HCV genotype (n)1 
   
0.695 
 
1 1 (5%) - 2 (10%) 
 
 
1a 8 (40%) 8 (40%) 6 (30%) 
 
 
1b 3 (15%) 4 (20%) 2 (10%) 
 
 
Mixed 1/3 1 (5%) - - 
 
 
2 1 (5%) - - 
 
 
3 6 (30%) 6 (30%) 9 (45%) 
 
 
4 NA 1 (5%) NA 
 
 
Prior SVR NA 1 (5%) 1 (5%) 
 
HCV treatment history1 
   
0.065 
 
Treatment experienced 6 (30%) 6 (30%) 6 (30%) 
 
 
Treatment naïve 14 (70%) 14 (70%) 10 (50%) 
 
 
On DAA treatment - - 4 (20%) 
 
Baseline routine laboratory 
tests 
    
 
Sodium (mmol/L)2 138.5 (SD 2.7) 137.6 (SD 1.4) 135.9 (SD 2.4) 0.002 
 
creatinine (µmol/L)2 68.2 (SD 14.6) 71.3 (SD 13.4) 68.2 (SD 16.9) 0.761 
 
ALT (U/L)3,6 63.5 (IQR 46.0-
97.3) 
155.5 (IQR 105.5-
223.5) 
55 (IQR 34.3-
88.5) 
<0.001 
 
AST (U/L)3,6 39.5 (IQR 30.0-
70.3) 
123.5 (IQR 78.5-
235.0) 
75.5 (IQR 53.8-
101.3) 
<0.001 
 
Platelet (x109/L)2 226.3 (SD 57.6) 164.4 (SD 32.8) 124.7 (SD 63.2) <0.001 
 
bilirubin (µmol/L)4 NA 14.5 (SD 4.5) 25.3 (SD 10.0) <0.001 
 
albumin (g/L)4 NA 40.4 (SD 2.8) 33.7 (SD 6.1) <0.001 
 
Proximity of sample collection 
to baseline routine laboratory 
tests (months) 
1.47 (SD 6.40) 
 
 
0.22 (SD 1.45) 0.01 (SD 0.76) NA 
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 Mild fibrosis 
(n=20) 
Cirrhosis 
(n=20) 
HCC 
(n=20) 
P- 
value 
Other laboratory tests 
    
 
INR4 NA 1.1 (SD 0.1) 1.2 (SD 0.1) <0.001 
 
AFP (µg/L)5,6 NA 5.8 (IQR 3.3-13.0) 8.6 (IQR 8.0-
21.3) 
0.129 
Sample collection to AFP 
(months) 
NA 0.03 (SD 2.48) 0.48 (SD 1.55) NA 
Clinical follow up (months) 16.7 (SD 7.2) 21.2 (SD 6.7) 3.3 (SD 3.0) NA 
Disease severity assessment 
Transient elastography LSM 
(kPa)4 
6.1 (SD 1.2) 19.2 (SD 8.5) NA <0.001 
FIB-
45,6 
 
1.2 (IQR 0.9-
1.9) 
3.2 (IQR 2.7-4.6) NA <0.001 
APRI5,6 
 
0.6 (IQR 0.3-
1.2) 
2.3 (IQR 1.1-4.5) NA <0.001 
CTP 
    
NA 
 
A NA 20 (100%) 8 (40%) 
 
 
B NA - 11 (55%) 
 
 
C NA - 1 (5%) 
 
MELD 
 
NA 7.31 (SD 0.67) 10.26 (SD 2.38) NA 
BCLC (n/%) 
   
NA 
 
0 NA NA 2 (10%) 
 
 
A NA NA 8 (40%) 
 
 
B NA NA 8 (40%) 
 
 
C NA NA 1 (5%) 
 
 
D NA NA 1 (5%) 
 
 
Following normality testing, P-values were calculated using the 1Chi-Square test, 2ANOVA, 
3Kruskal-Wallis test, 4unpaired t-test and 5Mann-Whitney test with significance defined as a 
P-value < 0.05. 6Data shown as median. Data are shown as mean values unless otherwise 
specified. (Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; APRI, 
aspartate aminotransferase to platelet ratio; AST, aspartate aminotransferase; BCLC, 
Barcelona clinic liver cancer; BMI, body mass index; CTP, Child-Turcotte-Pugh Score; 
DAA, direct acting antiviral drug; Fib-4; Fibrosis-4; HCC, hepatocellular carcinoma; HCV, 
Hepatitis C virus; INR, international normalized ratio; IQR, interquartile range; LSM, liver 
stiffness measurement MELD, model for end-stage liver disease score; NA, not applicable; 
SD, standard deviation; SVR, sustained virologic response). 
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3.4.2 MiRNA microarray screening phase 
 
To identify differential expression of circulating miRNA between (i) mild disease versus 
cirrhosis, and (ii) cirrhosis versus HCC, the Human Liver miFinder miScript miRNA PCR 
Array was used in 60 serum samples using the method outlined in Section 2.6.4. 
 
Preliminary analysis in n = 42 samples using quantile normalisation and pairwise 
comparison of all three groups suggested the presence of a batch effect. A trouble-
shooting process was undertaken to identify the cause of the batch effect. Technical 
variations in the process of miRNA isolation and cDNA preparation as well as array 
preparation and measurement were investigated. In addition, miRNAs were freshly 
isolated and possible ethanol and phenol contamination assessed by the use of a 
Spectrophotometer prior to testing (see Section 2.5.1). Freeze and thaw cycles of all 
samples and reagents were also minimised to ensure experimental conditions were 
optimal. All reagents used during the experimental work-flow were replaced in a step-wise 
fashion and calibration of all equipment used was confirmed before experiments were 
conducted. Human error was eliminated as cause of the batch effect by a comparing 
miRNA expression data generated by two different operators.  
 
Upon completion of this exhaustive process, two technical sources of the batch effect were 
identified. The first potential source of bias was decreased efficacy in the reverse 
transcription of miRNA to cDNA. The second potential source was the use of different Lot 
Numbers for the RT Kit and Liver miFinder Arrays. Overall reverse transcription and qPCR 
efficacy was assessed following the proprietary recommendation of miRTC QC- PPC QC ≤ 
7 (see Table 3.2). In this assessment, a lower value correlated with better overall array 
performance. This process took into account the steps of reverse transcription (miRTC 
QC) and the array performance itself (PPC QC). These results confirmed differences in the 
quality of reverse transcription efficacy between batches, although all met the proprietary 
threshold for quality control. 
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Table 3.2 Comparison of Qiagen specific microarray quality controls. 
 
Batch 1 Batch 2 Batch 3 Batch 4 
 
Median CP Median CP Median CP Median CP 
miRTC QC 24.24 25.07 26.16 27.19 
PPC QC 20.45 20.42 20.38 20.42 
miRTC 
QC-PPC QC 
3.79 4.65 5.78 6.77 
Comparison of Qiagen specific quality controls assessing reverse transcription efficacy 
(miRTC QC) and qPCR efficacy (PPC QC). Qiagen recommended overall quality control 
miRTC QC-PPC QC with a recommended cut-off value of ≤ 7. Data is displayed in median 
CP measurements of four different batches: Batch 1 (n = 36), Batch 2 (n = 6), Batch 3 (n = 
6), Batch 4 (n = 16). (Abbreviations: CP, Relative expression measured as crossing point 
value; miRTC QC, Qiagen reverse transcription quality control; miRTC QC-PPC QC, 
Qiagen recommended overall quality control cut-off calculations using reverse transcription 
quality control minus qPCR quality control; PPC QC, Qiagen qPCR efficacy quality 
control). 
 
Further troubleshooting was undertaken to improve RT efficacy and the experimental 
protocol was optimised. This included, but was not limited to, the use of different thermal 
cyclers, RT kits from new batches, and the replacement of used reagents to ensure 
nuclease-free workflow. To minimise technical variation as a source of bias, the study 
design was also adjusted. Instead of performing arrays as patients were enrolled, all 
miRNA isolation, cDNA preparation and array preparation and measurement was 
performed at the same time using the same Lot. No. for each kit and reagent required. 
This resulted in the performance of a total of n = 60 arrays divided into just two 
experimental batches (Batch 1 with n = 36 arrays; Batch 2 with n = 24 arrays). This data 
set was then plotted as a heat map to visualise any remaining batch effect (see Figure 
3.1).  
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Figure 3.1. Batch effect heat map. Heat map showing the clustering of Batch 1 (n = 36) 
and Batch 2 (n = 24). Data are shown as raw CP values. The clustering pattern, according 
to the “family tree” on the y-axis, suggests batch-specific clustering of miRNA expression 
and not clustering according to study groups or randomised clustering. (Abbreviations: CP, 
Crossing Point; miRNA, microRNA). 
 
MiRNA expression clustered impressively according to array batch, confirming the 
presence of a batch effect in the data set (see Figure 3.1). The batch effect was removed 
by transforming the raw data onto a normal distribution scale and cleaning the data, as 
described in Section 3.3.3. The remaining data set was normalised and a heat map re-
plotted, which confirmed removal of the batch effect (see Figure 3.2). 
70 
 
 
Figure 3.2. Re-distribution of miRNA expression on a heat map after removal of the 
batch effect. This heat map displays distribution of miRNA expression after generating a 
general linear model of Batch 1 and Batch 2 data to remove the batch effect followed by 
quantile normalisation. Random distribution of Batch 1 and Batch 2 data indicates 
successful batch effect removal, as indicated by the “family tree” in the x axis. Values 
show normalised expression on a normal distribution scale (Abbreviations: miRNA, 
microRNA). 
 
The resulting data set included 245 of the original 372 miRNAs measured on the array, 
following removal of 34 miRNAs, due to a lack of valid observations in both batches, and a 
further 93 miRNAs with less than 15% of valid observations (see Section 3.3.3). This data 
set was then analysed for differentially-expressed miRNAs using pairwise comparison of 
the groups of interest comparing patients with (i) mild disease versus cirrhosis (F0-2 vs. 
F4), and (ii) cirrhosis versus cirrhosis with HCC (F4 vs. HCC). The most differentially-
expressed miRNAs, based on a greater than 2-fold change in expression were selected, 
leaving 26 miRNA candidates in total. Each miRNA was then assessed to ensure a 
minimum of 60% of valid reading and statistical significance (defined as p < 0.05). This 
resulted in 11 potential and most promising miRNA candidates (see Table 3.3) selected for 
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further validation. Final short-listing was based on a qualitative assessment of scatterplot 
appearances, excluding miRNAs let-7b-3p and miRNA-1972, with preference given to 
those with “tighter” clustering of results. 
 
Table 3.3 Significantly differentially-expressed miRNA across the spectrum of CHC.  
 
Differentially expressed 
miRNAs in F4    
 (compared with F0-2) 
Differentially expressed miRNAs 
in HCC 
(compared with F4) 
ID Fold change P-value Fold change P-value 
let - 7b-3p -2.54 0.008 2.50 0.014 
miRNA- 122-5p 2.05 0.020 -3.21 <0.001 
miRNA- 142-3p 
 
-2.44 0.002 
miRNA- 149-3p -2.05 0.022 2.25 0.010 
miRNA- 151a-5p 
 
-2.03 0.014 
miRNA 1972 2.80 0.016 
miRNA- 19b-3p 2.14 0.005 
 
miRNA- 22-3p 2.31 0.011 
miRNA- 2277-3p -3.14 <0.001 2.81 0.003 
miRNA- 409-3p 
 
-4.33 <0.001 
miRNA- 4758-3p -2.31 0.015 2.87 0.004 
miRNA- 4767 -2.44 0.002 
 
miRNA- 486-5p 
 
2.27 0.002 
Differentially-expressed miRNAs were selected on the basis of P-value < 0.05 and fold 
change ˃ 1.9, with negative values reflecting reduced expression. (Abbreviations: F0-2, 
mild disease; F4, cirrhosis; CHC, chronic hepatitis C; HCC, cirrhosis with hepatocellular 
carcinoma). 
 
3.4.3 MiRNA expression validation phase 
 
Expression levels of the most differentially-expressed miRNAs were validated using qRT-
PCR for all 60 patient serum samples (see Sections 3.3.2 and 3.3.3). Significance levels of 
differential expression across the cohort for the miRNA candidates assessed using qRT-
PCR in the validation phase is shown in Table 3.4. Although the PCR array study showed 
significant differences in the expression of miRNA-149-3p, miRNA-2277-3p, miRNA-4758-
3p, miRNA-4767 and miRNA-22-3p across the study groups, qRT-PCR validation did not 
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confirm miRNA presence or significant differences in expression for these miRNAs, and 
miRNA-22-3p only showed a trend towards increased expression in cirrhotic patients 
compared with mild disease (p = 0.055). All serum samples were assessed for haemolysis 
with no statistical significant differential expression determined between groups, with an 
ANOVA of p = 0.192. 
 
Table 3.4 Significant associations of circulating miRNA expression with severity of 
disease in chronic Hepatitis C: Validation of selected miRNA expression levels.  
miRNA Overall P-value (ANOVA) P-value 
F0-2 vs.F4 F0-2 vs HCC F4 vs. HCC 
miRNA-122-5p <0.001 0.066 0.103 <0.001 
miRNA-142-3p 0.047 0.636 0.039 0.253 
miRNA-151a-5p 0.025 0.986 0.056 0.039 
miRNA-19b-3p 0.015 0.734 0.015 0.089 
miRNA-409-3p 0.03 0.023 0.417 0.32 
miRNA-486-5p <0.001 0.999 0.001 0.001 
P-values were calculated using 2ΔCP normalisation method and ANOVA with Tukey’s 
post hoc test with significance designated by a P-value < 0.05. (Abbreviations: F0-2, mild 
disease; F4, cirrhosis; HCC, cirrhosis with hepatocellular carcinoma). 
 
Differential expression levels for the 6 miRNA candidates validated using qRT-PCR are 
presented in Figure 3.3. Serum levels of miRNA-122-5p (Figure 3.3A) and miRNA-151a-5p 
(Figure 3.3C) were significantly decreased in HCC (p < 0.001 and p = 0.039, respectively), 
whereas expression of miRNA-486-5p (Figure 3.3B) was significantly increased in HCC 
patients compared with F4 patients (p = 0.001). Expression of miRNA-142-3p (Figure 
3.3D) was also significantly decreased in HCC compared to F0-2 alone (p = 0.039). 
MiRNA-409-3p (Figure 3.3E) was found to be significantly upregulated in cirrhosis (p = 
0.023). 
  
73 
 
 
Figure 3.3 Association between circulating miRNA levels and severity of hepatic 
fibrosis in HCV. There was significantly reduced expression of (A) miRNA-122-5p, (C) 
miRNA-151a-5p, (D) miRNA-142-3p and (F) miRNA-19b-3p in patients with HCC, 
compared with F4 patients, whereas significantly increased expression of (B) miRNA-486-
5p in patients with HCC, compared with F4 patients. There was significantly increased 
expression of (E) miRNA-409-3p in F4 patients, when compared with mild disease. Lines 
represent mean expression levels (± SEM). (Abbreviations: F0-2 = mild disease; F4 = 
cirrhosis; HCC = hepatocellular carcinoma; * p < 0.05, ** p < 0.01, *** p < 0.001). 
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3.4.4 Discriminating cirrhosis and HCC using miRNAs 
 
Receiver operating characteristics (ROC) curve analysis was performed to assess the 
potential of individual miRNA candidates to discriminate cirrhosis (compared with mild 
disease) and HCC (compared with cirrhosis alone). Using miRNA-409-3p and miRNA-122-
5p to distinguish cirrhosis from mild disease resulted in AUCs of 0.74 (p = 0.004) and 0.69 
(p = 0.023), respectively. Several miRNA candidates distinguished HCC patients from 
those with cirrhosis alone with AUCs of 0.85 for miRNA-122-5p (p < 0.001), 0.78  for 
miRNA-486-5p (p < 0.001), 0.70 for miRNA-151a-5p (p = 0.014),  and 0.60 for miRNA-
142-3p (p = 0.14; see Figure 3.4).  
 
Stepwise logistic regression, using forward selection and backward elimination, was used 
to select a miRNA panel that could distinguish cirrhosis (F4) from mild disease (F4 vs. F0-
2). A panel comprising miRNA-122-5p and miRNA-409-3p provided an AUC of 0.80 (p 
<0.001; see Figure 3.5A). Applying logistic regression to distinguish patients with HCC 
from those with cirrhosis alone generated a miRNA panel of miRNA-122-5p, miRNA-486-
5p and miRNA-142-3p with an AUC of 0.94 (p <0.001; see Figure 3.5B). The miRNA panel 
for HCC compared with cirrhosis was optimised during the model selection by including 
miRNA-142-3p. Despite being significantly associated with the presence of HCC, miRNA-
151a-5p was not included in the final panel during the model selection process because of 
a high level of correlation between miRNA-151a-5p and miRNA-122-5p. 
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Figure 3.4 ROC curve for individual serum miRNAs to identify cirrhosis or HCC in 
chronic hepatitis C. (A). ROC curve performance of miRNA-122-5p with AUC of 0.69 
(95% CI 0.51 - 0.86, p = 0.023) and miRNA-409-3p with AUC of 0.74 (95% CI 0.58 - 0.90, 
p = 0.004) to identify cirrhosis, compared with mild disease. (B) ROC curve performance of 
selected miRNAs to identify HCC, compared with cirrhosis, generated AUCs of 0.78 (95% 
CI 0.63 - 0.93, p < 0.001) for miRNA-486-5p, 0.70 (95% CI 0.54 - 0.87, p = 0.014) for 
miRNA-151a-5p; 0.85 (95% CI 0.72 - 0.97, p < 0.001) for miRNA-122-5p, and 0.60 (95% 
CI 0.42 - 0.78, p = 0.140) for miRNA-142-3p. (Abbreviations: 95% CI, 95% confidence 
interval; AUC, area under the curve; HCC, cirrhosis with hepatocellular carcinoma, ROC = 
receiver operating characteristics). 
  
76 
 
 
Figure 3.5 ROC curve of serum miRNA panels to identify cirrhosis or HCC in chronic 
Hepatitis C. (A) An assembled miRNA panel (comprising miRNA-122-5p and miRNA-409-
3p) performed well identifying cirrhosis, compared with mild disease, with an AUC of 0.80 
(95% CI 0.66 - 0.95, p < 0.001). (B) an assembled miRNA panel (comprising miRNA-122-
5p, miRNA-486-5p and miRNA-142-3p) performed very well identifying HCC, compared 
with cirrhosis, with an AUC of 0.94 (95% CI 0.87 - 1.00, p < 0.001). (Abbreviations: 95% 
CI, 95% confidence interval; AUC, area under the curve; HCC, cirrhosis with 
hepatocellular carcinoma, ROC = receiver operating characteristics). 
 
3.4.5 Cross-validation of miRNA panels 
 
To further assess the performance of miRNA panels, k-fold cross-validation (5-fold) was 
undertaken. Using 5-fold cross-validation, the cirrhosis panel of miRNA-409-3p and 
miRNA-122-5p generated an AUC of 0.79 (95% CI 0.65 - 0.93), with a sensitivity of 85.3%, 
specificity of 65.3%, PPV of 75%, NPV of 76%, and overall accuracy of 77.5% (see Figure 
3.6A). This used a panel-specific cut-point of 0.44 according to the statistical method 
outlined in Section 2.8.4. Using 5-fold cross-validation, the performance of the HCC 
miRNA panel (comprising miRNA-122-5p, miRNA-486-5p and miRNA-142-3p) generated 
an AUC of 0.91 (95% CI of 0.81 – 1.0), sensitivity of 81.3%, specificity of 86.7%, PPV of 
91%, NPV of 80% and overall accuracy of 85% (see Figure 3.6B). The panel-specific cut-
point was 0.65.  
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Figure 3.6 K-fold (5-fold) cross-validation ROC curve of serum miRNA panels to 
identify cirrhosis or HCC in chronic Hepatitis C. (A) a miRNA panel (comprising 
miRNA-122-5p and miRNA-409-3p) to distinguish cirrhosis from mild disease generated 
an AUC of 0.79 (95% CI 0.65 - 0.93) following 5-fold cross-validation. (B) a miRNA panel 
(comprising miRNA-122-5p, miRNA-486-5p and miRNA-142-3p) to distinguish patients 
with HCC from those with cirrhosis alone generated an AUC of 0.91 (95% CI 0.81 - 1.0) 
following 5-fold cross-validation. (Abbreviations: 95% CI, 95% confidence interval; AUC, 
area under the curve; HCC, cirrhosis with hepatocellular carcinoma, ROC = receiver 
operating characteristics). 
 
3.4.6 Comparative performance of APRI and FIB-4 to discriminate cirrhosis 
 
The abilities of the biochemical indices APRI and FIB-4 to discriminate cirrhosis (F4) from 
mild disease (F0-2) in this cohort were also assessed. Using the recommended FIB-4 cut-
off of 1.45 to exclude advanced fibrosis (F3-4) resulted in an AUC of 0.87 (p < 0.001) with 
a sensitivity of 95%, specificity of 50%, PPV of 70.4%, NPV of 92.3%, and overall 
accuracy of 77.5% in this cohort. Combining the proposed cirrhosis miRNA panel (miRNA-
409-3p and miRNA-122-5p) with FIB-4 improved diagnostic performance with an AUC of 
0.89 (p < 0.001, see Figure 3.7A). 
 
Applying an APRI cut-off of 1.0 to exclude cirrhosis resulted in an AUC of 0.84 (p < 0.001) 
with a sensitivity of 80%, specificity of 75%, PPV of 76.2%, NPV of 78.9%, and overall 
accuracy of 77.5%. Combining the proposed miRNA panel (miRNA-409-3p and miRNA-
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122-5p) with APRI improved diagnostic performance with an AUC of 0.87 (p < 0.001; see 
Figure 3.7B). 
 
3.4.7 Performance of AFP in identifying HCC 
 
In this cohort, the currently-accepted tumour marker AFP was a poor discriminator of HCC 
with an AUC of only 0.64 (p = 0.065). Using an AFP cut-off of > 20 µg/L to identify HCC, 
produced a sensitivity of 25%, specificity of 90%, PPV of 71.4%, NPV of 54.5%, and 
overall accuracy of 57.5%. In comparison, the proposed HCC miRNA panel (of miRNA-
122-5p, miRNA-486-5p and miRNA-142-3p) generated an AUC of 0.94 (p < 0.001). 
Combining AFP with the proposed miRNA panel did not improve its performance (AUC of 
0.94; see Figure 3.7C). 
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Figure 3.7 ROC curves to identify cirrhosis or HCC using FIB-4 or APRI alone, or in 
combination with circulating miRNA panels in chronic Hepatitis C. (A) In 
distinguishing cirrhosis, the performance of FIB-4 (AUC = 0.87, 95% CI 0.75 - 0.98, p < 
0.001; using a cut-off of > 1.45 to exclude advanced fibrosis) was enhanced in 
combination with the cirrhosis miRNA panel described in Figure 3A (AUC = 0.89, 95% CI 
0.79 - 0.99, p < 0.001). (B) In distinguishing cirrhosis, the performance of APRI (AUC = 
0.84, 95% CI 0.71 - 0.97, p < 0.001; using a cut-off of > 1.0 to exclude cirrhosis) was 
enhanced in combination with the cirrhosis miRNA panel described in Figure 3A (AUC = 
0.87, 95% CI 0.76 - 0.98, p < 0.001). (C)  AFP alone demonstrated poor diagnostic utility 
in the detection of HCC (AUC = 0.64, 95% CI 0.47 - 0.82, p = 0.065; using a cut-off of > 20 
to diagnose HCC) and when used in combination with the HCC miRNA panel described in 
Figure 3B there was no improvement in the HCC miRNA panel’s ability to detect HCC 
(AUC = 0.94, 95% CI 0.88 - 1.00, p < 0.001). (Abbreviations: 95% CI, 95% confidence 
interval; AFP, alpha-fetoprotein; APRI = aspartate aminotransferase to platelet ratio; AUC, 
area under the curve; Fib-4 = Fibrosis-4 biomarker panel; HCC, cirrhosis with 
hepatocellular carcinoma, ROC = receiver operating characteristics). 
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3.5 Discussion 
 
Despite the availability of new highly efficacious treatments, HCV remains a huge public 
health burden with millions of CHC patients worldwide affected by cirrhosis.291 
Distinguishing cirrhosis from mild disease is clinically important as these patients warrant 
early access to treatment to prevent progression to decompensated disease and require 
regular surveillance for complications, such as HCC, even if the virus is successfully 
cleared. The invasive nature of the gold standard liver biopsy, as well as the absence of 
highly accurate non-invasive biomarkers and limited access to technologies that non-
invasively stage fibrosis, mean that staging disease in CHC remains an important 
challenge in routine patient care.109 MiRNAs and their potential utility as circulating 
biomarkers have been studied in many diseases, including HCC.211 To date, several 
potential miRNAs have been identified but an optimal candidate or diagnostic panel have 
not been validated.  
 
In the current study, serum samples from 60 CHC patients across the spectrum of CHC, 
including cirrhosis and HCC, were used to identify potential miRNA biomarkers. During the 
discovery phase serum samples were screened for differentially expressed miRNAs using 
a miRNA PCR-based microarray. Validation, using independent qRT-PCR, was then 
undertaken to confirm differential expression in the most promising candidate miRNAs. 
These were then tested individually and in combination, as biomarker panels, to assess 
their abilities to correctly identify patients across the spectrum of disease. 5-fold cross 
validation, a statistical internal validation method, was utilised to assess the miRNA panel 
robustness. Their diagnostic accuracy was also compared with currently accepted clinical 
diagnostic tools.  
 
The circulating level of miRNA-409-3p was significantly increased in cirrhotic patients (F4) 
compared with those with only mild disease (F0-2). To date, human studies describing the 
role of miRNA-409-3p in fibrosis progression in liver disease are scarce. In a murine 
neoplastic model of hereditary tyrosinemia type 1, increased plasma expression levels 
correlated with markers of liver injury (gamma-glutamyl-transferase, alkaline 
phosphatase).305 Interestingly, studies using in vitro models of prostate cancer have 
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reported increased miRNA-409-3p levels in association with epithelial to mesenchymal 
transition (EMT), facilitating tumour growth and metastasis by targeting Ras suppressor 
protein 1.306, 307 In contrast, reduced expression of miRNA-409-3p has been described in 
other cancers, such as breast cancer308 and colorectal cancer,309, 310 suggesting a tissue-
specific role for miRNA-409-3p. Reported associations with EMT and tumour development, 
together with evidence from the current study of increased circulating levels in patients 
with cirrhosis, suggest a potential role for miRNA-409-3p as a mediator of progressive liver 
injury in CHC. 
 
MiRNA-122-5p is the most abundant miRNA expressed in liver.222 Increased levels of 
circulating miRNA-122-5p have been shown in liver diseases of different aetiologies such 
as Hepatitis B virus (HBV) infection311, alcoholic liver disease311, paediatric cystic fibrosis 
liver disease312 and HCV242. Furthermore, in CHC, circulating miRNA-122-5p levels have 
been shown to correlate with serum ALT and AST levels and tissue necrosis and 
inflammation. 239, 242 In the current study, I demonstrated that circulating serum levels of 
miRNA-122-5p were significantly decreased in CHC patients with HCC compared with 
cirrhosis alone. A previous study reported no significant differences in serum miR122-5p 
levels in HCC patients313 but included patients with multiple disease aetiologies, 
suggesting miR122-5p may have be specific for CHC-related HCC. Increased levels of 
miRNA-122-5p have been described in CHC-related HCC tissue samples,314, 315 while 
HBV-related HCC is associated with decreased levels of tissue expression.314, 316 These 
differences in miRNA-122-5p expression levels according to viral hepatitis subtype could 
be linked to the host-virus interactions, as it has been previously shown that miRNA-122 is 
directly involved in HCV replication.317, 318 Poorer overall survival has been described in 
HCC patients with lower levels of circulating miRNA-122-5p313 and lower expression of 
miRNA-122-5p in HCC tissue has been shown to correlate with poor prognosis and 
metastasis.314 These data clearly suggest the clinical importance of miRNA-122-5p in HCC 
development and patient outcomes. While the precise mechanisms involved require 
further investigation, the current study provides consistent evidence that serum levels of 
miRNA-122-5p may be useful as a non-invasive diagnostic biomarker of HCC.  
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In the current study, circulating miRNA-486-5p was the only miRNA showing increased 
peripheral expression in CHC patients with cirrhosis and HCC versus cirrhosis alone. 
Higher circulating miRNA-486-5p has been previously described in patients with HCC 
compared with healthy controls, although the aetiology of HCC and cirrhosis status was 
not reported.319 As a potential diagnostic test, it could be argued that the current study’s 
finding of differential expression in cirrhotic patients with and without HCC is more clinically 
significant. Interestingly, higher serum expression of miRNA-486-5p has been shown to be 
associated with longer recurrence-free survival in HCC patients.320 Conversely, reduced 
tissue expression of miRNA-486-5p in HCC, compared with adjacent non-tumorous tissue, 
has been reported in HCC of multiple aetiologies (including CHC)321-323 and tissue 
expression levels appear to correlate with earlier HCC recurrence following resection.321 
Further studies are required to explore the pathogenic mechanisms underlying these 
interesting and clinically relevant results. Downstream targets of miRNA-486-5p include 
Phosphoinositide-3-Kinase Regulatory Subunit 1 (PIK3R1) and NIMA Related Kinase 2 
(NEK2), which have been shown to play important roles in HCC proliferation, migration 
and invasion.321, 322 Furthermore, in vitro studies have reported that miRNA-486 
downregulates Insulin Like Growth Factor 1 Receptor (IGF-1R), Mechanistic Target Of 
Rapamycin Kinase (mTOR) and Signal Transducer And Activator Of Transcription 3 
(STAT3),323 which are part of the IGF signalling pathway and which, in turn, has been 
linked with HCC pathogenesis.324 In other cancers, such as non-small-cell-lung cancer, 
increased circulating expression levels and reciprocal reduced tissue expression levels of 
miRNA-486-5p have also been demonstrated,325, 326 while lower tissue expression of 
miRNA-486-5p has been demonstrated in advanced lung cancer and metastatic 
disease.326 In the latter study, the pro-tumorigenic Rho GTPase Activating Protein 5 
(ARHGAP5) was identified as a potential target of miRNA-486-5p, supporting its potential 
role as a tumour suppressor. In contrast, the oncogenic potential of miRNA-486-5p has 
been reported with increased tissue expression in cervical and prostate cancer through the 
targeting of Phosphatase and Tensin Homolog (PTEN).327, 328 Interestingly, miRNA-486-5p 
is located on chromosome 8q11.21, an area commonly deleted in HCC, which possibly 
accounts for the reduced tissue expression levels seen in HCC and supports its potential 
role as a tumour suppressor.122  
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The current study demonstrated significantly decreased expression of circulating miRNA-
151a-5p in cirrhotic patients with HCC compared with cirrhosis alone. While another study 
has described increased plasma expression of miRNA-151a-5p in viral hepatitis HCC, this 
was in comparison to healthy controls and non-viral hepatitis-related HCC patients.329 
Interestingly, as with miRNA-486-5p, opposite results are seen at the tissue level with 
increased expression of miRNA-151a-5p described in HCC tissue compared with adjacent 
non-tumorous tissue.122, 330 Further similarities are found with its chromosomal location, as 
miRNA-151a-5p is located in an area of the chromosome (8q24.3) that is frequently 
amplified in HCC,122, 330 potentially accounting for the higher tissue levels of miRNA-151. 
High expression levels of miRNA-151a-5p have also been correlated with intrahepatic 
metastasis, cell migration and invasion through the targeting of Rho GDP Dissociation 
Inhibitor Alpha (RhoGDIA),122 while FAK (the host gene of miRNA-151a-5p) is usually co-
expressed with miRNA-151a-5p and it has been suggested that the two function 
synergistically to enhance HCC cell motility.122 Other cancer tissues, such as gastric 
cancer331 and papillary thyroid carcinoma,332 also show increased expression of miR-151a-
5p, while studies of urothelial carcinoma did not find differential expression,333 suggesting 
that the role of miRNA-151a-5p in cancer could be tissue specific. Overall, however, there 
is growing evidence that miRNA-151a-5p is associated with cancer progression and that it 
may have a pro-oncogenic function, although further studies of the downstream targets of 
miRNA-151a-5p are needed.  
 
When comparing miRNA expression levels in patients with mild disease and cirrhotic 
patients with HCC, I found significantly decreased expression of circulating miRNA-142-3p 
in the HCC group. Several previous studies have reported miRNA-142-3p to be 
downregulated in HCC tissue334-336 and functional studies have demonstrated a potential 
role for miR-142-3p in the inhibition of migration, proliferation and invasion in vitro by 
targeting Rac Family Small GTPase 1 (RAC1) and TGF-β.335-337 One study has reported 
increased levels of circulating and tissue miRNA-142-3p338 in HCC, although 
discrepancies may be accounted for by methodological differences. 
 
I performed ROC curve analysis using stepwise logistic regression to identify a miRNA 
panel for the diagnosis of cirrhosis compared with mild disease in CHC. The resulting 
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cirrhosis miRNA panel (comprising miRNA-122-5p and miRNA-409-3p) resulted in an AUC 
of 0.80. When combined with APRI, its performance improved with an AUC of 0.87 and the 
combination of the proposed miRNA panel with FIB-4 resulted in an AUC of 0.89. Although 
these results need to be validated in a prospective study and a larger study cohort, the 
combination of this miRNA panel with other tools highlights the clinical potential of miRNAs 
to non-invasively identify patients with cirrhosis with very good diagnostic accuracy. 
 
I also performed ROC curve analysis using the proposed HCC miRNA panel and 
demonstrated the ability of miRNA-122-5p, miRNA-486-5p and miRNA-142-3p to 
discriminate cirrhosis with HCC from cirrhosis alone with an AUC of 0.94. This result was 
substantially better than the diagnostic performance of AFP to identify HCC (AUC = 0.64) 
highlighting the enormous potential clinical advantages of the proposed miRNA panel over 
the HCC tumour biomarker currently used in clinical practice. Combining AFP with the 
miRNA panel did not improve the diagnostic performance. Further prospective validation of 
a miRNA panel comprising miRNA-122-5p, miRNA-486-5p and miRNA-142-3p in a larger 
study cohort is obviously required but the diagnostic potential of this panel is certainly 
promising.  
 
Some discrepancies between miRNA expression levels in the current study and 
expression levels in other miRNA studies have been observed. This inter-study variation 
has also been previously reported by others.339, 340 Common causes are methodology 
differences – such as miRNA source, quality control, RNA isolation, qRT-PCR strategy or 
data normalisation – highlighting the urgent need for standardised methods and reporting 
for cell-free miRNAs.229, 341  
 
This study contributes to the considerable interest over recent years in miRNAs as 
biomarkers of chronic liver disease. Two recent meta-analyses339, 340 have concluded that 
miRNAs have great potential as non-invasive biomarkers, especially in the diagnosis of 
cirrhosis and HCC, and highlighted a number of candidate miRNAs. These studies found, 
however, that the quality of studies in this area is highly variable, significant heterogeneity 
exists, and results are often contradictory. Meta-analysis identified that high frequency 
miRNAs (e.g. miRNA-122-5p in HCC) may prove the most specific and combinations of 
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non-invasive biomarkers and/or panels of miRNAs appear to be more accurate in 
distinguishing disease. These findings are consistent with those of the current study, as is 
the conclusion that further high-quality work is needed to validate promising preliminary 
results.  
 
In comparison to recent studies, strengths of the current study include: the use of controls 
with clinically-relevant disease (i.e. mild disease vs. cirrhosis, cirrhosis vs. HCC) instead of 
healthy controls; the measurement of circulating rather than tissue-based miRNA levels 
(which are much less accessible to clinicians in routine clinical practice); and the use of 
serum expression levels rather than plasma (which generally delivers sub-optimal results). 
 
There are some limitations to this study, however, that need to be considered when 
evaluating the results. The study population includes only two patients that completed their 
DAA treatment and achieved a SVR. To be applicable to the broader HCV community and 
with increasing numbers of DAA treatment, these findings require validation in a larger 
patient cohort, including those who have achieved SVR. This study included patients with 
all HCV genotypes, with genotypes 1 and 3 being over-represented. The utility of a miRNA 
panel as a diagnostic test across all genotypes warrants further investigation, especially as 
DAA treatment options become more efficacious and less reliant on genotyping. Of note, 
this study identified multiple miRNAs that distinguished mild disease from cirrhosis using 
patients who were allocated to their study groups retrospectively. Although these patients 
were followed-up for a mean of 21.2 months to confirm the allocation, the proposed 
cirrhosis-specific miRNA panel would benefit from prospective validation. This should 
include validation in a study cohort with biopsy-proven fibrosis across all stages to confirm 
that the panel can discriminate mild disease (F0-2) from advanced fibrosis (i.e. F3) and 
cirrhosis (F4). Similarly, a prospective study of the proposed HCC miRNA panel in CHC 
patients subsequently diagnosed with HCC would be beneficial. 
 
In conclusion, this study has identified the differential expression of several circulating 
miRNAs in the serum of patients across the spectrum of disease severity due to CHC. 
Specifically, I have identified miRNA-409-3p and miRNA-486-5p as possible biomarkers of 
the development of cirrhosis and HCC, respectively. Combining the expression levels of 
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different miRNAs, I have developed diagnostic panels that could potentially be used to 
stratify CHC and diagnose early HCC. Further validation of the miRNA panels is required 
before translation into clinical practice, but these excellent preliminary results support the 
potential use of miRNAs as non-invasive biomarkers to improve the identification of 
patients with cirrhosis and HCC. The current study also identifies a selection of candidate 
miRNAs that could be investigated in functional studies to identify downstream targets and 
elucidate their roles in disease development and new therapeutic strategies. 
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CHAPTER 4                                                             
Exploring the functional targets of differentially-
expressed microRNAs in HCC…. 
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4.1 Introduction 
 
In the previous chapter, 5 circulating miRNA candidates were significantly differentially-
expressed in patients with HCC when compared to those with mild disease or cirrhosis 
alone (Table 3.4). The most significant differentially expressed miRNAs in HCC patients 
(compared with cirrhotic patients) were identified in order to select the most promising 
HCC miRNA candidates and a short-list comprising miRNA-122-5p, miRNA-486-5p and 
miRNA-151a-5p was finalised. MiRNA-122-5p was selected as it has been well-
characterised previously,211, 225, 342-347 while miRNA-151a-5p and miRNA-486-5p were also 
selected as promising miRNA candidates associated with the development of HCC in the 
setting of cirrhosis. After reviewing the literature, it appears that increased miRNA-151a-5p 
expression in HCC tissue has previously been reported.122, 330 Additionally, miRNA-151a-
5p is located on chromosome 8q24.3, a highly amplified region in HCC. Taken together, 
these results suggest that miRNA-151a-5p could represent a pro-oncogenic miRNA and, 
thus, identification of the downstream targets of miRNA-151a-5p are of great interest. To 
date, only a few targets of miRNA-151a-5p have been described, such as RhoGDIA and 
FAK, both of which are associated with increased HCC cell motility.122, 330 Regarding the 
other candidate identified in the previous chapter, miRNA-486-5p, decreased expression 
levels have been reported in HCC tissue samples.321-323 Located on the chromosome 
8q11.21, miRNA-486-5p is located at the site of a commonly deleted chromosomal region 
in HCC.122 It has therefore been suggested that miRNA-486-5p potentially functions as a 
tumour suppressor with PIK3R1 and NEK2, both associated with HCC proliferation and 
invasion, as potential downstream targets.321, 322 Based on these preliminary results, more 
research is required to investigate the potential pro-oncogenic or tumour suppressor 
functions of these miRNAs. 
 
The identification of miRNA targets commonly uses target prediction algorithms such as 
PicTar166, miRDB270, 271 or TargetScan.167, 272-275 Target prediction algorithms attempt to 
incorporate identified mechanisms as part of the miRNA posttranscriptional regulation and 
include annotations of previously described miRNA targets. Although target prediction 
continuously improves accuracy, it does not represent the full or true repertoire of miRNA 
regulation. The most important binding of miRNA and mRNA occurs within the RISC 
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complex and is subject to Watson-Crick base pairing of the miRNA seed region. The 
miRNA seed region is at nucleotide 2-7 from the 5’ miRNA end and contains a minimum of 
6 base pairs (bp).164-168 Yet, several factors beyond seed region binding need to be 
considered for accurate target prediction, such as Watson-Crick pairing at nucleotides 12-
17 or synergistic effects of closely spaced miRNAs.164-168 It has also been shown that 
effective targets reside preferentially in a local AU-rich context, close to 3’UTR ends but 
sufficiently distant from stop codons.275 These are known factors that are incorporated into 
algorithms such as TargetScan, but target prediction remains imprecise as processes are, 
as expected, much more complex in reality. The context of the actual seed matching itself 
remains as important as any predicted or anticipated seed matching. For example, 3’ UTR 
isoforms can vary between cell types and therefore modulate miRNA binding sites.193 
Another layer of complexity within the cell is added by target site accessibility, with RNA 
binding proteins or translation efficiency affecting miRNA/target interaction (see Section 
1.3.2).189-192 As a result, target prediction algorithms cannot identify all true mRNA targets 
and therefore, in reality, any purported readout of identified targets remains incomplete 
and does not reflect the full extent of miRNA regulation (including post-transcriptional 
regulation).  
 
An alternative approach to identify miRNA targets is based on an experimental approach. 
Mutation to the mRNA or reporter gene construct studies, such as luciferase reporter 
assays, are the ideal method to validate individual miRNA–mRNA interactions but are 
time- and cost-intensive and cannot be performed on a larger genomic scale.165-167 
Microarray profiling, on the other hand, only detects target degradation and does not 
account for other modes of post-transcriptional regulation.185 Another approach is the use 
of synthetic biotinylated miRNA duplexes to isolate and identify miRNA targets. This 
experimental protocol was first described by Ørom and colleagues348, 349 and has since 
been optimised to identify miRNA-mRNA interactions.253 This method, colloquially known 
as a “pull-down” assay, is based on the transfection of synthetic biotinylated miRNA 
duplexes into the cell type of interest. Transfection, or the introducing of the miRNA duplex 
into the cells, is followed by the actual “pull-down”, where the biotinylated miRNA, which is 
incorporated into the RISC/mRNA complex, is bound to streptavidin coated beads. After 
interaction with cellular mRNA, these beads are then magnetically separated from the 
remainder of the sample and the specific mRNA targets “captured” by the beads can be 
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isolated. This protocol generates an mRNA enriched sample representing all miRNA 
targets on a global scale. In this chapter of the thesis, the putative mRNA targets of 
miRNA-151a-5p and miRNA-486-5p in normal hepatocytes and HCC cells were 
investigated using this experimental pull-down approach. The functional effects of over-
expression of these miRNAs on hepatocytes and HCC cells were also assessed using in 
vitro proliferation and migration assays.  
 
4.2 Aims and hypothesis  
 
It was hypothesised that differentially-expressed serum miRNAs identified to be associated 
with the HCC, target the expression of specific hepatocyte genes that may regulate 
carcinogenesis pathways in the development of HCC. 
Therefore, the second aim of this thesis is to characterise the functional roles and 
purported target genes of differentially-expressed miRNAs identified in Aim 1 in the 
pathogenesis of HCC progression. 
 
4.3 Methods 
4.3.1 Biotin pull-down assay, sequencing, target prediction and IPA analysis 
 
To identify specific mRNA targets of miRNA-151a-5p and miRNA-486-5p, a pull-down 
assay was performed in the normal hepatocyte cell line IHH and in the hepatoma cell line 
Huh7 (see Section 2.3.1). Cells were transfected using a fluorescein-labelled miRNA 
mimic negative control (Bioneer Corporation) to assess transfection efficiency using 
Lipofectamine2000 (Invitrogen by Thermo Fisher Scientific) as transfection reagent (see 
Section 2.3.2) with transfection efficiency of 47% for IHH cell (n = 3) and 48% for Huh7 
cells (n = 3). IHH and Huh7 cells were then (transiently) transfected with miRNA-151a-5p 
or miRNA-486-5p (see Section 2.3.2) using the miRNA duplex designed for the pull-down 
assay (see Table 2.3). The pull-down was performed in biological replicates (n = 3) with 
the detailed assay protocol described previously (see Section 2.3.3). At 24 hours post-
transfection, the cells were harvested into one sample and this sample was then split 
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again into a whole lysate sample, creating a control sample and a pull-down sample, with 
each representing an enriched target mRNA sample, as described in Section 2.3.3. 
 
Extracted RNA from these pull-down assays was assessed for concentration and quality 
(RIN score > 7) using the Agilent Bioanalyzer 2100 microfluidics-based electrophoresis 
platform (Agilent Technologies) as described in Section 2.5.2. Double-stranded RNA 
libraries were prepared using the TruSeq RNA Library Prep Kit (Illumina Inc.) using a 
starting concentration of 200 ng per library and subject to next generation sequencing 
using the NextSeq500 (Illumina Inc.). Sequencing data was processed and analysed as 
described in Section 2.7.4 and Section 2.8.4, respectively. Significant differential 
expression, using p > 0.05 and FC > 1.5 (logFC > 0.6), was then analysed to identify the 
putative mRNA targets of miRNA-151a-5p and miRNA-486-5p. IPA analysis was then 
used to identify the overlap of these targets with known canonical pathways, resulting in a 
short-list of the top canonical pathways targeted by their respective miRNA (see Section 
2.7.5). The putative mRNA targets where then compared to the performance of target 
prediction algorithms, such as miRDB and TargetScan as described in Section 2.7.5.  
 
4.3.2 RNA extraction, reverse transcription, qRT-PCR and analysis 
 
To assess expression of putative mRNA targets identified by the pull-down assay, qRT-
PCRs of selected mRNA candidates were performed. Cells were seeded into 6-well tissue 
culture plate (Greiner Bio-One) at a cell density of 200,000 cells per well for both cell lines. 
These cells were transfected, using transient transfection of miRNA mimics purchased 
from Sigma-Aldrich (see Table 2.2), as described in Section 2.3.2. At the time point 24, 48 
and 72 hours post-transfection, cells were harvested and the RNA was isolated using 
RNeasy® Mini Kit (Qiagen; see Section 2.4.1). Samples were assessed for contaminants 
using the NanodropTM 2000 spectrophotometer (Thermo Fisher Scientific; see Section 
2.5.1) and reverse transcribed using SensiFASTTM cDNA Synthesis Kit (Bioline; see 
Section 2.6.3). The qRT-PCR was performed using platinum SYBR Green qPCR Super 
Mix-UDG (Thermo Fisher Scientific) with protocol and primers described detailed in 
Section 2.6.6. PCR data was analysed using the 2-ΔΔCP method (see Section 2.8.3), with β-
actin functioning as an endogenous reference gene. Statistically significant differential 
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expression at each individual time point was determined using t-test with statistical 
significance defined as p < 0.05.  
 
4.3.3 Functional assays and miRNA expression levels 
 
To perform proliferation and migration assays cells were seeded into 10 cm tissue culture 
dishes (Corning Inc.) as described in Section 2.3.4 and Section 2.3.5, respectively. Cells 
were transfected using miRNA mimics supplied by Qiagen (see Table 2.2) and re-seeded 
as previously described (see Section 2.3.4 for proliferation assay and Section 2.3.5 for the 
migration assay). In parallel, the remainder of the transfected cells were seeded into 6-well 
tissue culture plates (Greiner Bio-One) for baseline expression measurements. Both 
assays were then incubated in the IncuCyte Zoom live cell analysis system (Essen 
Bioscience) and analysed using GraphPad Prism v.7 (GraphPad Software; see Section 
2.8.6).  
 
Prior to imaging in the IncuCyte Zoom live cell analysis system (Essen Bioscience), the 
cells seeded into a 6-well tissue culture plate (Greiner Bio-One), harvested and RNA 
isolated using the modified RNeasy® Mini Kit protocol (Qiagen; see Section 2.4.2). RNA 
was reverse transcribed using the miScript II RT Kit (Qiagen, see Section 2.6.1) and qRT-
PCR was performed using the miScript SYBR® Green PCR Kit (Qiagen, see Section 
2.6.4). MiRNA expression was determined using the 2ΔCP (see Section 2.8.3), with RNU6 
functioning as the endogenous reference gene. 
 
4.4 Results 
4.4.1 Downstream target identification using biotin pull-down assay 
 
To identify biologically relevant mRNA targets of miRNA-151a-5p and miRNA-486-5p, a 
biotin-based pull-down assay was performed. To achieve this, biotin-labelled miRNA 
duplexes of their respective miRNAs were transfected into both Huh7 and IHH cells. 
Target mRNA-miRNA complexes were captured using streptavidin-coated beads and 
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mRNA targets were enriched in the pull-down sample compared to a whole cell lysate 
control taken from the same cells before pull-down. Captured mRNAs were identified using 
RNA NGS with the sequencing quality metrics shown in Table 4.1 and Table 4.2. One 
library, miRNA-486-5p transfected Huh7 control number 2, was excluded from further 
analysis due to poor alignment performance with a mapping rate of less than 90% (Table 
4.1). 
 
Hierarchical cluster analysis of miRNA-151a-5p pull-down in IHH cells revealed tight 
clustering of control samples versus pull-down samples (n = 3, see Figure 4.1A), whereas 
clustering of miRNA-151a-5p pull-down in Huh7 showed some variation (n = 3), with 
control sample one and pull-down sample one clustering together rather than with the 
other control or pull-down samples (see Figure 4.1C). The MvA plot analysis showed the 
distribution of the data with “M” representing log ratio and “A” representing mean average 
of the pull-down data. The MvA analysis confirmed successful target identification using a 
fold change of greater than 1.5 (log fold change > 0.6) and a minimum expression intensity 
with more than 4 million counts (log count per million > 2) as shown in Figure 4.1B and 
Figure 4.1D. 
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Table 4.1. RNA next-generation sequencing metrics for the miRNA-151a-5p pull-down assay. 
Sample label Cell line miRNA-duplex 
transfected 
Sample 
type 
Read 
Length 
Mapped 
reads 
Mapping 
Rate* 
Exonic 
Rate* 
Intronic 
Rate* 
Intergenic 
Rate* 
IHH151Ctrl1 IHH miRNA-151a-5p Control 1 76 34553491 0.95 0.92 0.06 0.02 
IHH151Ctrl2 IHH miRNA-151a-5p Control 2 76 36776064 0.95 0.92 0.06 0.03 
IHH151Ctrl3 IHH miRNA-151a-5p Control 3 76 30708216 0.94 0.92 0.05 0.03 
IHH151PD1 IHH miRNA-151a-5p Pull-down 1 76 34440266 0.95 0.91 0.07 0.02 
IHH151PD2 IHH miRNA-151a-5p Pull-down 2 76 29708260 0.96 0.91 0.06 0.02 
IHH151PD3 IHH miRNA-151a-5p Pull-down 3 76 31421398 0.96 0.92 0.06 0.02 
Huh7151Ctrl1 Huh7 miRNA-151a-5p Control 1 76 21415106 0.97 0.92 0.04 0.03 
Huh7151Ctrl2 Huh7 miRNA-151a-5p Control 2 76 29340760 0.96 0.93 0.05 0.02 
Huh7151Ctrl3 Huh7 miRNA-151a-5p Control 3 76 28652198 0.95 0.93 0.05 0.03 
Huh7151PD1 Huh7 miRNA-151a-5p Pull-down 1 76 34285916 0.96 0.94 0.04 0.02 
Huh7151PD2 Huh7 miRNA-151a-5p Pull-down 2 76 32163651 0.96 0.94 0.05 0.01 
Huh7151PD3 Huh7 miRNA-151a-5p Pull-down 3 76 28071306 0.96 0.94 0.05 0.01 
Sequencing metrics for n = 12 pull-down (PD) and control (Ctrl) samples following bioinformatic processing. Each pull-down experiment, 
using miRNA-151a-5p, was performed in triplicate in both IHH and Huh7 cells. Enriched pulldown samples were compared to whole cell 
lysates control samples. Table summarising paired-end sequencing read length, RNA mapping rate and mapping count, exonic, intronic 
and intergenic rate following alignment to reference genome. *1.00 equals 100%. Samples were labelled according to the cell type 
transfected, the microRNA transfected and whether they are control or pull-down samples (Abbreviations: IHH, immortalised human 
hepatocytes; Huh7, human hepatoma-derived cell line). 
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Table 4.2. RNA next-generation sequencing metrics for the miRNA-486-5p pull-down assay. 
Sample label Cell line miRNA-duplex 
transfected 
Sample 
type 
Read 
Length 
Mapped 
reads 
Mapping 
Rate* 
Exonic 
Rate* 
Intronic 
Rate* 
Intergenic 
Rate* 
IHH486Ctrl1 IHH miRNA-486-5p Control 1 76 35726056 0.96 0.92 0.05 0.02 
IHH486Ctrl2 IHH miRNA-486-5p Control 2 76 34762363 0.95 0.93 0.05 0.02 
IHH486Ctrl3 IHH miRNA-486-5p Control 3 76 20378341 0.96 0.92 0.05 0.02 
IHH486PD1 IHH miRNA-486-5p Pull-down 1 76 35473537 0.95 0.92 0.06 0.02 
IHH486PD2 IHH miRNA-486-5p Pull-down 2 76 20991744 0.95 0.92 0.06 0.02 
IHH486PD3 IHH miRNA-486-5p Pull-down 3 76 29304451 0.96 0.92 0.06 0.02 
Huh7486Ctrl1 Huh7 miRNA-486-5p Control 1 76 23720971 0.97 0.91 0.04 0.04 
Huh7486Ctrl2 Huh7 miRNA-486-5p Control 2 76 13517345 0.69 0.93 0.05 0.02 
Huh7486Ctrl3 Huh7 miRNA-486-5p Control 3 76 26387852 0.96 0.93 0.05 0.03 
Huh7486PD1 Huh7 miRNA-486-5p Pull-down 1 76 22823923 0.91 0.94 0.05 0.02 
Huh7486PD2 Huh7 miRNA-486-5p Pull-down 2 76 34167665 0.96 0.93 0.05 0.02 
Huh7486PD3 Huh7 miRNA-486-5p Pull-down 3 76 32901615 0.96 0.93 0.05 0.02 
Sequencing metrics for n = 12 pull-down (PD) and control (Ctrl) samples following bioinformatic processing. Each pull-down experiment, 
using miRNA-486-5p, was performed in triplicate in both IHH and Huh7 cells. Enriched pulldown samples were compared to whole cell 
lysates control samples. Table summarising paired-end sequencing read length, RNA mapping rate and mapping count, exonic, intronic 
and intergenic rate following alignment to reference genome. *1.00 equals 100%. Samples were labelled according to the cell type 
transfected, the microRNA transfected and whether they are control or pull-down samples (Abbreviations: IHH, immortalised human 
hepatocytes; Huh7, human hepatoma-derived cell line). 
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Figure 4.1. Pull-down metrics of miRNA-151a-5p in IHH and Huh7 cells. Hierarchical 
cluster analysis of miRNA-151a-5p pull-down in (A) IHH cells and (C) Huh7 cells showing 
clustering of whole cell lysate controls (n = 3) and miRNA duplex transfected pull-down 
samples (n = 3). MvA plot of miRNA-151a-5p pull-down target identification in (B) IHH and 
(D) Huh7 cells, showing presence of mRNA targets with a log fold change > 0.6 (fold 
change > 1.5) and expression intensity of > 2 logCPM. (Abbreviations: Ctrl, Control; IHH, 
immortalised human hepatocytes; Huh7, human hepatoma-derived cell line; logCPM, log 
count per million; logFC, log fold change; miRNA, microRNA; PD, pull-down). 
 
Hierarchical cluster analysis of miRNA-486-5p pull-down experiments showed some 
experimental variation in IHH cells with control and pull-down sample two clustering 
together (see Figure 4.2A). In comparison, cluster analysis in Huh7 cells showed tight 
clustering within control and pull-down samples (see Figure 4.2C). (As explained earlier, 
the miRNA-486-5p transfected Huh7 control number 2 sample was excluded from further 
analysis). MvA plots of miRNA-486-5p pull-down data confirmed successful target 
97 
 
identification with targets reaching a fold change > 1.5 and > 4 CPM (see Figure 4.2B and 
Figure 4.2D). Exclusion of one sample from the analysis due to poor alignment 
performance potentially impacted the number of targets identified in the MvA plot. 
 
 
Figure 4.2. Pull-down metrics of miRNA-486-5p in IHH and Huh7 cells. Hierarchical 
cluster analysis of miRNA-486-5p pull-down in (A) IHH cells and (C) Huh7 cells showing 
clustering of whole cell lysate controls (n = 3) and miRNA duplex transfected pull-down 
samples (n = 3). MvA plot of miRNA-486-5p pull-down target identification in (B) IHH and 
(D) Huh7 cells, showing presence of mRNA targets with a log fold change > 0.6 (fold 
change > 1.5) and expression intensity of > 2 logCPM. (Abbreviations: Ctrl, Control; IHH, 
immortalised human hepatocytes; Huh7, human hepatoma-derived cell line; logCPM, log 
count per million; logFC, log fold change; miRNA, microRNA; PD, pull-down). 
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Differential expression analysis of pull-down data identified 2320 putative miRNA-151a-5p 
targets in IHH cells and 1041 in Huh7 cells, with a P-value < 0.05 and a fold change > 1.5, 
and 2016 and 468 putative miRNA-486-5p targets in IHH and Huh7 cells, respectively (see 
Table 4.3). 
 
Table 4.3. Differential expression analysis comparing control versus pull-down 
samples. 
miRNA Cell line mRNA 
targets (total) 
mRNA targets with 
FDR adjustment  
(p < 0.05) 
mRNA targets with 
FDR and FC 
adjustment (FC > 1.5) 
MiRNA-151a-5p IHH 12373 6495 2320 
MiRNA-151a-5p Huh7 11637 4623 1041 
MiRNA-486-5p IHH 12358 6906 2016 
MiRNA-486-5p Huh7 11655 1135 468 
Putative pull-down targets identified following differential expression analysis comparing 
whole cell lysate control and enriched pull-down samples. Targets were selected based on 
the FDR, using a level of significance of p < 0.05, and a fold change > 1.5. (Abbreviations: 
FC, fold change; FDR, false discovery rate; IHH, immortalised human hepatocytes; Huh7, 
human hepatoma-derived cell line; miRNA, microRNA). 
 
Differentially expressed mRNA targets identified by pull-down experiments were also 
compared to target prediction algorithms such as TargetScan 7.2 and miRDB. Combining 
both prediction algorithms identified 51 potential mRNA targets for miRNA-151a-5p and 
250 mRNA targets for miRNA-486-5p. This number is unusually low considering the 
prediction algorithm searches for potential binding sites of selected miRNAs within the 
genome and does not distinguish between individual cell types. In comparison, the pull-
down assay identified 4451 and 3413 putative mRNA targets for miRNA-151a-5p and 
miRNA-486-5p, respectively. This number combines pull-down data of both cell lines, IHH 
and Huh7, for the respective miRNAs and represents common significant putative mRNA 
targets.  
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Figure 4.3. Venn diagram showing number of common putative targets between 
pull-down assay and target prediction algorithm. Putative pull-down targets were 
compared with a list of mRNA targets identified by the target prediction algorithm 
TargetScan 7.2 and miRDB for (A) miRNA-151a-5p and (B) miRNA-486-5p. Pull-down 
targets were identified at a level of significance of p < 0.05. (Abbreviations: miRNA, 
microRNA). 
 
Following this analysis, Ingenuity Pathway Analysis (IPA) was performed to identify 
canonical pathways involving the putative pull-down mRNA targets. Interestingly, miRNA-
151a-5p pull-down targets overlapped with several cancer pathways such as EGF, 
ERK/MAPK and p53 signaling. ‘Molecular Mechanisms of Cancer’ was identified as most 
common category of canonical pathways involved (see Table 4.4).  
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Table 4.4. miRNA-151a-5p pull-down assay: IPA analysis of putative mRNA targets.  
 
Top Canonical Pathways P-value Overlap 
(n) 
Overlap 
(%) 
MiRNA-151a-5p 
IHH 
EGF Signaling 1.51E-06 20/68 29.40% 
Molecular Mechanisms of Cancer 1.68E-06 65/394 16.50% 
B Cell Receptor Signaling 3.08E-06 38/191 19.90% 
p53 Signaling 4.84E-05 24/111 21.60% 
AMPK Signaling 5.65E-05 38/216 17.60% 
MiRNA-151a-5p 
Huh7 
Breast Cancer Regulation by Stathmin1 1.49E-08 30/205 14.60% 
ERK/MAPK Signaling 4.12E-07 27/200 13.50% 
HIPPO Signaling 1.64E-06 16/87 18.40% 
Molecular Mechanisms of Cancer 4.53E-06 39/394 9.90% 
Superpathway of Inositol Phosphate 
Compounds 
9.37E-06 27/235 11.50% 
Analysis highlighting the top canonical pathways involving putative pull-down targets, with 
a level of significance of p < 0.05. Data are displayed as the proportion of pull-down 
targets that overlapped with the total number of targets within each pathway and their 
respective overlap percentage.(Abbreviations: IHH, immortalised human hepatocytes; IPA, 
Ingenuity Pathway Analysis; Huh7, human hepatoma-derived cell line; miRNA, microRNA). 
 
IPA analysis of miRNA-486-5p pull-down targets identified several cancer pathways, such 
as the ERK5, Renal Cell Carcinoma Signalling and ‘Molecular Mechanisms of Cancer’ 
pathways. The miRNA-486-5p pull-down in Huh7 cells identified Hif1α Signalling as one of 
the top canonical pathways, which is involved in the VEGF pathway, a prominent HCC 
pathway (see Table 4.5).   
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Table 4.5. miRNA-486-5p pull-down assay: IPA analysis of putative mRNA targets. 
 
Top Canonical Pathways P-value Overlap 
(n) 
Overlap 
(%) 
MiRNA-486-5p 
IHH 
ERK5 Signalling 1.06E-05 17/66 25.80% 
Sirtuin Signalling Pathway 2.81E-05 44/292 15.10% 
Estrogen Receptor Signalling 1.70E-04 23/128 18% 
Molecular Mechanisms of Cancer 3.63E-04 51/394 12.90% 
Telomerase Signalling 4.24E-04 20/111 18% 
MiRNA-486-5p 
Huh7 
Renal Cell Carcinoma Signalling  2.65E-04 8/83 9.60% 
ERK5 Signalling 3.55E-04 7/66 10.60% 
Hif1α Signalling 6.41E-04 9/118 7.60% 
RhoGDI Signalling 9.46E-04 11/177 6.20% 
Molecular Mechanisms of Cancer 1.13E-03 18/394 4.60% 
Analysis highlighting the top canonical pathways including putative pull-down targets, 
statistical significance with p < 0.05, overlap of pull-down targets with the total number of 
targets within the pathway and their overlap percentage. (Abbreviations: IHH, immortalised 
human hepatocytes; IPA, Ingenuity Pathway Analysis; Huh7, human hepatoma-derived 
cell line; miRNA, microRNA). 
 
Five putative mRNA targets per pull-down experiment were selected for further expression 
analysis. The selection of these targets was based on their involvement in the top 
canonical pathway highlighted within the IPA analysis, prominence within the selected 
pathway (with key functional components such as receptors or transcription factors given 
priority), and overall fold change. These included ITGA2, ELK3, EP300 and EGFR within 
the ERK/MAPK pathway and Hif1α within the VEGF pathway for miRNA-151a-5p; and 
EP300, MAP2K5 (MEK5) and EGFR within the ERK/MAPK pathway, and ROCK2 and 
Hif1α within the VEGF pathway for miRNA-486-5p. Profound IPA analysis and comparison 
of several cancer pathways, published because of their purported involvement in HCC, 
has also highlighted potential oncogenes and tumour suppressors as putative mRNA 
targets identified via the pull-down assay. Therefore, 5 additional targets for miRNA-151a-
5p and 4 additional targets for miRNA-486-5p were selected for further expression 
analysis, including potential oncogenes Yap1 and MET and potential tumour suppressors 
PTEN, XPO4 and UBE2H for miRNA-151a-5p, as well as the potential oncogene Yap1 
and MET and potential tumour suppressors PTEN and UBE2H for miRNA-486-5p. 
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4.4.2 Putative target confirmation using qRT-PCR 
 
In total, 10 putative mRNA targets for miRNA-151a-5p and 9 putative mRNA targets for 
miRNA-486-5p were selected for qRT-PCR analysis (see Section 4.4.1). Differential 
expression of selected targets was measured 24h, 48h and 72h after miRNA transfection 
in both cell lines, IHH and Huh7. All measurements were performed using biological 
triplicates. Unfortunately, Hif1α had to be excluded from further analysis due to melt curve 
inconsistency of the designed primer. Following qRT-PCR analysis, differential expression 
was determined using the t-test to compare expression at each time point with potential 
mRNA targets shown with an arbitrary selected P-value < 0.1.  
 
MiRNA-151a-5p transfected IHH cells showed a trend towards increased PTEN 
expression (p = 0.057) at 24h post-transfection (see Figure 4.4A), but differential 
expression of all other putative mRNAs could not be validated in IHH or Huh7 cells (all P-
values > 0.1) Analysis of miRNA-486-5p qRT-PCR data showed a significant decrease of 
PTEN expression at 24h post-transfection (p = 0.026) and significantly decreased 
expression of MET at 48h post transfection, when compared to controls at the same time 
point (see Figure 4.4). ). Interestingly, this significantly decreased expression was only 
observed in IHH cells and not Huh7 cells. Putative mRNA targets, selected based on their 
involvement in the ERK/MAPK and VEGF pathways, did not reveal any statistically 
significant differential expression on qRT-PCR. Three targets showed trends towards 
differential expression as follows: EGFR (p = 0.071) with reduced expression at 48h, and 
MAP2K5 (p = 0.057) and EP300 (p = 0.083) with reduced expression at 24h (see Figure 
4.5). 
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Figure 4.4. qRT-PCR analysis of putative target oncogene and tumour suppressor 
genes. (A) PTEN expression in miRNA-151a-5p transfected IHH cells at different time 
points; (B) PTEN expression in miRNA-486-5p transfected IHH cells at different time 
points; and (C) MET expression in miRNA-486-5p transfected IHH cells at different time 
points. (P-values were calculated using the t-test comparing expression at each time point. 
Data represents triplicates, shown as mean ± SEM). (Abbreviations: IHH, immortalised 
human hepatocytes; Met1, receptor tyrosine kinase; miRNA, microRNA; PTEN, 
phosphatase and tensin homolog). 
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Figure 4.5. qRT-PCR validation of putative target genes. (A) EGFR expression in 
miRNA-486-5p transfected IHH cells at different time points; (B) MAP2K5 expression in 
miRNA-486-5p transfected IHH cells at different time points; and (C) EP300 expression in 
miRNA-486-5p transfected IHH cells at different time points. (P-values were calculated 
using the t-test comparing expression at each time point. Data represents triplicates, 
shown as mean ± SEM). (Abbreviations: EGFR, epidermal growth factor receptor; EP300, 
E1A binding protein P300; IHH, immortalised human hepatocytes; MAP2K5 (MEK5), 
mitogen-activated protein kinase 5; miRNA, microRNA). 
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Although no statistically significant decreased expression was observed, all examined 
targets that showed a trend toward inhibition by miR-486-5p in IHH cells belonged to the 
ERK5 signalling pathway (see Figure 4.6). 
 
Figure 4.6. ERK5 pathway showing putative pull-down targets of miRNA-486-5p in 
IHH cells. Putative pull-down targets inhibited by miR-486-5p in IHH cells, with a trend 
towards significance, are highlighted with a blue arrow. Significant putative pull-down 
targets not currently validated using qRT-PCR within the ERK5 pathway are highlighted in 
red. (Abbreviations: EGFR, epidermal growth factor receptor; EP300, E1A binding protein 
P300; ERK5, extracellular-signal-regulated kinase 5; IHH, immortalised human 
hepatocytes; MAP2K5 (MEK5), mitogen-activated protein kinase 5; miRNA, microRNA). 
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4.4.3 Functional assays 
 
As outlined previously, IPA analysis of putative mRNA targets of miRNA-151a-5p and 
miRNA-486-5p underlined their involvement in cancer-related pathways such as PTEN, 
Yap1 and ERK5 pathways. Therefore, the effect of miRNA-151a-5p and miRNA-486-5p 
overexpression on the phenotype of normal hepatocytes (IHH) and hepatoma cells (Huh7) 
was further investigated using functional assays for cell proliferation and migration. 
 
4.4.3.1 MiRNA-151a-5p 
 
After miRNA-151a-5p overexpression, a comparison of the proliferation of control and 
transfected IHH (n = 3) and Huh7 (n = 4) cells resulted in no significant differences in 
proliferation rates over 96 hours with P=values of 0.202 and 0.309, respectively. 
Assessment of the transfection efficiency at baseline (time = 0 hours) revealed an average 
of 149-fold higher miRNA-151a-5p expression compared with control transfected IHH 
cells, whereas miRNA-151a-5p levels in Huh7 cells were on average 76-fold higher than in 
control transfected cells. Although observed proliferation rates did not reach statistically 
significant differences, there was a trend towards reduced proliferation in miRNA-151a-5p 
transfected IHH as well as Huh7 cells (see Figure 4.7). 
 
Assessing the effect of miRNA-151a-5p transfection on migration, no statistically 
significant differences in migration in IHH or Huh7 cells were observed when compared 
with control transfected cells. Analysing the growth rate constant (k) resulted in P-values of 
0.480 and 0.192, respectively, for the miRNA-151a-5p migration assay in IHH and Huh7 
cells. Both experiments were performed in triplicate and baseline (time = 0 hours) 
transfection efficiency showed a 9-fold higher expression of miRNA-151a-5p in IHH cells 
and 4-fold higher expression in Huh7 cells when compared to control transfected cells (see 
Figure 4.8).  
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Figure 4.7. MiRNA-151a-5p proliferation assay. (A) Proliferation assay with percentage 
of confluence over 96 hours and (B) growth rate, shown as rate constant (k), of miRNA-
151a-5p transfected cells compared to control transfected IHH cells. No statistically-
significant differences in growth rate were overserved (p = 0.202). The IHH proliferation 
assay was performed in n = 3 and baseline transfection efficiency showed a 149-fold 
higher miRNA-151a-5p expression compared with control transfected cells. (C) 
Proliferation assay showing miRNA-151a-5p transfected Huh7 cells confluence over 96 
hours and (B) growth rate, shown as rate constant (k), of miRNA-151a-5p transfected cells 
compared with control transfected Huh7 cells. No statistically significant differences in 
growth rate were overserved (p = 0.309). Huh7 proliferation assay was performed n = 4 
and baseline transfection efficiency showed 76-fold higher miRNA-151a-5p expression 
compared with control transfected cells. All data are shown as mean ± SEM. Statistical 
significance was determined using paired t-tests, with significance designated as a P-value 
< 0.05.(Abbreviations: IHH, immortalised human hepatocytes; Huh7, human hepatoma-
derived cell line; miRNA, microRNA). 
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Figure 4.8. MiRNA-151a-5p migration assay. (A) Migration assay presenting percentage 
of wound density over 24 hours and (B) growth rate, shown as rate constant (k), of 
miRNA-151a-5p transfected cells compared with control transfected IHH cells. No 
statistically significant differences in growth rate were overserved (p = 0.480). IHH 
migration assay was performed n = 3 and baseline transfection efficiency showed a 9-fold 
higher miRNA-151a-5p expression compared with control transfected cells. (C) Migration 
assay showing miRNA-151a-5p transfected Huh7 cells wound density over 24 hours and 
(B) growth rate, shown as rate constant (k), of miRNA-151a-5p transfected cells compared 
with control transfected Huh7 cells. No statistically significant differences in growth rates 
were observed (p = 0.192). Huh7 migration assay was performed n = 3 and baseline 
transfection efficiency showed a 4 fold higher miRNA-151a-5p expression compared to 
control transfected cells. All data are shown as mean ± SEM. Statistical significance was 
determined using paired t-test with significance designated a P-value < 0.05. 
(Abbreviations: IHH, immortalised human hepatocytes; Huh7, human hepatoma-derived 
cell line; miRNA, microRNA). 
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4.4.3.2 MiRNA-486-5p 
 
To investigate the potential effects of miRNA-486-5p on proliferation and migration of IHH 
and Huh7, the same experimental set-up was followed as that previously described for 
miRNA-151a-5p.  
 
A proliferation assay was performed using miRNA-486-5p transfected IHH (n = 3) and 
Huh7 (n = 4) cells compared with control transfected cells. No statistically significant 
change in growth rate constants (k) were overserved over 96 hours for IHH (p = 0.498) or 
Huh7 (p = 0.560).  Assessing transfection efficiency at baseline (time = 0 hours) revealed 
a 308-fold higher transfection of miRNA-486-5p in IHH cells and 318-fold higher 
expression of miRNA-486-5p in Huh7 cells when compared with control transfected cells 
(see Figure 4.9). 
 
The effect of miRNA-486-5p transfection on cell migration was assessed in IHH and Huh7 
cells. No statistically significant differences were observed in the growth rate constants (k) 
of miRNA-486-5p transfected IHH (p = 0.877) or Huh7 (p = 0.279) cells when compared 
with control transfected cells. All migration assays were performed in triplicate and run for 
24 hours. Assessing baseline transfection efficiency (time = 0 hours) revealed a 15-fold 
higher miRNA-486-5p expression of IHH transfected cells and 5-fold higher miRNA-486-5p 
expression levels in Huh7 cells compared with control transfected cells (see Figure 4.10). 
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Figure 4.9. MiRNA-486-5p proliferation assay. (A) Proliferation assay showing miRNA-
486-5p transfected IHH cells confluency over 96 hours and (B) growth rate, shown as rate 
constant (k), of miRNA-486-5p transfected cells compared with control transfected IHH 
cells. No statistically significant difference in growth rate was overserved with p = 0.498. 
IHH proliferation assay was performed (n = 3) and baseline transfection efficiency showed 
a 308-fold higher miRNA-486-5p expression compared with control transfected cells. (C) 
Proliferation assay showing miRNA-486-5p transfected Huh7 cells confluency over 96 
hours and (D) growth rate, shown as rate constant (k), of miRNA-486-5p transfected cells 
compared with control transfected Huh7 cells. No statistically significant difference in 
growth rate was overserved with p = 0.560. Huh7 proliferation assay was performed (n = 
4) and baseline transfection efficiency showed a 318-fold higher miRNA-486-5p 
expression compared with control transfected cells. All data shown as mean ± SEM. 
Statistical significance determined using paired t-test with significance designated a P-
value < 0.05. (Abbreviations: IHH, immortalised human hepatocytes; Huh7, human 
hepatoma-derived cell line; miRNA, microRNA). 
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Figure 4.10. MiRNA-486-5p migration assay. (A) Migration assay showing miRNA-486-
5p transfected IHH cells wound density over 24 hours and (B) growth rate, shown as rate 
constant (k), of miRNA-486-5p transfected cells compared with control transfected IHH 
cells. No statistically significant difference in growth rate was overserved with p = 0.877. 
IHH migration assay was performed (n = 3) and baseline transfection efficiency showed a 
15-fold higher miRNA-486-5p expression compared to control transfected cells. (C) 
Migration assay showing miRNA-486-5p transfected Huh7 cells wound density over 24 
hours and (B) growth rate, shown as rate constant (k), of miRNA-486-5p transfected cells 
compared with control transfected Huh7 cells. No statistically significant difference in 
growth rate was overserved with p = 0.0.279. Huh7 migration assay was performed (n = 3) 
and baseline transfection efficiency showed a 5-fold higher miRNA-486-5p expression 
compared with control transfected cells. All data shown as mean ± SEM. Statistically 
significance determined using paired t-test with significance designated a P-value < 0.05. 
(Abbreviations: IHH, immortalised human hepatocytes; Huh7, human hepatoma-derived 
cell line; miRNA, microRNA). 
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4.5 Discussion 
 
In Chapter 3, serum levels of miRNA-151a-5p and miRNA-486-5p were significantly 
dysregulated in HCC patients compared with cirrhotic patients, with miRNA-151a-5p 
decreased and miR-486-5p increased. Based on these results and literature findings, there 
appears to be increasing evidence that these 2 miRNAs function as pro-oncogenic and 
tumour-suppressor miRNA, respectively.122, 321, 322, 330 Identifying the actual mRNA targets 
of each of these miRNAs is critical to a better understanding of the roles that these 
miRNAs might play in the pathogenesis of HCC. As previously discussed, commonly-
utilised mRNA target prediction tools that purport to identify such downstream targets have 
limited predictive value and are thought not to provide a true representation of the global 
mRNAs affected by differential expression of miRNA-151a-5p and miRNA-486-5p.  
 
In the current study, following up results from Chapter 3, investigations on the genes 
targeted by miRNA-151a-5p and miRNA-486-5p were conducted to identify their potential 
involvement in HCC development.  A pull-down assay was performed to identify putative 
mRNA targets of the selected miRNAs specific to liver cells. In the subsequent pathway 
analysis, several potential pathways affected by miRNA-151a-5p and miRNA-486-5p were 
identified and individual targets were selected for initial mRNA expression analysis. To 
further explore putative effects, preliminary functional assays were performed to 
investigate the effects of miRNA-151a-5p and miRNA-486-5p on cellular behaviour (i.e. 
proliferation and migration).  
 
Previous studies of miRNA-151a-5p and miRNA-486-5p have focused on investigations 
into specific chromosomal location or targets identified through target prediction 
algorithms. Performing a pull-down assay allowed the unbiased identification of putative 
mRNA targets specific to the miRNA of interest and the selected cell types. Using two cell 
lines, an immortalised normal human hepatocyte (IHH) and human hepatoma (Huh7) cell 
line,I identified targets that may have the potential to regulate the development of HCC. 
Interestingly, pull-down experiments performed in the cancerous Huh7 cells resulted in 
fewer putative mRNAs being identified when compared with pull-down experiments in IHH 
cells. This could represent a true observation with fewer targets available for miRNA 
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binding in a cancer cell line. Technical variation was observed as shown in the hierarchical 
clustering of the pull-down assays, with the clustering of miRNA-151a-5p pull-downs in 
Huh7 cells and the clustering of miRNA-486-5p pull-downs in IHH cells, in particular, 
showing some cluster variation. This could be explained with day-to-day technical variation 
of experimental performance, such as transfection efficiency or cell harvesting, 
contributing to variability. Of note, one sample had to be excluded due to poor alignment 
post-sequencing. Removal of one control sample in the miRNA-486-5p pull-downs in Huh7 
could have also potentially contributed to the lower number of targets identified.  
 
The direct comparison of the pull-down assays with target prediction algorithms 
demonstrated the potential of this experimental approach for target identification. Target 
prediction, such as TargetScan or miRDB, can vary widely and potentially returns only a 
low number of results. Performing target prediction for miRNA-151a-5p generated only 10 
targets using TargetScan and only 43 targets using miRDB. In addition to the low number 
of targets identified, both prediction algorithms predicted very different targets with an 
overlap of only 2 genes. For miRNA-486-5p, TargetScan and miRDB overlapped in only 
47 targets. Target prediction relies on several parameters beyond seed region binding 
such as Watson-Crick pairing at nucleotides 12-17 and synergistically effects of closely 
spaced miRNAs. Effective targets also reside preferentially in a local AU-rich context, 
close to 3’UTR ends but with sufficient distance to stop codons.275 Depending on the 
algorithm used, variations in only one of these parameters can lead to a variation in 
predicted targets, including the lack of prediction of actual targets. When compared to the 
experimental target identification there was an overlap of 16 targets for miRNA-151a-5p 
and 59 targets for miRNA-486-5p.  
 
When comparing putative targets identified through the pull-down assays with known 
pathways using the pathway analysis software IPA, a significant overlap with several 
cancer pathways was identified. For example, miRNA-151a-5p targets were linked with 
EGF, p53, and ERK/MAPK signalling as well as to overall Molecular Mechanisms of 
Cancer pathway. MiRNA-486-5p targets were also linked with ERK5 and Hif1α signalling 
as well as the Molecular Mechanisms of Cancer Pathways. Observing an overlap between 
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the pull-down targets identified and known cancer related pathways supported a potential 
link between miRNA-151a-5p and miRNA-486-5p and HCC.  
 
Preliminary expression analysis of selected putative targets in miR-151a-5p or miR-486-5p 
transfected cells showed very few genes with resultant decreased expression levels using 
qRT-PCR. MiRNAs are not only known to bind to mRNA and lead to degradation but also 
interfere with translation itself, which cannot be validated using qRT-PCR. To adequately 
validate mRNA targets identified through the pull-down assays, luciferase assays are 
traditionally required, as well as Western blot analysis to assess the impact on actual 
protein levels. Using PCR, however, did allow the identification of direct effects of 
transfected miRNAs on selected putative mRNA target levels. MiRNA-151a-5p transfection 
of IHH cells (a cell line representing healthy hepatocytes) resulted in increased PTEN 
expression, although not statistically significant, at 24 hours post–transfection. This was at 
odds with the expectation that transfection would induce a reduction in PTEN, if one 
considers PTEN to be a tumour suppressor and miRNA-151a-5p as potentially oncogenic. 
Observing an increase in PTEN suggests that any oncogenic function of miR-151a-5p may 
be caused through an indirect effect by activating other molecular pathways. It could also 
be speculated that increased levels of PTEN may be a consequence of cell defence 
mechanisms in response to pro-oncogenic miRNA activity, although this would require 
further extensive investigation to elucidate the precise mechanisms involved. 
 
Transfecting the purported tumour suppressor miRNA-486-5p into IHH cells also resulted 
in unexpected differential expression of PTEN. A statistically significant reduction in 
expression was observed at 24 hours post-transfection. This direct targeting of PTEN by 
miRNA-486-5p was unexpected as a miRNA acting as potential tumour suppressor would 
be expected to bind (thus inhibit) oncogenes rather than tumour-suppressor genes. In line 
with its potential tumour suppressor role, the potentially oncogenic MET was significantly 
downregulated by the miRNA-486-5p. Again, it could be speculated that, miRNA-486-5p 
may act to maintain the normal hepatocyte phenotype by degrading the oncogenic MET 
mRNA in IHH cells, but this potential mechanism requires future study.  
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A trend towards decreased expression of EGFR, MAP2K5 (MEK5) and EP300 in miRNA-
486-5p-transfected IHH cells was identified. Although no statistical significance was 
observed, a potential suppressive effect of miRNA-486-5p (via mRNA degradation) would 
be interesting as these targets are all part of the ERK5 pathway and increased expression 
of ERK5 has been shown in HCC in vitro350 and amplified levels of MAPK7 (which 
encodes ERK5) have been demonstrated in HCC tissue.351  Assessing ERK5 expression 
levels in cirrhotic and HCC tissue shows a distinct nuclear localisation of ERK5, compared 
to cytoplasmic expression in normal liver tissue.352 Rovida et al. demonstrated that 
inhibition of ERK5 reduces proliferation and regulates cell motility and invasiveness in 
HCC in vitro. In vivo, using Huh7 xenograft nude mice, a decrease in tumour size was 
observed after injection with an ERK5 inhibitor.352 If further validation studies could confirm 
a potential inhibitory effect of miRNA-486-5p on EGFR, MAP2K5 and EP300, as active 
players in the ERK5 pathway, it would suggest a role in HCC proliferation and 
development. Of course, until further studies are done, this role is purely speculative but 
this potential miRNA-486-5p regulated pathway does present an interesting area for future 
research. 
 
When performing functional assays, no significant changes in proliferation and/or migration 
of miRNA-151a-5p and miRNA-486-5p transfected cells were observed. Given the 
potential inhibitory effect of miRNA-486-5p on the ERK5 pathway, a reduction in 
proliferation could have been expected352 but was not seen. This discrepancy could have 
been due to technical variation, such as transfection efficiency, suggesting that higher or 
more stable miRNA-486-5p levels are required to affect cell proliferation. Following 
miRNA-151a-5p transfection of IHH and Huh7 cells, a trend towards decreased 
proliferation was observed. MiRNA-151a-5p has previously been reported to increase cell 
migration and invasion,122 but alterations in cell proliferation have not been described. 
Interestingly, this study did not observe any significant changes in migration after 
transfecting cells with miRNA-151a-5p or miRNA-486-5p. Once again, this may have been 
due to the fact that baseline transfection efficiency was low in all migration assays 
performed, potentially caused by the required re-seeding of cells six hours after 
transfection. I also observed moderate variability of results across the migration assays 
performed, suggesting that further optimisation of this assay is needed before any firm 
conclusions can be drawn. 
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There are clearly limitations to this study that need to be addressed. Based on a 
reasonable assumption of consistent transfection efficiency, a direct effect of miRNA 
binding would have been expected to be present at both time points. Unfortunately, 
however, baseline transfection efficiencies in the proliferation and migration assays were 
somewhat variable, with the migration assays being particularly affected by low 
transfection efficiency as the cells had to be reseeded 6 hours post-transfection. For future 
experiments an alternative mode of transfection is recommended, such as a lentivirus 
based stable transfection system. Using stable transfection for any future experiments 
would enable a more sensitive assessment of differential expression or alterations in 
cellular behaviours, such as proliferation and migration. It is important to note that even if 
no changes in mRNA expression could be identified following miRNA transfection, this 
does not mean that the putative targets are not actual targets. This is due to the fact that 
PCR is not ideal for assessing target validation and all putative targets identified by pull-
down assays require confirmation by luciferase assay. Other assays to identify functional 
roles of miRNA-151a-5p and miRNA-486-5p include anchorage-dependant growth assay 
or clonogenicity assay, to assess the tumorigenesis effects of both miRNAs. In addition, 
any potential effect of miRNA-151a-5p and miRNA-486-5p should be replicated in multiple 
hepatocyte and hepatoma cell lines before any definitive conclusions can be drawn. Thus, 
these experiments should be regarded as a pilot study to identify putative targets that 
could be further explored and validated in future studies.  
 
In conclusion, this study attempted to identify several putative mRNA targets of miRNA-
151a-5p and miRNA-486-5p in a hepatocyte and hepatoma cell line. Pathway analysis 
suggests that several of these targets are involved in known cancer pathways, such as 
ERK/MAPK signalling. Additional validation studies are needed to confirm these putative 
target genes and their potential role in HCC. However, initial expression studies suggest 
miRNA-486-5p could target the ERK5 pathway. Technical difficulties and some variability 
of results were also experienced, potentially caused by transient transfection, highlighting 
the importance of stable experimental conditions in this area of research. It is proposed 
that any future validation studies should be performed using stable transfection to 
investigate the effects of miRNAs of interest on cellular phenotype and expression. While 
more functional assays would be needed to assess the potential impact of miRNAs on 
other cancer characteristics, such as invasiveness or chemoresistance, the current study 
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does provide important and novel preliminary results in an emerging field. Overall this 
study created the foundation for functional studies of miRNA-151a-5p and miRNA-486-5p 
in HCC development. 
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CHAPTER 5                                                              
MicroRNA-451a and early HCC: Promise and pitfalls of… 
using microRNAs as biomarkers….. 
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5.1 Introduction 
 
Progressive chronic liver disease can eventually lead to cirrhosis, which is a major risk 
factor for the development of HCC. With ongoing injury, regenerative nodules arise from 
areas of localised proliferation in a response to hepatocyte injury and these, via 
progressive dysplasia and malignant transformation, can evolve into HCC. Although 
regenerative nodules typically occur within the cirrhotic liver, where the nodules are 
surrounded by fibrous septa, these nodules can also occur in non-cirrhotic healthy 
parenchyma.94 Depending on the histological characteristics, dysplastic nodules are 
categorised as either low-grade or high-grade. Low-grade dysplastic nodules are 
histologically difficult to distinguish from regenerative nodules. High-grade dysplastic 
nodules, however, can be identified by cellular changes such as increased cell density and 
disorganised architecture. Dysplastic nodules, especially high-grade dysplastic nodules, 
are pre-malignant lesions that cannot yet be characterised as HCC.94 Interestingly, 
dysplastic nodules are found in approximately 15-25% of cirrhotic livers,95, 96 with high-
grade dysplastic lesions at highest risk of progression to HCC.97, 98 A prospective study 
examining malignant transformation rates of macronodules, including regenerative and 
dysplastic nodules, showed that approximately 2-3% progress to HCC within a year, 15% 
in two years, 31% in three years, and around half progress to HCC in five years.353 With 
the growth of these lesions the likelihood of malignancy increases, with those measuring 2 
cm or more in maximal diameter having a high chance of being HCC.94 
 
HCC has a high prevalence and is now the sixth most common cancer worldwide, with an 
estimated 782,000 new cases diagnosed in the year 2012 alone.87 Several cellular 
processes are altered during hepatocarcinogenesis. In HCC, angiogenesis is especially 
altered in dysplastic nodules that progress to HCC. During the transition from a benign to a 
malignant lesion vessel formation proliferates and the density of unpaired arteries and 
capillary units increases. This process is especially evident during the switch from low-
grade to high-grade nodules.77, 82, 83 Other features of hepatocarcinogenesis can include 
changes to venous drainage (changing from hepatic vein to hepatic sinusoids to portal 
vein),103 accumulation of fat in high-grade dysplastic nodules and HCCs of less than 1.5 
cm due to insufficient development of tumour arterial supply,104 increased iron 
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accumulation,105 and decreasing expression of OATP, which is an organic anion 
membrane transport protein106, 107 
 
The diagnosis of HCC relies on imaging surveillance as the only accepted tumour-
biomarker AFP has suboptimal sensitivity and specificity for surveillance and diagnosis in 
most cases.113, 115 Although it has an impressive specificity at very high levels, AFP 
demonstrates poor specificity at low levels and suboptimal sensitivity in association with 
small or indeterminate lesions.116 Imaging surveillance routinely comprises 6-monthly 
ultrasound scans, which has an estimated sensitivity of 94% for the detection of HCC 
across all stages but only 63% sensitivity for early HCC.113 Typically, the identification of a 
suspicious lesion on ultrasound is then followed up use of dynamic scanning (CT/MRI). 
Lesions identified can be assessed using the LI-RADS classification, which determines the 
likelihood of HCC based on imaging characteristics using a standardised approach. LI-
RADS stratifies lesions into definitely benign lesion (LI-RADS 1), probably benign (LI-
RADS 2), intermediate probability of being HCC (LI-RADS 3), probably HCC (LI-RADS 4) 
and definitely HCC (LI-RADS 5).112 This approach, however, does not confirm the 
diagnosis for all lesions identified. For 14-23% of indeterminate lesions, where the imaging 
is inconclusive, diagnosis is delayed until interval growth consistent with malignancy can 
be demonstrated on follow-up imaging.114, 303 Biopsy of indetermined liver lesions is 
recommended but, due to the small lesion size, sampling error can be high and repeat 
biopsy can be necessary. Also, biopsy is asscociated with significant risks, such as 
bleeding and needle tract seeding.114, 117 
 
Identification of early HCC is crucial for access to curative treatments. The BCLC 
classification recommends curative treatment (comprising resection, ablation, or liver 
transplantation) only for tumours of less than 3 cm in size. Larger, multinodular tumours 
and/or those with portal vein invasion are usually amenable to only palliative treatment 
approaches, such as TACE or systemic chemotherapy (e.g. Sorafenib).52, 119 Importantly, if 
HCC is detected and treated early, the 5 year survival rate of a compensated patient with 
single HCC is very good at around 68%, whereas patients with multifocal HCCs have a 
terrible 5 year survival of around 19%.120 
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5.2 Aims and hypothesis 
 
It was hypothesised that the development of HCC in cirrhotic patients is associated with a 
distinct miRNA expression profile, or “signature”, that could be quantified in circulating 
blood as a means to diagnose early HCC.  
 
The third aim of this thesis, therefore, is:  
A. To identify circulating miRNAs whose expression profile is associated with early 
HCC; and  
B. To identify miRNAs that are differentially expressed in patients with atypical or 
indeterminate liver lesions that are ultimately diagnosed as HCC. 
 
5.3 Material and methods 
5.3.1 Patient recruitment and characteristics 
 
In total, 99 patients with cirrhosis were enrolled in this study, subdivided into 3 overall 
study cohorts as follows: compensated cirrhosis (CC, n = 30); “early” HCC measuring less 
than 2.5 cm in size (HCC, n = 25); and cirrhotic patients with an atypical or indeterminate 
lesion on initial dynamic imaging (n = 44). Serum samples were obtained from patients 
with compensated cirrhosis during routine clinical review and dedicated serum samples 
were obtained from patients with HCCs less than 2.5cm in size at the time of diagnosis of 
early HCC. Patients with indeterminate lesions were followed with serial imaging (in 
accordance with standard of care and subsequently allocated to a further sub-group based 
upon whether the indeterminate lesion proved benign on follow-up (F/U Benign, n = 32) or 
malignant (F/U HCC, n = 12). For all patients with indeterminate lesions (i.e. F/U Benign 
and F/U HCC groups), serum samples were collected around the time the lesion was first 
detected and these patients were prospectively surveilled in accordance with standard of 
care Patient recruitment criteria and data collection methods have been described earlier 
(see Section 2.1), with patients enrolled through the Royal Brisbane and Women’s 
Hospital Liver Clinic (n = 94) and the Sir Charles Gairdner Hospital liver clinic (n = 5). All 
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clinical assessments were based on expert specialist assessment according to accepted 
professional guidelines. Diagnosis of HCC was based on the currently-accepted AASLD 
Professional Guidelines for the diagnosis and management of HCC.109, 110, 114  All liver 
lesions were assessed according to LI-RADS criteria, with individual findings confirmed by 
a single hepatologist according to the (then) latest version (version 2017) and verified by a 
single radiologist. 
 
5.3.2 RNA extractions, reverse transcription, sequencing and qRT-PCR 
 
The screening phase to identify differentially expressed miRNA candidates was performed 
using small RNA NGS on a pilot sample subset as follows: CC n = 15, F/U Benign n = 12, 
F/U HCC n = 8 and HCC n = 15. Circulating miRNA was isolated from non-haemolysed 
serum using the Plasma/Serum RNA Purification Mini Kit (Norgen Biotek Corp; see 
Section 2.4.4). Serum was assessed for haemolysis using the NanodropTM 
spectrophotometer (Thermo Fisher Scientific; see Section 2.5.1) and circulating miRNA 
was isolated using the Plasma/Serum RNA Purification Mini Kit (Norgen Biotek Corp; see 
Section 2.4.4). MiRNA quantification, within the limit of detection, was performed using the 
Small RNA Bioanalyzer Kit (Agilent Technologies; see Section 2.5.2). Small RNA libraries 
were prepared using the NEBNext® Small RNA Library Prep Set (New England Biolabs) 
followed by sequencing on the Illumina HiSeq 2000 platform (Illumina Inc.). The protocol 
for library preparation has been described in detail in Section 2.6.8. 
 
The top 5 miRNA candidates were selected for qRT-PCR validation, with the validation 
phase being performed on the full study cohort of 99 patients (see Section 5.3.1). Isolation 
of miRNA was repeated using the Plasma/Serum RNA Purification Mini Kit (Norgen Biotek 
Corp), followed by NanodropTM (Thermo Fisher Scientific) assessment (see Sections 2.4.4 
and 2.5.1). Isolated miRNA was reverse transcribed using the miScript II RT Kit (Qiagen; 
see Section 2.6.1) followed by qRT-PCR using the miScript miRNA PCR system (Qiagen, 
see Section 2.6.4). Details of the primers used for qRT-PCR validation are presented in 
Table 2.4.  
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5.3.3 Data normalisation and statistical analysis 
 
MiRNA sequencing data was analysed as described in detail in Section 2.7.3. Accounting 
for low sequencing yield, only samples with ˃ 500 miRNA reads following exceRpt 
alignment were included in the statistical analysis. Differential expression analysis (see 
Section 2.8.4) was performed using the voom/limma method (see Section 2.8.4) with 
statistical significance defined as p < 0.05 and log fold change > 2. Novel miRNA 
identification was performed using the mirPRo pipeline as described in detail in Section 
2.7.3. Statistical significance of novel miRNA was determined using t-test, with statistical 
significance defined as p < 0.05. 
 
All results were internally validated, based on qRT-PCR analysed using the 2ΔCP method 
(see Section 2.8.3), with relative expression normalised to the expression levels of 
miRNAs let-7i-5p and let-7f-5p. Endogenous reference miRNA were selected based on the 
NormFinder algorithm (MOMA, see Section 2.7.2). Statistical significance was determined 
using an unpaired t-test (two group comparison) or a one-way ANOVA with Tukey’s post 
hoc comparison (see Section 2.8.3). Outliers within the dataset were assessed using the 
ROUT method in GraphPad Prism v.7 (GraphPad Software, see Section 2.8.3). 
 
5.3.4 Panel design, ROC curves and k-fold cross-validation 
 
Stepwise logistic regression was used to derive numerous different miRNA panels to 
identify the panel with the best prediction for HCC. Following the miRNA panel design, as 
described in Section 2.8.5, 𝑝𝑖 was determined using the following equations 
Function C: HCC vs all other groups (CC, F/U Benign and F/U HCC) 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = -1.77 – (0.68 × ∆CP miR-451a)  
 
Function D: F/U HCC and HCC vs CC and F/U Benign 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = -0.98– (0.50 × ∆CP miR-451a)  
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The diagnostic accuracy, and quality parameters of individual miRNAs and the miRNA 
panel were assessed using ROC curve analysis. ROC curve performance and k-fold 
cross-validation were performed as described in Section 2.8.5. 
 
5.4 Results 
5.4.1 Patient characteristics 
 
In total, 99 patients with chronic liver disease of various liver aetiologies were allocated to 
the study cohort. This included 30 patients with compensated cirrhosis (CC) and no 
lesions detected on routine surveillance, 25 patients with a solitary HCC less than 2.5 cm 
in size (HCC), and 44 patients with indeterminate lesions that were followed-up with serial 
imaging. For 32 patients with initially indeterminate lesions, the ultimate diagnosis was a 
truly benign lesion (F/U Benign; n = 32) after a mean follow-up of 23.3 months (SD 9.4), 
whereas 12 patients had indeterminate lesions that were ultimately diagnosed and 
managed as HCC (F/U HCC; n = 12) after a mean follow up 19.5 months (SD 7.8). During 
follow-up, 6 patients died and 5 patients received a liver transplant (all allocated to either 
HCC or F/U HCC study cohorts). Patients allocated in the F/U benign study cohort did not 
develop any malignancy during their follow-up period of follow-up of nearly 2 years (mean 
23.3 months; Table 5.1). 
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Table 5.1. Demographic and clinical characteristics of patients across all early HCC study groups. 
 
 
 Compensated cirrhosis 
(n = 30) 
F/U Benign 
(n = 32) 
F/U HCC 
(n = 12) 
HCC (≤ 2.5cm) 
(n = 25) 
P-
value 
Gender  (n/%)1 
Male 18 (60%) 25 (78%) 9 (75%) 21 (84%) 0.203 
Female 12 (40%) 7 (22%) 3 (25%) 4 (16%) 
Demographics2 
Age (years) 57.2 (SD 8.7) 57.4 (SD 10.5) 64.6 (SD 9.4) 61.1 (SD 8.4) 0.059 
BMI (Kg/m2) 30.2 (SD 7.0) 28.6 (SD 6.4) 27.4 (SD 5.2) 27.7 (SD 5.1) 0.407 
Aetiology (n/%)1 
ALD 3 (10%) 5 (16%) 3 (25%) 2 (8%) 0.906 
NASH 7 (23%) 5 (16%) 3 (25%) 4 (16%) 
HCV 18 (60%) 19 (59%) 5 (42%) 17 (68%) 
Other 2 (7%) 3 (9%) 1 (8%) 2 (8%) 
Baseline routine laboratory tests3,4 
Albumin (g/L) 41.0 (IQR40.0-43.0) 38.0 (IQR 34.5-42.0) 35.5 (IQR 32.5-37.8) 39.0 (IQR 35.5-42.0) 0.004 
ALT (U/L) 54.0 (IQR27.0-157.8) 44.0 (IQR 26.0-60.0) 22.5 (IQR 16.8-42.5) 50.0 (IQR 23.0-82.5) 0.009 
AST (U/L) 64.0 (IQR26.8-118.8) 46.0 (IQR 31.0-76.0) 43.0 (IQR 21.0-52.5) 54.0 (IQR 37.0-94.0) 0.31 
Billirubin (µmol/L) 14.0 (IQR11.8-19.3) 17.0 (IQR 13.5-23.3) 23.5 (IQR 9.3-33.3) 18.0 (IQR 14.5-25.0) 0.204 
Creatinine (µmol/L) 70.5 (IQR55.8-80.8) 69.0 (IQR 59.2-88.3) 78.5 (IQR 58.8-9.38) 70.0 (IQR 63.0-81.0) 0.756 
Platelet (x109/L)2 199.0 (IQR141.8-233.8) 135.5 (IQR 105.0-229.3) 102.5 (IQR 73.3-180.8) 138.0 (IQR 90.5-174.0) 0.007 
Sodium (mmol/L) 138.0 (IQR 136.0-139.0) 138.0 (IQR 136.0-139.0) 137.0 (IQR 135.3-138.8) 137.0 (IQR 136.0-139.0) 0.838 
Proximity of sample collection to baseline routine laboratory tests (months) 
 0.4 (SD 1.1) 0.1 (SD 1.0) 0.2 (SD 0.6) 0.1 (SD 0.3) NA 
Other laboratory tests 
INR3,4 1.1 (IQR 1.0-1.1) 1.2 (IQR 1.1-1.3) 1.2 (IQR 1.1-1.4) 1.2 (IQR 1.1-1.4) 0.001 
AFP (µg/L) 3,4 3.5 (IQR 2.2-7.9) 4.7 (IQR 2.6-7.0) 3.6 (IQR 2.1-28.4) 7.7 (IQR 3.2-22.0) 0.127 
Sample collection to 
AFP (months) 
0.3 (SD 4.6) 0.3 (SD 1.9) 0.3 (SD 0.8) 1.2 (SD 3.5) NA 
Clinical follow up (months) 
 32.7 (SD 7.0) 23.3 (SD 9.4) 19.5 (SD 7.8) 15.0 (SD 10.8) NA 
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 Compensated cirrhosis 
(n = 30) 
F/U Benign 
(n = 32) 
F/U HCC 
(n = 12) 
HCC (≤ 2.5cm) 
(n = 25) 
P-
value 
Disease severity assessment 
CTP A (n) 29 28 8 22 NA 
CTP B (n) 1 4 4 2  
CTP C (n) - - - 1  
MELD 7.0 (IQR 6.0-8.0) 9.0 (IQR 7.0-11.0) 10.0 (IQR 8.3-12) 9.0 (IQR 7.0-12.0)  
Baseline LI-RADS (n) 
2 - 2 - - NA 
3 - 30 12 -  
4 - - - 12  
5 - - - 13  
Follow-up LI-RADS (n) 
0 - 9 - - NA 
1 - 1 - -  
2 - 13 - -  
3 - 9 - -  
4 - - 7 -  
5 - - 5 -  
Data shown as mean values unless otherwise specified. Following normality testing, P-values were calculated using the 1Chi-Square 
test, 2ANOVA, 3Kruskal-Wallis test, 4Data shown as median.  Data are complete for the entire cohort, except AST (n = 96) and BMI (n = 
92). (Abbreviations: AFP, alpha-fetoprotein; ALD, alcoholic liver disease; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BMI, body mass index; CTP, Child-Turcotte-Pugh Score; F/U Benign, Benign lesion diagnosed after follow-up; F/U 
HCC, hepatocellular carcinoma diagnosed after follow-up; HCC, hepatocellular carcinoma; HCV, Hepatitis C Virus; INR, international 
normalized ratio; IQR, interquartile range; MELD, model for end-stage liver disease score; NA, not applicable; NASH, non-alcoholic 
steatohepatitis; SD, standard deviation). 
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5.4.2 MiRNA next-generation sequencing screening phase 
 
Next generation sequencing was used to identify differentially expressed circulating 
miRNAs in a preliminary set of 50 serum samples across 4 sub-groups (CC, n = 15; F/U 
Benign, n = 12 samples; F/U HCC, n = 8; and HCC, n = 15).  As part of the sequencing 
preparation pipeline, quality control of isolated circulating miRNA was performed on the 
bioanalyzer (see Section 2.5.2) assessing differences in the quantity of miRNA between 
different samples. This step demonstrated variability of miRNA yield across samples and 
differences in the overall yield of serum miRNA isolated. As a result, the library preparation 
protocol was modified (see Section 2.6.8), to address low sample yield. Of note, even 
though all individual library preparations used a fixed sample volume (6 µL) to maximise 
sample input, concentrations were found to be below 1 ng per sample, which fell below the 
manufacturer’s recommended sample input of 5 ng for isolated small RNA. As a result of 
low RNA input, high levels of adapter dimer were observed during the library preparation, 
requiring the addition of a library clean-up step. As a result, during the sequencing itself, 
the protocol was amended and 10% PhiX was added to account for low sequencing 
diversity (see Section 2.6.8). 
 
Analysis of the sequencing data highlighted suboptimal performance of several miRNA 
libraries during the sequencing run. Quality control analysis showed inefficient library 
clustering, an overrepresentation of PhiX and high levels of artefacts, indicative of low 
library quality. Several samples did not yield sufficient miRNA readings (≤ 500 miRNA 
reads in total) and were subsequently excluded from the differential expression analysis 
(see Table 5.2). The resulting dataset included 30 of the original 50 libraries across all four 
study groups with the following quality control metrics (see Table 5.3). 
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Table 5.2. Distribution of next-generation sequencing libraries based on quality. 
Study group Samples submitted 
for NGS (n) 
Samples included in 
NGS analysis (n) 
Samples excluded 
from NGS analysis (n) 
CC n = 15 n = 9 n = 6 
F/U Benign n = 11 n = 5 n = 6 
F/U HCC n = 8 n = 4 n = 4 
HCC n = 16 n = 12 n = 4 
Following the exceRpt pipeline analysis, samples with ≤ 500 miRNA reads were excluded, 
whereas samples with ˃ 500 miRNA reads were included in the differential expression 
analysis. (Abbreviations: CC, compensated cirrhosis; F/U Benign, Benign lesion post 
follow up; F/U HCC, hepatocellular carcinoma post follow-up; HCC, hepatocellular 
carcinoma; NGS, next-generation sequencing) 
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Table 5.3. Sequencing quality metrics of samples included in statistical analysis. 
Library 
description  
Total reads Total base 
count in 
Megabases 
Bases ≥ 
Q30 (%) 
Read count 
post adapter 
clipping 
Read count 
post 
alignment  
miRNA 
read 
count 
CC 1 38,401,998 1,959 85.09 718,533 157,105 48,361 
CC 2 8,133,824 415 74.13 979,860 343,524 109,977 
CC 6 150,241 8 52.25 89,089 10,853 1,229 
CC 7 6,349,702 324 73.95 671,371 108,386 18,013 
CC 10 7,102,431 362 75.78 754,038 101,285 4,943 
CC 11 5,737,844 293 76.99 493,352 105,856 18,566 
CC 12 5,050,107 258 74.12 584,566 185,062 58,950 
CC 14 849,796 43 35.45 463,707 58,739 779 
CC 15 2,126,219 108 51.87 646,694 75,816 6,366 
F/U Benign 3 624,939 32 88.92 461,143 53,710 6,016 
F/U Benign 7 595,896 30 92.13 562,022 18,795 2,966 
F/U Benign 10 493,546 25 91.20 353,219 12,985 1,588 
F/U Benign 14 2,598,577 133 90.42 704,242 369,387 23,567 
F/U Benign 20 937,442 48 87.90 455,362 42,769 6360 
F/U HCC 1 3,731,140 190 73.18 336,915 60,670 13,588 
F/U HCC 4 1,565,941 80 90.10 1,369,846 125,761 14,271 
F/U HCC12 489,712 25 92.12 426,665 10,552 1,354 
F/U HCC15 81,631 4 87.17 32,996 8,247 1,166 
HCC 1 1,346,385 69 93.58 455,247 391,379 39,687 
HCC 2 2,762,813 141 92.72 1,299,159 1,143,069 184,125 
HCC 3 332,266 13 95.20 304,247 15,085 2,574 
HCC 4 398,544 20 78.28 223,719 59,440 7,590 
HCC 5 616,479 31 96.28 589,616 11,391 1,492 
HCC 6 207,684 11 94.64 188,104 7,818 1,469 
HCC 7 3,327,625 170 88.61 953,945 662,514 142,759 
HCC 9 422,164 22 95.25 394,762 9,009 805 
HCC 10 959,735 49 91.98 261,738 210,867 33,632 
HCC 11 64,691 3 93.08 51,889 8,652 1,635 
HCC 12 57,030 3 80.04 26,201 7,311 676 
HCC 16 58,122 3 89.94 69,145 10,525 1,706 
Samples selected following exceRpt pipeline analysis based on the selection criteria ˃ 500 
miRNA reads. (Abbreviations: CC, compensated cirrhosis; F/U Benign, Benign lesion post 
follow up; F/U HCC, hepatocellular carcinoma post follow up; HCC, hepatocellular 
carcinoma; Q30, number of bases passing the Illumina Inc. specific quality score). 
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This dataset of 30 NGS libraries was then analysed for differentially expressed miRNAs 
across all 4 study cohorts. A list of the most differentially expressed miRNAs was 
assembled based on P-value < 0.05 and log fold change ≥ 2, as well as their dynamic 
expression across the range of study cohorts (identifying changing expression levels in 
patients with compensated cirrhosis versus those with lesions confirmed as benign via 
follow-up versus those with lesions confirmed as HCC via follow-up versus those with 
immediately diagnosable HCC). While all comparisons were assessed, the focus of this 
study was the selection of miRNA expression profiles that could facilitate the early 
diagnosis of HCC, and therefore miRNAs with dynamic expression across these cohorts 
that identified patients with early HCC (whether via follow-up or immediately diagnosable) 
were prioritised for further analysis. As a result, the five most promising miRNAs (see 
Table 5.4) were selected for further validation. 
 
Table 5.4. Significantly differentially expressed miRNAs in early HCC compared to 
compensated cirrhosis. 
No. miRNA F/U Benign 
(logFC) 
F/U HCC 
(logFC) 
HCC 
(logFC) 
P-value 
1 hsa-let-7a-3p -1.15 -5.94 -4.13 0.009 
2 hsa-let-7c-5p -0.93 -6.73 -2.82 <0.001 
3 hsa-miRNA-127-3p 2.85 -3.76 -1.52 0.042 
4 hsa-miRNA-451a -1.56 -1.61 -2.58 0.048 
5 hsa-miRNA-93-5p 1.87 4.67 4.63 0.025 
Sub-group miRNA expression levels were quantified relative to their expression levels in 
patients with CC. P-values were calculated using voom/limma method with significance 
designated by a P-value < 0.05. (Abbreviations: CC, compensated cirrhosis; FC, fold 
change; F/U Benign, Benign lesion post follow up; F/U HCC, hepatocellular carcinoma 
post follow up; hsa, homo sapiens HCC, hepatocellular carcinoma; miRNA, microRNA). 
 
Amongst the miRNAs that were not included in the list of 5 most promising miRNAs 
selected for further validation were those that I previously identified in CHC-related HCC 
(see Section 3.4.3) as they did not satisfy selection criteria. Although miRNA-122-5p and 
miRNA-151a-5p expression levels reached statistical significance, with p = 0.005 and p = 
0.008 respectively, the logFC for both miRNAs were considered too low (see Table 5.5). 
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Table 5.5. Differential expression of miRNAs previously identified in chronic 
Hepatitis C-related hepatocellular carcinoma in Chapter 3. 
No. miRNA F/U Benign 
(logFC) 
F/U HCC 
(logFC) 
HCC 
(logFC) 
P-value 
1 hsa-miRNA-122-5p -1.79 -1.25 
 
-1.53 0.005 
2 hsa-miRNA-142-3p 0.69 -0.07 -0.92 0.820 
3 hsa-miRNA-151a-5p -1.24 -1.36 0.93 0.008 
4 hsa-miRNA-486-5p 0.63 0.28 0.89 0.233 
Sub-group miRNA expression levels were quantified relative to their expression levels in 
patients with CC. P-values were calculated using voom/limma method with significance 
designated by a P-value < 0.05. (Abbreviations: CC, compensated cirrhosis; FC, fold 
change; F/U Benign, Benign lesion post follow up; F/U HCC, hepatocellular carcinoma 
post follow up; hsa, homo sapiens HCC, hepatocellular carcinoma; miRNA, microRNA). 
 
5.4.3 MiRNA expression validation phase 
 
The expression levels of the top 5 differentially-expressed miRNA candidates were 
validated using qRT-PCR. Although significant differential expression was identified in the 
NGS-based discovery phase, statistically significant differential expression for miRNA-93-
5p, let-7c-5p and let-7a-3p was not confirmed during qRT-PCR validation (see Table 5.6). 
Furthermore, miRNA-127-3p was not consistently expressed in the serum of study 
participants, with a lack of expression observed in 25 patient samples (distributed across 
all study groups). The absence of expression was confirmed via repeated qRT-PCR 
measurements and, therefore, miRNA-127-3p was excluded from further validation 
analyses. All serum samples were assessed for haemolysis with no statistical significant 
differential expression determined between groups, with an ANOVA of p = 0.339. 
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Table 5.6. Circulating miRNA expression in early HCC: Validation of selected miRNA 
expression levels using real-time PCR. 
miRNA Overall P-
value 
(ANOVA) 
P-value 
CC vs. 
F/U 
Benign 
 
CC vs. 
F/U 
HCC 
 
CC vs. 
HCC 
 
F/U Benign 
vs. F/U 
HCC 
 
F/U 
Benign 
vs. HCC 
 
F/U HCC 
vs. HCC 
 
Let-7a-
3p 
0.281 
 
0.711 
 
0.660 
 
0.936 
 
0.981 
 
0.386 
 
0.410 
 
Let-7c-
5p 
0.313 
 
0.809 
 
0.641 
 
0.999 
 
0.252 
 
0.752 
 
0.729 
 
miRNA-
93-5p 
0.096 
 
0.536 
 
0.994 
 
0.130 
 
0.581 
 
0.777 
 
0.213 
 
miRNA-
451a 
0.002 
 
0.013 
 
0.377 
 
0.002 
 
0.891 
 
0.843 
 
0.556 
 
P-values were calculated using 2ΔCP normalisation method and ANOVA with Tukey’s post 
hoc test with significance designated by a P-value < 0.05. (Abbreviations: CC, 
compensated cirrhosis; FC, fold change; F/U Benign, Benign lesion post follow up; F/U 
HCC, hepatocellular carcinoma post follow up; hepatocellular carcinoma; miRNA, 
microRNA). 
 
Following validation, significant differential expression was confirmed for miRNA-451a via 
ANOVA (p = 0.002). Post hoc analysis of miRNA-451a expression demonstrated 
significantly increased expression in patients with compensated cirrhosis vs truly benign 
lesions (p = 0.013) and compensated cirrhosis vs HCC (p = 0.002; see Table 5.6 and 
Figure 5.1A). To assess the robustness of this result, the ROUT method in Prism (see 
Section 2.8.3) was used to identify potential outliers within the CC study sub-group. 
Removal of the confirmed outlier in the CC sub-group (see Figure 5.1) did not affect the 
statistical significance of miRNA-451a expression (ANOVA p = 0.005).  
 
By allocating all follow-up patients into either the CC or HCC patient cohorts, according to 
the ultimate diagnosis based on serial imaging, statistically significant differential 
expression was observed for miRNA-451a (p = 0.040; see Figure 5.1B). Removal of the 
outlier within the cirrhosis group (see Figure 5.1B), however, reduced the significance of 
this differential expression (p = 0.058).  
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Figure 5.1. Differential expression of miRNA-451a in HCC. (A) miRNA-451a shows an 
increased expression in F/U Benign lesions compared to cirrhosis (p = 0.013) and HCC, 
compared to cirrhosis (p = 0.002). (B) Regrouping patients into two study cohorts, cirrhosis 
and HCC, shows increased expression of miRNA-451a in HCC, compared to cirrhosis (p = 
0.040). Lines represent mean expression levels (± SEM). * p < 0.05, ** p < 0.01. 
(Abbreviations: CC, compensated cirrhosis; F/U Benign, Benign lesion post follow up; F/U 
HCC, hepatocellular carcinoma post follow up; hepatocellular carcinoma) 
 
5.4.4 Accuracy of miRNA-451a in diagnosing early HCC  
 
The potential of miRNA-451a (i) to discriminate small HCC from all other groups, and (ii) to 
discriminate early HCC (i.e. grouping HCC and F/U HCC) from cirrhosis without HCC (i.e. 
grouping cirrhosis and F/U Benign) was assessed using ROC curve analysis. Using the 
Youden’s index, described in Section 2.8.5, the miRNA specific cut-point of 0.24 was used 
to derive an AUC of 0.66 (95% CI 0.54 - 0.78, p = 0.009), with a sensitivity of 72%, 
specificity of 61%, PPV of 38%, NPV of 87% and overall accuracy of 64% for the diagnosis 
of HCC compared to all other groups (see Figure 5.2A). Discriminating early HCC (i.e. 
grouping HCC and F/U HCC) from cirrhosis without HCC (i.e. grouping cirrhosis and F/U 
benign lesions), using a miRNA-451a specific cut-point of 0.37, resulted in an AUC of 0.63 
(95% CI 0.51 – 0.74, p = 0.018), with a sensitivity of 68%, specificity of 61%, PPV of 51%, 
NPV of 76% and an overall accuracy of 64% (see Figure 5.2B). Performing stepwise 
logistic regression, using forward and backward elimination, could not generate a 
microRNA panel that increased diagnostic performance.  
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Figure 5.2. ROC curve performance of miRNA-451a in HCC. (A) miRNA-451a 
performance to identify HCC, when compared to cirrhosis, F/U benign and F/U HCC, with 
an AUC of 0.66 (95% CI 0.54 - 0.78, p = 0.009). (B) miRNA-451a performance to identify 
early HCC (grouping F/U HCC and HCC) compared to cirrhosis and F/U benign lesions 
with an AUC of 0.63 (95% CI 0.51 – 0.74, p = 0.018). (Abbreviations: 95% CI = 95% 
confidence interval; AUC, area under the curve; CC, compensated cirrhosis; FC, fold 
change; F/U Benign, Benign lesion post follow up; F/U HCC, hepatocellular carcinoma 
post follow up; HCC, hepatocellular carcinoma; miRNA, microRNA; ROC = receiver 
operating characteristics). 
 
5.4.5 Cross-validation of miRNA panels 
 
To further assess the robustness of using miRNA-451a to diagnose early HCC, k-fold 
cross-validation (5-fold) analysis was performed. This generated performance 
characteristics for miRNA-451a in the identification of HCC compared to all other groups, 
using a Youden’s index-derived cut-point of 0.24, of an AUC of 0.70 (95% CI 0.58 – 0.81), 
sensitivity of 68%, specificity of 60%, PPV of 37%, NPV of 85%, and overall accuracy of 
60% (see Figure 5.3A). Performing 5-fold cross-validation for miRNA-451a for the 
identification of early HCC (i.e. grouping F/U HCC and HCC) from cirrhosis without HCC 
(i.e. grouping cirrhosis and F/U Benign) resulted in an AUC 0.66 (95% CI 0.55 to 0.77), 
sensitivity of 62%, specificity of 54%, PPV of 42%, NPV of 72% and overall accuracy of 
55% (see Figure 5.3B). As mentioned in Section 5.4.4, this analysis used the comparison 
specific cut-point of 0.37 
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Figure 5.3. K-fold (5-fold) cross-validation ROC curve of miRNA-451a in HCC. (A) 
miRNA-451a 5-fold cross-validation performance to identify HCC, when compared to 
cirrhosis, F/U benign and F/U HCC, demonstrates an AUC of 0.70 (95% CI 0.58 – 0.81). 
(B) 5-fold cross-validation performance of miRNA-451a to identify early HCC (grouping 
F/U HCC and HCC) when compared to cirrhosis and F/U benign lesions demonstrates an 
AUC 0.66 (95% CI 0.55 to 0.77). (Abbreviations: 95% CI = 95% confidence interval; AUC, 
area under the curve; CC, compensated cirrhosis; FC, fold change; F/U Benign, Benign 
lesion post follow up; F/U HCC, hepatocellular carcinoma post follow up; HCC, 
hepatocellular carcinoma; miRNA, microRNA; ROC = receiver operating characteristics). 
 
5.4.6 Performance of AFP in identifying early HCC 
 
Within this study cohort, the accepted tumour marker AFP identified HCC (compared to all 
other groups) with an AUC of 0.65 (95% CI 0.51 - 0.78, p = 0.016) using a cut-off of > 20 
µg/L. This includes a sensitivity of 71%, specificity 11%, PPV of 21%, NPV of 53%, and 
overall accuracy of 26%. Combining both AFP and miRNA-451a resulted in a marginally 
improved AUC of 0.68 (95% CI 0.56 – 0.80). In the detection of early HCC (i.e. grouping 
HCC and F/U HCC) compared to cirrhosis without HCC (i.e. grouping cirrhosis and F/U 
Benign), AFP demonstrated an AUC of 0.60 (95% CI 0.48 – 0.73, p = 0.044), a sensitivity 
of 28%, specificity of 92%, PPV of 67%, NPV of 68% and overall accuracy of 68%. This 
analysis used an AFP cut-off of > 20 µg/L to diagnose HCC. Combining AFP and miRNA-
451a to a diagnostic panel results in an improved diagnostic performance with an AUC of 
0.69 (95% CI 0.57 – 0.80).  
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Figure 5.4. ROC curves to identify HCC using AFP alone or in combination with 
miRNA-451a. (A) AFP alone demonstrated poor diagnostic utility in the detection of HCC 
(compared to all other groups) with an AUC of 0.65 (95% CI 0.51 - 0.78, p = 0.016) using a 
cut-off of > 20 µg/L to diagnose HCC. When used in combination with miRNA-451a 
(described in Figure 5.2A) there was only a minor improvement in miRNA-451a ability to 
detect HCC (AUC = 0.68, 95% CI 0.56 – 0.80). (B) In the detection of early HCC (grouping 
F/U HCC and HCC) when compared to cirrhosis and F/U benign lesions AFP 
demonstrates and AUC of 0.60 (95% CI 0.48 – 0.73, p = 0.044) using a cut-off of > 20 µg/L 
to diagnose early HCC. When used in combination with miRNA-451a there was an 
improvement in the identification of early HCC with an AUC of 0.69 (95% CI 0.57 – 0.80). 
(Abbreviations: 95% CI = 95% confidence interval; AFP = alpha-fetoprotein; AUC, area 
under the curve; CC, compensated cirrhosis; FC, fold change; F/U Benign, Benign lesion 
post follow up; F/U HCC, hepatocellular carcinoma post follow up; HCC, hepatocellular 
carcinoma; miRNA, microRNA; ROC = receiver operating characteristics). 
 
5.4.7 Identification of novel miRNA in HCC 
 
Next generation sequencing was used to identify novel, previously undescribed circulating 
miRNAs in cirrhosis and HCC. Strong variability identified in the miRNA yield, as described 
in Section 5.4.2, affected the total number of libraries included in the subsequent analysis. 
Only samples with more than 10,000 reads mapped to known pre-miRNAs were included, 
resulting in a reduced dataset of n = 12 serum samples. For the purpose of novel miRNA 
identification F/U HCC (n = 2) and HCC (n =4) were grouped together and compared with 
cirrhotic patients (CC, n = 6).  
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Expression of 4 novel, previously undescribed miRNAs was identified in each group (n = 
12): novel miRNA-AW1 (designated AW-1, Anna Weis-1), with a median of 311 reads 
(IQR 156 – 617, see Figure 5.5), novel miRNA-AW2, with a median of 274 reads (IQR 130 
– 500, see Figure 5.6), novel miRNA-AW3, with a median of 134 reads (IQR 100 – 238, 
see Figure 5.7) and novel miRNA-AW4, with a median of 73 reads (IQR 54 – 127, see 
Figure 5.8). Differential expression analysis between cirrhosis and HCC (i.e. all HCC 
patients, grouping HCC with FU/HCC) did not show any significant differential expression 
of the most abundant miRNA (novel miRNA-AW1, p = 0.748, see Figure 5.9A). In contrast, 
significantly increased expression for novel miRNA-AW2 (p = 0.001, see Figure 5.9B), 
novel miRNA-AW3 (p = 0.001, see Figure 5.9C) and novel miRNA-AW4 (p < 0.001, see 
Figure 5.9D) was found when comparing HCC and cirrhosis. 
 
 
Figure 5.5. Structure of novel miRNA-AW1 in HCC. Predicted precursor miRNA 
structure of most abundantly expressed circulating novel miRNA-AW1 and predicted 
chromosomal location. No significant differential expression was found in HCC (n = 6), 
compared with cirrhosis (n = 6); p = 0.748. Statistical significance was determined using t-
test. (Abbreviations: AW1 = Anna Weis-1; hsa, Homo sapiens; miRNA, microRNA). 
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Figure 5.6. Structure of novel miRNA-AW2 in HCC. Predicted precursor miRNA 
structure of differentially expressed circulating novel miRNA-AW2 and predicted 
chromosomal location. Significant differential expression was found in HCC (n = 6), 
compared with cirrhosis (n = 6); p = 0.001. Statistical significance was determined using t-
test. (Abbreviations: AW2 = Anna Weis-2; hsa, Homo sapiens; miRNA, microRNA). 
 
 
 
Figure 5.7. Structure of novel miRNA-AW3 in HCC. Predicted precursor miRNA 
structure of differentially expressed circulating novel miRNA-AW3 and predicted 
chromosomal location. Significant differential expression was found in HCC (n = 6), 
compared with cirrhosis (n = 6); p = 0.001. Statistical significance was determined using t-
test. (Abbreviations: AW3 = Anna Weis-3; hsa, Homo sapiens; miRNA, microRNA). 
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Figure 5.8. Structure of novel miRNA-AW4 in HCC. Predicted precursor miRNA 
structure of differentially expressed circulating novel miRNA-AW4 and predicted 
chromosomal location. Significant differential expression was found in HCC (n = 6), 
compared with cirrhosis (n = 6); p < 0.001. Statistical significance was determined using t-
test. (Abbreviations: AW4 = Anna Weis-4; hsa, Homo sapiens; miRNA, microRNA). 
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Figure 5.9. Differential expression of novel miRNAs in HCC. Increased expression of 
(A) novel miRNA-AW1 (p = 0.748), (B) novel miRNA-AW2 (p = 0.001), (C) novel miRNA-
AW3 (p = 0.001) and (D) novel miRNA-AW4 (p = 0.001) in HCC, compared to cirrhosis. 
F/U HCC (n = 2) and HCC (n =4) patients were grouped together and compared with 
cirrhotic patients (CC, n = 6). Lines represent mean expression levels (± SEM). * p < 0.05, 
** p < 0.01, *** p < 0.001. (Abbreviations: CC, compensated cirrhosis; F/U HCC, 
hepatocellular carcinoma post follow-up; hepatocellular carcinoma; miRNA, microRNA) 
 
5.5 Discussion 
 
Early diagnosis of HCC remains crucial to the provision of curative treatments to patients 
to improve their overall survival rate,52, 119, 120 yet diagnosis of early HCC usually relies on 
routine surveillance ultrasound imaging which lacks sensitivity in the detection of small 
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lesions. Furthermore, once a suspicious lesion is identified, follow up dynamic scanning 
(using CT/MRI) can still result in an indeterminate lesion meaning possible intervention is 
delayed. Such lesions, consistent with either an early HCC or a dysplastic/regenerative  
nodules, are monitored until interval growth can be demonstrated and a definite diagnosis 
made.113, 114 This approach delays early treatment with curative methods, and can 
decrease patient survival. 
 
This study used serum samples 99 patients with cirrhosis to identify potential circulating 
miRNAs as biomarkers of early HCC detection. To identify differentially-expressed miRNA 
candidates, serum samples from 50 cirrhotic patients (including those with early HCCs that 
were only diagnosed over time using serial imaging) were screened using small RNA 
NGS. During the validation phase, 5 of the most promising miRNA candidates were 
selected for qRT-PCR validation in the full cohort of 99 patients. This process confirmed 
the significant differential expression of miRNA-451a and a potential for this miRNA to 
correctly distinguish patients with early HCC. Its diagnostic performance was then 
assessed using ROC curve analysis, individually and in combination with AFP. 
 
Although no studies have reported on the serum levels of miRNA-451a in HCC patients, 
multiple studies have reported decreased levels of miRNA-451a in HCC tissue of patients 
with HBV and non-HBV patients, when compared to adjacent non-tumorous tissues.354-356 
Following resection, lower levels of miRNA-451a in HCC tissue have been correlated with 
poorer outcomes, including reduced overall and disease-free survival, increased lymph 
node metastasis and increased vascular invasion.355, 356 In vitro models of HCC confirm 
decreased expression of miRNA-451a in several hepatoma cell lines, such as Huh7 or 
HepG2,356 with inhibition of miRNA-451a leading to increased proliferation, colony 
formation, tumour size and tumour weight.356 Conversely, increased in vitro miRNA-451a 
expression results in reduced proliferation and decreased colony numbers and size.356 
Furthermore, higher levels of miRNA-451a decrease migration of HCC cell lines355, 357 and 
inhibit invasion,355 suggesting a potential tumour suppressor role for miRNA-451a. Animal 
studies support this, with decreased tumour size, reduced blood vessel density and less 
metastasis seen in association with increased levels of tissue miRNA-451a.355, 358 This 
reciprocal expression of serum and tissue samples is commonly reported in miRNA 
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studies, however, one limitation of this study is that no miRNA tissue levels were accessed 
to enable tissue miRNA quantitation. Therefore, it was not possible to assess whether the 
increased serum miRNA-451a expression was associated with a corresponding decrease 
in HCC tissue. 
 
Several miRNA-451a targets have been reported, including genes within the IL-6R-
STAT3-VEGF signalling pathway that regulates angiogenesis in HCC.358 IKK-β, which is 
an important factor in the NF-κB pathway, has also been described as a miRNA-451a 
target, suggesting a potential link to inflammatory disease and cancer development.356, 359 
Other targets of miRNA-451a include the oncogene c-Myc, which is increased in HCC 
tissue samples,355, 360 and activating transcription factor 2 (ATF2), which has been linked 
to cellular stress response such as hypoxia.357, 361 Interestingly, miRNA-451a also appears 
to exhibit an effect on the cell cycle by potentially promoting apoptosis.355, 356 
 
In other cancers, such as gastric cancer, higher plasma miRNA-451a levels are seen 
when compared to samples either from the same patient following cancer treatment, or in 
healthy controls, while decreased miRNA expression has been reported in gastric cancer 
tissues samples.362, 363 A separate study assessing lymph node metastasis in gastric 
cancer also reported differences in serum miRNA-451a expression, with higher levels 
seen in patients without lymph node metastasis.364 This supports the findings of another 
study in which increased expression levels of miRNA-451a in gastric cancer tissue were 
correlated with higher overall patient survival.365 Several other cancers exhibit a similar 
miRNA-451a expression pattern, with decreased expression in cancer tissues (such as 
lung cancer,366, 367 papillary thyroid carcinoma,368 breast cancer,369 colorectal cancer,370 or 
oesophageal cancer371) and higher circulating miRNA-451a expression levels (e.g. in the 
serum of patients with oesophageal cancer371). Interestingly, reduced tumour tissue 
expression levels of miRNA-451a in colorectal cancer and papillary thyroid carcinoma also 
correlated with advanced tumour stages,368, 370 and metastasis and increased tumour size 
in breast cancer.372  
 
Functional studies of miRNA-451a suggest potential targets with tumour suppressor roles 
within the PI3K/AKT/mTOR pathway, such as tuberous sclerosis 1 Protein (TSC1).363, 368 
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Similarly, a tumour suppressive role has been described within the HP1γ/miRNA-451/c-
Myc feedback loop in prostate cancer, with miRNA-451a directly targeting c-Myc.373 The 
oncogene c-Myc has also been implicated as a potential miRNA-451a target in HCC. One 
study showed increased c-Myc levels in HCC tissue samples and an inverse correlation 
between miRNA-451a and c-Myc levels,355 highlighting the potential tumour suppressor 
role of this miRNA in HCC. The current study’s finding of increased serum miRNA-451a 
levels in HCC may reflect reduced tissue expression of miRNA-451a and higher oncogene 
activity in lesions that become HCC. However, tissue miR451a expression levels were not 
determined in this study. 
 
Multiple studies are investigating the link between miRNA-451a expression and response 
to therapy. For example, high miRNA-451a expression has been reported in patients who 
respond to treatment with trastuzumab (a her2 monoclonal antibody that has had a major 
beneficial impact on survival in her2 positive breast cancer) when compared with those 
who do not respond to treatment.374 It has also been suggested that high levels of miRNA-
451a enhances breast cancer cell sensitivity to tamoxifen in vitro,375 predict radio-
sensitivity in rectal cancer,376 or are induced by radiation therapy in colorectal cancer.377 
Stereotactic external beam radiotherapy and selective internal radiation therapy are 
treatment modalities that are increasingly used in certain patients with HCC and whether 
such a relationship between radiation therapy responses and miRNA-451a expression 
levels exists in HCC is intriguing, albeit well beyond the scope of the current study.  
 
It has been reported that miRNA-451a is the most abundant miRNA in circulating red 
blood cells (erythrocytes).378 The rupture of erythrocytes (haemolysis), can impact non-
invasive biomarker studies with the release of miRNAs of red blood cell origin affecting 
peripheral serum and plasma samples. In particular, increased levels of miRNA-451a in 
haemolysed serum and plasma samples can be measured before visual colour change of 
plasma samples is noticeable.379 Haemolysis is usually assessed by the measurement of 
absorbance at 414 nm of optical density, using a cut-off of 0.2 to indicate haemolysis.379 
Some studies, however, have suggested that the ∆CP of miRNA-451a and miRNA-23a, a 
miRNA apparently expressed independent of haemolysis, can be used to identify 
haemolysis, with a cut-off of CP > 5 indicating red blood cell contamination and CP > 7-8 
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indicating haemolysis.380, 381 382 The development of such methods does highlight the fact 
that haemolysis could affect the differential expression of several potentially useful serum 
biomarkers, including miRNA-451a.380 The importance of careful sample selection and 
handling in biomarker studies was suggested by a recent study that assessed biobanking 
requirements.383 This study recommended the use of serum over plasma for miRNA 
studies as serum samples appear less susceptible to technical factors affecting variability, 
are less prone to haemolysis due to delayed processing of samples stored at room 
temperature, and yield higher levels of endogenous reference miRNAs.383 For these 
reasons, it is expected that the use of promptly-processed serum samples in this current 
study should confer confidence in the quantification of differential expression of circulating 
miRNAs (including miRNA-451a) in HCC and compensated cirrhosis. Serum samples 
were also assessed for haemolysis and no difference in optical density was seen across 
the study groups, suggesting that increased miRNA-451a expression in the HCC cohort 
was not due to haemolysis.   
 
In the current study, differential expression of miRNA-451a was highest in those with 
definite HCC. Unexpectedly, the sub-group with the next highest level of miRNA-451a 
expression was the F/U Benign cohort (i.e. those with indeterminate lesions that 
subsequently proved benign), with the F/U HCC cohort showing only a trend towards 
increased expression. Although unexpected, this result could be explained by the relatively 
small sample size (n=12) in the F/U HCC study group. Alternatively, increased expression 
of miRNA-451a in the F/U Benign cohort may suggest that altered miRNA-451a 
expression plays a role in facilitating dysplasia or that differential expression of miRNA-
451a in patients with cirrhosis may not be specific to HCC, but rather associated with the 
development of discrete liver lesions (e.g. regenerative nodules that are benign but 
potentially susceptible to the development of dysplasia). Based on the literature, it could 
be postulated that increased circulating levels of miRNA-451a correlate with reduced 
tissue expression of miRNA-451a facilitating the tumour microenvironment (e.g. via 
angiogenesis, hypoxia) with subsequent malignant transformation dependent on additional 
factors. In a study of colorectal cancer, increased serum expression of miRNA-451a (as 
well as miRNA-491) was seen in patients with adenomas (compared with healthy controls) 
but interestingly patients with colorectal cancer and adenomas had similar levels of 
expression.384 
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In the current study, the differential expression of miRNA-451a in early HCC (i.e. grouping 
F/U HCC and HCC patients together) was also studied. Here, increased expression of 
miRNA-451a was observed compared with expression in patients without HCC but the 
significance of the association was modest (p = 0.040) and significance was lost after 
removing potential outliers (p = 0.058). Once again, this result could reflect the relatively 
low patient numbers and further validation of these preliminary results is warranted. 
 
In the current study, ROC curve analysis was used to assess the performance of miRNA-
451a to (i) distinguish patients with confirmed HCC from those with cirrhosis grouped 
together with an indeterminate lesion at follow-up, and ii) distinguish patients with early 
HCC (by grouping F/U HCC and HCC together) compared with all other patients with 
cirrhosis but without HCC. The diagnostic performance of miRNA-451a, based on ROC 
curve analysis, was poor with AUCs of 0.66 and 0.63, respectively. Internal validation, 
using k-fold cross-validation, resulted in a slight improvement with AUCs of 0.70 and 0.66, 
respectively – suggesting that outliers negatively impacted on the diagnostic performance 
as assessed by traditional ROC curve analysis. Using stepwise logistic regression, a 
potential miRNA panel could not be identified using the 5 validated miRNAs, with all 
calculations identifying miRNA-451a as best candidate to diagnose early HCC. While this 
result is disappointing, it is perhaps not unexpected as differential expression of other 
miRNA candidates lacked statistical significance during the validation phase or only 
showed a trend towards differential expression in HCC. 
 
When assessing the performance of any potential biomarker, such as miRNA-451a, it is 
important to compare it with the diagnostic performance of any competitor. In this patient 
cohort, AFP also performed poorly with AUCs of 0.65 and 0.60 to distinguish patients with 
HCC and early HCC (grouping F/U HCC and HCC), respectively, which is obviously 
comparable with the diagnostic performance of miRNA-451a. Combining AFP and miRNA-
451a improved diagnostic accuracy marginally, with an AUC of 0.68 for HCC detection and 
an AUC of 0.69 for early HCCs. Whether poor accuracy relates to the performance of the 
putative biomarker or the size of the study cohort is debatable, but validation of these 
preliminary findings in a larger patient cohort would be interesting. For now, the diagnostic 
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performance of miRNA-451a, either alone or in combination with AFP, remains 
suboptimal. 
 
In the current study, 4 potentially novel miRNAs were identified. All of these miRNAs were 
abundantly expressed in both study groups investigated (cirrhosis and HCC). 
Unfortunately, due to overall low sequencing performance, the novel miRNA analysis 
could only be performed on a small subset of samples. Interestingly though, 3 of the 4 
novel miRNAs identified demonstrated significantly increased expression in HCC 
compared with cirrhosis, suggesting these miRNAs could be interesting miRNA candidates 
for further testing as diagnostic biomarkers of HCC.  
 
The preliminary results relating to novel miRNAs, however, must be treated with caution as 
this is the first description of previously undescribed miRNAs and they were only identified 
in a small patient sample. As such, these preliminary findings remain to be validated. No 
immediate conclusion can therefore be drawn until these novel miRNAs are validated 
using qRT-PCR to assure that these are ubiquitously expressed in all study participants 
and the sequence is indeed a novel miRNA and does not represent degraded RNA 
fragments. It is envisaged that these novel miRNA sequences will be registered in miRNA 
databases allowing independent confirmation by other studies. These novel miRNAs could 
then be added to prospective validation studies of the candidate miRNAs identified in this 
thesis.  
 
In comparison with recent studies, a major strength of the current study is the inclusion of 
a clinically-relevant liver lesions, namely definite small HCC and atypical lesions, to identify 
novel biomarkers in early, treatable HCC. This methodology sought to identify candidate 
miRNAs that could prove specific to HCC development by prospectively recruiting patients 
with atypical lesions that are subsequently diagnosed as either early HCCs or truly benign 
lesions. There are, however, some limitations to this study that need to be considered 
when evaluating the results. In this study the selection criteria for patients with early HCC 
was extended to 2.5cm, while any validation study would arguably benefit from a more 
strict definition of early HCC including only patients with HCC < 2cm. The patient numbers 
within the F/U HCC sub-group were relatively low, when compared to the other study sub-
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groups, thereby potentially limiting power to detect significant differential expression of 
miRNAs. Technical difficulties were also experienced during the sequencing library 
preparation, leading to a further loss of discovery potential of differentially expressed 
miRNAs in early HCC and atypical liver lesions that ultimately prove malignant. The 
accepted differential expression analysis methodology used in this study only accounts for 
highly abundant miRNAs and potentially loses miRNAs with relatively low expression, but 
nonetheless significant differential expression, across the study groups. Furthermore, 
MiRNA-451a levels in this study were only measured in serum, and not in corresponding 
HCC liver tissue. 
 
In conclusion, miRNA-451a was identified as a promising candidate biomarker for HCC, 
showing dynamic expression across the spectrum of clinically-relevant liver lesions. 
Increased serum expression of miRNA-451a could have enormous clinical potential as a 
biomarker of early HCC (particularly if larger studies return more definitive results and, 
importantly, also involve a prospective recruitment cohort with indeterminate lesions). 
Biomarker studies also help to shed light on the pathogenesis and possible treatment of 
various disease stages in CLD. In the current study, miRNA-451a has been identified as a 
potential HCC biomarker candidate. Information regarding the roles played by potential 
new biomarkers, such as miRNA-451a, that prove specific to HCC could provide new 
information about how tumours develop and how they could be treated. To date, using 
miRNAs to guide prognosis after treatment has not been done prospectively and, if 
validated, this provide extremely useful information.127 
 
Finally, in undertaking this thesis, a study cohort was established in an attempt to identify 
miRNA biomarker candidates that potentially distinguish regenerative nodules from high 
risk dysplastic nodules and early HCC. Although the results of the current study suggest 
miRNA-451a currently lacks sufficient diagnostic accuracy as a biomarker for HCC, its 
performance in this patient cohort was actually comparable with the currently accepted 
tumour marker, AFP. Furthermore, with the establishment of 4 clinically relevant study 
sub-groups, the current study was able to identify 5 differentially-expressed miRNA 
candidates although, for technical reasons, significant differential expression could only be 
validated in miRNA-451a. It is anticipated that further studies with larger numbers of 
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patient samples will be undertaken to further investigate these preliminary candidates and 
potentially confirm a novel miRNA that is specific to early HCC and could act as diagnostic 
biomarker that facilitates early intervention in this lethal disease. 
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CHAPTER 6                                                             
Differential microRNA expression in decompensated….. 
cirrhosis…….. 
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6.1 Introduction 
 
In chronic liver disease, the progression from fibrosis to cirrhosis marks a transition point 
beyond which patients are at increased risk of cirrhosis-related complications. These not 
only include HCC but also the features of decompensated and advanced cirrhosis that 
contribute to patient morbidity and mortality, such as the accumulation of ascites and 
variceal bleeding. Cirrhosis is usually characterised as relatively asymptomatic 
compensated cirrhosis and more symptomatic decompensated cirrhosis, which is in turn 
characterised by the development of end-organ, hepatic dysfunction and portal 
hypertension. It is estimated that 5–7% of patients progress from compensated to 
decompensated cirrhosis annually.37 A sub-classification of cirrhosis into 4 clinical stages 
with differing prognoses has been proposed,37 however validated models to predict an 
individual patient’s progression along that spectrum of cirrhosis are lacking. 
 
Decompensated cirrhosis is a systemic disease with multiple circulatory and metabolic 
changes that can lead to multi-organ dysfunction385 and increased sensitivity to 
infections.386 Complications of cirrhosis are generally the consequence of altered liver 
architecture leading to portal hypertension, the hyperdynamic circulatory syndrome due to 
peripheral arterial vasodilation, and a chronic inflammatory state. Specific cirrhosis-related 
complications include the development of varices and variceal bleeding, accumulation of 
ascites that can become complicated by SBP, hepato-pulmonary syndrome, renal 
impairment, (either as an acute kidney injury or chronic renal impairment) and hepatic 
encephalopathy.71, 73 With the onset of decompensated cirrhosis, the survival of patients 
dramatically decreases from a median of more than 12 years to approximately 2 years.37 
In addition to decompensation events, patients with any stage of cirrhosis develop HCC at 
a rate of approximately 3% per year.37 The only definitively curative treatment for 
decompensated cirrhosis, with or without HCC, remains liver transplantation.  
 
Varices and ascites are two major and relatively common complications associated with 
cirrhosis and the development of PHT. Unfortunately these complications can only really 
be addressed once they appear and there are limited primary prophylactic interventions 
that are evidence-based. The gold standard to identify varices remains endoscopy 
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although, as a valuable health care resource, access to endoscopy is often limited. 
Recently, the Baveno VI consensus statement,76 recommended a non-invasive 
assessment to identify a subset of cirrhotic patients whose risk of clinically-significant 
varices is very low.  
 
While this approach is very promising in terms of health care resource utilisation, there is 
currently no predictive scoring system that can identify patients at highest risk of clinically 
significant varices (and therefore acute gastrointestinal bleeding) or developing ascites 
(who may benefit from more intensive dietary input and/or initiation of diuretic therapy). 
Currently-accepted blood-based non-invasive biomarkers can stratify patients according to 
fibrosis severity, or function as liver related outcome scores (i.e. predict mortality, risk of 
decompensation or HCC occurrence),387 but they have limited applicability in the prediction 
of incident complications such as varices or ascites. On clinical grounds, there is certainly 
a role for a non-invasive biomarker that can identify patients at highest risk of life-
threatening or morbid complications of cirrhosis. Ideally this would be easily accessible 
and reproducible and requires little technical expertise to perform the test.  
 
It is unclear whether miRNA could be developed as a non-invasive biomarker in 
decompensated cirrhosis and to-date there are limited data identifying candidates 
associated with different stages of cirrhosis. As previously discussed, however, miRNAs 
do represent ideal circulating biomarkers that could be further developed in this context. In 
the first instance, however, further data are needed.  
 
6.2 Aims and hypothesis  
 
It was hypothesised that patients with compensated and decompensated cirrhosis have 
different biomarker expression profiles and that the development of cirrhosis-related 
complications is associated with dynamic changes in the expression of individual miRNAs. 
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The fourth aim of this thesis, therefore, is to identify circulating serum biomarkers that are 
associated with the appearance of cirrhosis-related complications such as ascites, varices 
and/or variceal bleeding, (with a view to potentially predicting the incidence of the 
complications in patients with cirrhosis). 
 
6.3 Material and methods 
6.3.1 Patient recruitment and characteristics  
 
This study identified 136 patients with cirrhosis that were retrospectively allocated into the 
following study cohorts: compensated cirrhosis (CC, n=30); compensated cirrhosis with 
varices (CC/V, n=30); cirrhosis with ascites (A, n=60) and cirrhosis with incident variceal 
bleeding (VB, n=16). Each patient was allocated into only one study cohort. Of note, 
cirrhotic patients with ascites (A) may have included patients with varices, and patients 
with an episode of variceal bleeding (VB) may have included patients with ascites. In such 
cases, patients were allocated into the more advanced disease cohort, namely the ascites 
and variceal bleeding sub-groups, respectively. Patients in the varices study cohort had 
endoscopy-proven varices but no other complications of decompensated cirrhosis. 
Furthermore, patients allocated to the varices cohort (in addition to those in the 
compensated cirrhosis study cohort) did not have a history of any prior decompensation. 
Patients in the ascites study cohort included patients with any degree of ascites (including 
clinical ascites, medically-controlled ascites and/or imaging evidence of ascites) but none 
of these patients had a history of variceal bleeding. All patients in this study were enrolled 
through the course of usual clinical care at the Royal Brisbane and Women’s Hospital 
Liver Clinic. Diagnoses were made based on expert specialist assessment following 
accepted professional guidelines. Data collection and patient recruitment have been 
described in detail in Section 2.1.  
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6.3.2 RNA extractions, reverse transcription, NGS and qRT-PCR 
 
During the screening phase differentially expressed serum miRNA candidates were 
selected using small RNA NGS. Sequencing was performed on a smaller subset of 
samples using 15 serum samples per study group (CC, CC/V, A and VB). Prior to 
circulating miRNA isolation using the Plasma/Serum RNA Purification Mini Kit (Norgen 
Biotek Corp; see Section 2.4.4) all samples were assessed for haemolysis using the 
NanodropTM spectrophotometer (Thermo Fisher Scientific; see Section 2.5.1). Serum 
miRNA isolation was quantified using the Small RNA Bioanalyzer Kit (Agilent 
Technologies; see Section 2.5.2). As described in Section 2.6.8, small RNA libraries were 
prepared using the NEBNext® Small RNA Library Prep Set (New England Biolabs) and 
sequencing performed using the Illumina HiSeq 2000 platform (Illumina Inc.). 
 
For the validation phase, circulating miRNA isolation was repeated using the 
Plasma/Serum RNA Purification Mini Kit (Norgen Biotek Corp). Prior to reverse 
transcription using the miScript II RT Kit (Qiagen; see Section 2.6.1), miRNA isolations 
were assessed for contamination using NanodropTM (Thermo Fisher Scientific) 
measurements. The actual qRT-PCR validation was performed using the miScript miRNA 
PCR system (Qiagen; see Section 2.6.4), validating the expression of ten selected miRNA 
candidates (see Table 2.4). 
 
6.3.3 Data normalisation and statistical analysis 
 
Analysis of the miRNA NGS dataset has been described in detail in Section 2.7.3. 
Following exceRpt pipeline analysis samples with ˃ 500 miRNA reads have been included 
for statistical analysis. Differential expression analysis using voom/limma method has been 
described in Section 2.8.4, with the following selection criteria: statistical significance p < 
0.05, log fold change > 2 and dynamic expression across the spectrum of disease. Novel 
miRNA identification was performed using the mirPRo pipeline as described in detail in 
Section 2.7.3. Statistical significance of novel miRNA was determined using t-test, with 
statistical significance defined as p < 0.05. 
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The qRT-PCR dataset was analysed using the 2ΔCP method (see Section 2.8.3). 
Endogenous reference miRNA used for normalisation, miRNAs let-7i-5p and let-7f-5p, 
were identified using the NormFinder algorithm (MOMA; see Section 2.7.2). Identification 
of statistical significance used the unpaired t-test (two group comparison) or one-way 
ANOVA with Tukey’s post hoc comparison (more than two group comparisons). Outliers 
were assessed using the ROUT method in GraphPad Prism v.7 (GraphPad Software). The 
statistical analysis used during the validation phase has been described in more detail in 
Section 2.8.3.  
 
6.3.4 Panel design, ROC curves and k-fold cross-validation 
 
Stepwise logistic regression was used to derive miRNA panels. Following the miRNA 
panel design, as described in Section 2.8.5, 𝑝𝑖 was determined using the following 
equations 
 
Function E: CC/V vs CC 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = -1.36 + (-1.20 × ∆CP miR-10b-5p + 0.81× ∆CP miR-101-3p)  
 
Function F: A vs CC 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = 4.65 + (-1.80 × ∆CP miR-10a-5p + 1.88 × ∆CP miR-146a-5p)  
 
Function G: VB vs CC 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = 3.62 + (-1.42 × ∆CP miR-10a-5p)  
 
Function H: A and VB vs CC and CC/V 
ln (
𝑝ᵢ
1−𝑝ᵢ
) = 6.01+ (-0.92 × ∆CP miR-423-3p + 2.14 × ∆CP miR-146a-5p - 1.21× ∆CP miR-
10a-5p)  
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ROC curve analysis for individual miRNAs was performed using GraphPad Prism v.7 
(GraphPad Software). MiRNA panel design, panel ROC curve analysis and k-fold cross-
validation was performed in R (version 3.3.3) as described in detail in Section 2.8.5. 
 
6.4 Results 
6.4.1 Patient characteristics 
 
In total, 136 patients with cirrhosis of various aetiologies were identified retrospectively for 
the purposes of this study. This cohort comprised 30 patients with compensated cirrhosis 
(CC), 30 patients with compensated cirrhosis and varices (CC/V), 60 patients with ascites 
(A) and 16 patients with a variceal bleed (VB). The compensated cirrhosis study group 
used in this cohort was the same control group used for a previous study, described in 
Section 5.4.1. Detailed patient demographics and the clinical characteristics of each cohort 
are described in Table 6.1. Clinical follow-up of these patients was conducted for a mean 
period of 32.7 months (SD 7.0) for compensated cirrhosis, 26.6 months (SD 7.4) for 
compensated cirrhosis with varices, 19.4 months (SD 9.8) for ascites and 15.7 months (SD 
5.4) for patients with variceal bleeding. During clinical follow-up, 28 patients died (all 
allocated to either the ascites or variceal bleeding cohorts) and 4 patients received a liver 
transplant (3 patients allocated to the ascites cohort, 1 patient allocated to the varices 
cohort). While all of the varices sub-group had undergone endoscopy to confirm the 
presence of varices, only 43.3% of patients in the control cohort of compensated cirrhosis 
alone had undergone endoscopy to exclude varices. Patients in the control cohort, 
however, were all selected based on platelet counts within the normal reference range (> 
140 (x109/L)2), the absence of signs of portal hypertension (namely, splenomegaly or 
ascites), and no history of variceal bleeding. The majority of variceal bleeding patients (12 
of 16 patients; 75%) were enrolled within 3 months of their bleeding episode. 
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 Table 6.1. Demographic and clinical characteristics of cirrhotic patients across all study groups for decompensated disease. 
 Compensated cirrhosis 
 
(n = 30) 
Compensated 
cirrhosis with varices 
(n = 30) 
Ascites 
 
(n = 60) 
Variceal bleeding 
 
(n = 16) 
 
P-
value 
Gender (n/%)1 
Male 18 (60%)  17 (57%) 44 (73%) 14 (87%) 0.099 
Female 12 (40%) 13 (43%) 16 (27%) 2 (13%) 
Demographics2 
Age (years) 57.2 (SD 8.7) 58.3 (SD 11.2) 56.6 (SD 9.3) 53.9 (SD 9.7) 0.516 
BMI (Kg/m2)  30.2 (SD 7.0) 32.1 (SD 8.4) 29.6 (SD 7.4) 27.6 (SD 6.6) 0.26 
Aetiology (n/%)1 
ALD 3 (10%) 3 (10%) 26 (44%) 11 (69%) <0.001 
NASH 7 (23%) 13 (44%) 12 (20%) 1 (6%) 
HCV 18 (60%) 10 (33%) 17 (28%) 4 (25%) 
Other 2 (7%) 4 (13%) 5 (8%) - 
Baseline routine laboratory tests3,4 
Albumin (g/L) 41.0 (IQR40.0-43.0) 37.0 (IQR 32.8-39.3) 32.5 (IQR 28.0-35.0) 33.5 (IQR 28.0-37.5) <0.001 
ALT (U/L) 54.0 (IQR 27.0-157.8) 35.0 (IQR 24.0-79.0) 32.0 (IQR 22.0-45.8) 25.0 (IQR 13.5-32.8) <0.001 
AST (U/L) 64.0 (IQR 26.8-118.8) 48.5 (IQR 27.5-73.3) 59.5 (IQR 40.3-76.0) 51.0 (IQR 35.5-73.5) 0.536 
Billirubin (µmol/L) 14.0 (IQR 11.8-19.3) 21.5 (IQR 13.0-30.0) 34.5 (IQR 23.3-55.3) 25.5 (IQR 20.0-36.0) <0.001 
Creatinine (µmol/L) 70.5 (IQR 55.8-80.8) 65.5 (IQR 55.8-75.0) 74.5 (IQR 59.3-92.0) 71.5 (IQR 55.5-88.0) 0.09 
Platelet (x109/L)2 199.0 (IQR 141.8-233.8) 94.5 (IQR 64.8-153.0) 104.5 (IQR 73.5-153.3) 148.0 (IQR 81.5-200) <0.001 
Sodium (mmol/L) 138.0 (IQR 136.0-139.0) 139.0 (IQR 137.0-140.0) 135.0 (IQR 133.0-138.0) 135.5 (IQR 134.0-137.8) <0.001 
Proximity of sample collection to baseline routine laboratory tests (months) 
 0.4 (SD 1.1) 0.4 (SD 0.9) 0.4 (SD 1.5) 0.1 (SD 0.5) NA 
Other laboratory tests 
INR3,4 1.1 (IQR 1.0-1.1) 1.2 (IQR 1.1-1.3) 1.4 (IQR 1.2-1.6) 1.4 (IQR 1.3-1.4) <0.001 
AFP (µg/L)3,4 3.5 (IQR 2.2-7.9) 4.4 (IQR 2.8-7.2) 4.0 (IQR 2.8-6.6) 5.8 (IQR 4.1-7.9) 0.243 
Sample collection to AFP 
(months) 
0.3 (SD 4.6) 0.1 (SD 3.0) 0.6 (SD 2.8) 0.6 (SD 1.4) NA 
Clinical follow up (months) 
 32.7 (SD 7.0) 26.6 (SD 7.4) 19.4 (SD 9.8) 15.7 (SD 5.4) NA 
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 Compensated cirrhosis 
 
(n = 30) 
Compensated 
cirrhosis with varices 
(n = 30) 
Ascites 
 
(n = 60) 
Variceal bleeding 
 
(n = 16) 
 
P-
value 
Disease severity assessment 
CTP A (n) 29 26 15 6 NA 
CTP B (n) 1 4 29 7  
CTP C (n) - - 16 3  
MELD4 7.0 (IQR 6.0-8.0) 9.5 (IQR 7.0-11.0) 12.5 (IQR 10.0-17.0) 11.0 (IQR 11.0-14.5)  
All data shown as mean values unless otherwise specified. Following normality testing, P-values were calculated using the 1Chi-Square 
test, 2ANOVA, 3Kruskal-Wallis test, 4Data shown as median. Data are complete for the entire cohort, except for BMI (n = 131) and AFP (n 
= 133). (Abbreviations: AFP, alpha-fetoprotein; ALD, alcoholic liver disease; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BMI, body mass index; CTP, Child-Turcotte-Pugh Score; HCV, Hepatitis C Virus; INR, international normalized ratio; 
IQR, interquartile range; MELD, model for end-stage liver disease score; NA, not applicable; NASH, non-alcoholic steatohepatitis; SD, 
standard deviation). 
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6.4.2 MiRNA next-generation sequencing screening phase 
 
The miRNA screening phase was conducted using NGS on a smaller subset of patient 
samples as follows: 15 patients with compensated cirrhosis, 15 patients with compensated 
cirrhosis and varices, 15 patients with ascites and 15 patients with variceal bleeds. 
 
Unfortunately, as previously described in Section 5.4.2, low miRNA yield and poor library 
performance limited the numbers of samples available for differential expression analysis. 
Following bioinformatics analysis, as described in Section 6.3.3, overall only 23 out of 37 
libraries reached more than 500 miRNA reads to be included in ongoing analysis (see 
Table 6.2). Of note, the NGS library performance of two groups in particular was 
suboptimal, namely those performed using the serum of patients with varices (CC/V) and 
ascites (A).  
 
Table 6.2. Next-generation sequencing library performance. 
Study group Samples submitted (n) 
for NGS 
Samples included in 
NGS analysis (n) 
Samples that had to 
be excluded (n) 
CC n = 15 n = 9 n = 6 
CC/V n = 15 n = 2 n = 13 
A n = 15 n = 4 n = 11 
VB n = 15 n = 8 n = 7 
Following the exceRpt pipeline analysis, samples with ≤ 500 miRNA reads were excluded, 
whereas samples with ˃ 500 miRNA reads were included in the differential expression 
analysis. (Abbreviations: A, cirrhosis with ascites; CC, compensated cirrhosis; CC/V, 
compensated cirrhosis with varices; NGS, next-generation sequencing; VB, cirrhosis with 
variceal bleeding). 
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Table 6.3. Sequencing quality metrics of samples included in statistical analysis. 
Library 
description 
Total reads Total base 
count in 
Megabases 
Bases 
≥ Q30 
(%) 
Read count 
post adapter 
clipping 
Read count 
post 
alignment 
miRNA 
read 
count 
CC1 38,401,998 1,959 85.09 718,533 157,105 48,361 
CC2 8,133,824 415 74.13 979,860 343,524 109,977 
CC6 150,241 8 52.25 89,089 10,853 1,229 
CC7 6,349,702 324 73.95 671,371 108,386 18,013 
CC10 7,102,431 362 75.78 754,038 101,285 4,943 
CC11 5,737,844 293 76.99 493,352 105,856 18,566 
CC12 5,050,107 258 74.12 584,566 185,062 58,950 
CC14 849,796 43 35.45 463,707 58,739 779 
CC15 2,126,219 108 51.87 646,694 75,816 6,366 
CC/V8 4,369,736 223 71.25 685,544 282,940 89,378 
CC/V14 8,385,605 428 68.30 1,071,241 304,258 51,160 
A7 2,075,144 106 77.96 1,959,454 50,459 2,862 
A9 87,834 4 85.66 28,038 7,832 1,275 
A11 265,571 14 79.78 233,635 7,247 699 
A15 377,449 19 79.13 349,965 8,776 731 
VB3 535,275 27 81.15 454,804 10,767 577 
VB4 1,550,761 79 92.62 606,727 465,802 48,079 
VB11 1,280,835 65 93.20 580,712 177,704 35,986 
VB12 1,069,209 55 91.04 717,061 29,548 1,103 
VB13 1,289,917 66 93.39 491,445 364,545 66,214 
VB14 947,043 48 92.35 123,363 35,889 1,273 
VB15 697,396 36 90.50 115,173 48,567 2,699 
VB16 209,820 11 94.13 164,755 15,720 2,412 
Sequencing quality metrics for n = 30 samples included into statistical analysis. Samples 
selected following exceRpt pipeline analysis based on the selection criteria ˃ 500 miRNA 
reads. (Abbreviations: A, cirrhosis with ascites; CC, compensated cirrhosis; CC/V, 
compensated cirrhosis with varices; Q30, number of bases passing the Illumina Inc. 
specific quality score; VB, cirrhosis with variceal bleeding). 
 
The assembled screening phase dataset, using data obtained from n = 23 patient 
samples, was analysed for differentially expressed miRNAs. MiRNA candidate selection 
used the following criteria: statistically significant P-value < 0.05, log fold change > 2, and 
a dynamic expression across study cohorts. The expression dynamics of all potential 
miRNA candidates were qualitatively assessed for (i) specificity to one complication sub-
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group (i.e. cirrhosis with varices, ascites or variceal bleeding), or (ii) specificity to the 
development of clinically-significant decompensation (i.e. grouping patients with ascites 
and variceal bleeding together as advanced decompensation). After this analysis, a list of 
ten of the most promising differentially expressed miRNA candidates was assembled for 
further validation (see Table 6.4). Of note, miRNA-493-3p was included into the further 
validation cohort due to the high log fold change in compensated cirrhosis patients with 
varices when compared to control patients alone.  
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Table 6.4. Significantly differentially expressed miRNAs in compensated and 
decompensated liver disease. 
No. miRNA CC/V 
(logFC) 
A 
(logFC) 
VB 
(logFC) 
P-value 
1 hsa-miRNA-101-3p -0.32 -2.39 -1.71 0.001 
2 hsa-miRNA-10a-5p 2.43 5.26 5.84 <0.001 
3 hsa-miRNA-10b-5p 0.09 -0.04 3.35 0.011 
4 hsa-miRNA-144-3p -0.22 -5.85 -5.1 0.012 
5 hsa-miRNA-146a-5p 2.48 4.67 4.75 <0.001 
6 hsa-miRNA-223-5p -0.37 -0.24 -3.34 0.007 
7 hsa-miRNA-22-3p 0.66 -3.7 0.02 0.006 
8 hsa-miRNA-27b-3p 0.73 -4.07 -0.92 0.006 
9 hsa-miRNA-423-3p 1.76 6.11 6.33 <0.001 
10 hsa-miRNA-493-3p 5.25 -0.63 -1.09 0.13 
P-values were calculated using voom/limma method with significance designated by a P-
value < 0.05. All logFC are relative to the compensated cirrhosis control group. 
(Abbreviations: A, cirrhosis with ascites; CC, compensated cirrhosis; CC/V, compensated 
cirrhosis with varices; FC, fold change; hsa, Homo sapiens; miRNA, microRNA; VB, 
cirrhosis with variceal bleeding). 
 
6.4.3 MiRNA expression validation phase 
 
Following the NGS miRNA screening phase using the smaller subset of samples, 10 
miRNA candidates were validated using qRT-PCR using the complete sample set from the 
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whole cohort of 136 patients. Despite identifying significant differential expression during 
the sequencing-based screening phase, differential expression of 4 miRNAs (miRNA-144-
3p, miRNA-146a-5p, miRNA-223-5p and miRNA-423-3p) could not be validated during the 
qRT-PCR validation phase. Furthermore, differential expression of miRNA-493-3p (which 
was selected during the screening phase as the most promising potential miRNA 
biomarker for varices) could not be validated following qRT-PCR as only 16 out of 60 valid 
readings were obtained across all study cohorts. As a result these miRNAs was excluded 
from any further analysis. All serum samples were assessed for haemolysis with no 
statistical significant differential expression determined between groups, with an ANOVA of 
p = 0.081. 
 
Following qRT-PCR validation, 5 miRNAs were differentially expressed across the 
spectrum of cirrhosis based on ANOVA analysis (see Table 6.5). Expression levels for 
individual patients within each study cohort are shown in Figure 6.1. 
 
Table 6.5. Circulating miRNA expression in compensated and decompensated liver 
disease: Validation of selected miRNA expression levels using quantitative real-time 
PCR. 
miRNA Overall P-
value 
(ANOVA) 
P-value 
CC vs 
CC/V 
CC vs A CC vs 
VB 
CC/V vs 
A 
CC/V vs 
VB 
A vs VB 
miRNA-10a-5p <0.001 
 
0.020 
 
0.001 
 
<0.001 0.975 
 
0.233 
 
0.298 
 
miRNA-10b-5p <0.001 
 
0.010 
 
<0.001 
 
0.031 
 
0.993 
 
0.999 
 
0.999 
 
miRNA-22-3p 0.037 
 
0.998 
 
0.175 
 
0.116 
 
0.249 
 
0.155 
 
0.834 
 
miRNA-27b-3p 0.042 
 
0.690 
 
0.948 
 
0.035 
 
0.887 
 
0.268 
 
0.053 
 
miRNA-101-3p 0.003 
 
0.354 
 
0.244 
 
0.997 
 
0.001 
 
0.644 
 
0.322 
 
P-values were calculated using 2ΔCP normalisation method and ANOVA with Tukey’s 
post hoc test with significance designated by a P-value < 0.05. (Abbreviations: A, cirrhosis 
with ascites; CC, compensated cirrhosis; CC/V, compensated cirrhosis with varices; 
miRNA, microRNA; VB, cirrhosis with variceal bleeding). 
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MiRNA-22-3p was differentially expressed (p = 0.037) but significant differential 
expression was not observed on post-hoc comparison between patient cohorts (see Table 
6.5). MiRNA-27b-3p and miRNA-101-3p demonstrated significantly increased expression 
associated with variceal bleeding (compared with compensated cirrhosis) and the 
presence of ascites (compared with cirrhosis with varices but no ascites), respectively (see 
Figure 6.1). When performing outlier analysis for miRNA-101-3p using the ROUT method 
(see Section 2.8.3), one outlier in the CC sub-group was identified. Removing this outlier 
for differential expression analysis increased the significance of variance across the 
groups, with an overall P-value of < 0.001 (by ANOVA). Post hoc comparison between 
sub-groups for miRNA-101-3p identified significantly increased expression in the serum of 
patients with ascites (A) compared with CC patients (p < 0.001) and CC/V patients (p < 
0.001). When assessing dynamic differential expression of miRNAs, expression of miRNA-
10a-5p and miRNA-10b-5p increased significantly with increasing disease severity with the 
highest expression levels seen in patients with the most advanced disease (VB cohort; see 
Figure 6.1 and Table 6.5). 
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Figure 6.1. Association between circulating miRNA levels and spectrum of 
decompensated liver disease. (A) miRNA-10a-5p and (B) miRNA-10b-5p show an 
increased expression across the spectrum of decompensated liver disease, whereas (C) 
miRNA-22-3p shows only a trend towards an increase in expression with decompensated 
liver disease. (D) miRNA-27b-3p and (E) miRNA-101-3p show an increased expression 
between the study groups variceal bleed and ascites respectively, when compared to 
compensated cirrhosis. Lines represent mean expression levels (± SEM). * p < 0.05, ** p < 
0.01, *** p < 0.001.  
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To assess microRNA expression in advanced decompensated cirrhosis, patients with 
ascites and variceal bleeding were grouped and compared with patients with compensated 
cirrhosis (± varices) but no history of variceal bleeding or ascites In this sub-group, 4 
differentially expressed miRNAs (i.e. miRNA-10a-5p, miRNA-10b-5p, miRNA-22-3p and 
miRNA-101-3p) all showed significantly increased expression in patients with advanced 
decompensation (p = 0.002, p = 0.010, p = 0.005 and p = 0.003, respectively; see Figure 
6.2). MiRNA-146a-5p expression was decreased in patients with advanced 
decompensated cirrhosis, when compared to compensated cirrhosis, with a P-value 
bordering on the level of significance (p = 0.050).  
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Figure 6.2. Circulating miRNA levels in decompensated cirrhosis. (A) miRNA-10a-5p, 
(B) miRNA-10b-5p, (C) miRNA-22-3p, (D) miRNA-101-3p and (E) miRNA-146a-5p show 
an increased expression in decompensated cirrhosis, when compared to compensated 
cirrhosis alone. Lines represent mean expression levels (± SEM). * p < 0.05, ** p < 0.01. 
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6.4.4 Discriminating patients across the spectrum of decompensated liver disease 
using miRNAs 
 
To assess the diagnostic potential of selected miRNA candidates to distinguish patients 
with (i) varices, (ii) ascites, (iii) variceal bleeding compared to compensated cirrhosis and 
(iv) advanced decompensation (grouping ascites and variceal bleeding) compared to 
compensated cirrhosis (± varices), ROC curve analysis was performed.  
 
In identifying patients with varices, compared with cirrhosis alone, miRNA-10a-5p and 
miRNA-10b-5p generated AUCs of 0.70 (95% CI 0.57 - 0.84, p = 0.008) and 0.70 (95% CI 
0.57 - 0.83, p = 0.008), respectively (see Figure 6.3A). Using miRNA-10a-5p, miRNA-10b-
5p and miRNA-101-3p to distinguish patients with ascites from cirrhosis alone, resulted in 
AUCs of 0.72 (95% CI 0.60 - 0.83, p = 0.001), 0.71 (95% CI 0.59 - 0.83, p = 0.001), and 
0.72 (95% CI 0.59 - 0.84, p = 0.001), respectively (see Figure 6.3B). In identifying patients 
with variceal bleeding, compared with cirrhosis alone, miRNA-10a-5p, miRNA-10b-5p and 
miRNA-27b-3p generated AUCs of 0.80 (95% CI 0.66 - 0.94, p = 0.001), 0.71 (95% CI 
0.55 - 0.86, p = 0.021), and 0.73 (95% CI 0.57 - 0.89, p = 0.011), respectively (see Figure 
6.3C).  
 
There were mixed results when using miRNA expression to distinguish patients with 
advanced decompensated cirrhosis, grouping patients with ascites and variceal bleeding, 
from compensated cirrhosis. These analyses generated AUCs of 0.63 (95% CI 0.53 - 0.72, 
p = 0.012) for miRNA-10a-5p, 0.61 (95% CI 0.51 to 0.70, p = 0.031) for miRNA-10b-5p, 
0.62 (95% CI 0.53 - 0.72, p = 0.013) for miRNA-22-3p, and AUC of 0.73 (95% CI 0.65 - 
0.82, p < 0.001) for miRNA-101-3p (see Figure 6.3D). Once again, reduced expression of 
miRNA-146a-5p demonstrated a trend towards an ability to discriminate advanced 
decompensated cirrhosis from compensated cirrhosis, with an AUC of 0.60 (95% CI 0.50 - 
0.70, p = 0.050).  
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Figure 6.3. ROC curve analysis for individual serum miRNAs to identify patients with 
complications of cirrhosis and advanced decompensation. (A) Identifying patients 
with cirrhosis and varices without bleeding: MiRNA-10a-5p generated an AUC of 0.70 
(95% CI 0.57 - 0.84, p = 0.008) and miRNA-10b-5p generated an AUC of 0.70 (95% CI 
0.57 - 0.83, p = 0.008) to distinguish patients with varices compared with cirrhosis alone. 
(B) Identifying patients with cirrhosis and ascites: MiRNA-10a-5p generated an AUC of 
0.72 (95% CI 0.60 - 0.83, p = 0.001), miRNA-10b-5p generated an AUC of 0.71 (95% CI 
0.59 - 0.83, p = 0.001), and miRNA-101-3p generated an AUC of 0.72 (95% CI 0.59 - 0.84, 
p = 0.001) to distinguish patients with ascites compared with cirrhosis alone. (C) 
Identifying patients with cirrhosis and variceal bleeding: MiRNA-10a-5p generated an AUC 
of 0.80 (95% CI 0.66 - 0.94, p = 0.001), miRNA-10b-5p generated an AUC of 0.71 (95% CI 
0.55 - 0.86, p = 0.021), and miRNA-27b-3p generated an AUC of 0.73 (95% CI 0.57 - 0.89, 
p = 0.011) to distinguish patients with variceal bleeding compared with cirrhosis alone. (D) 
Identifying patients with advanced decompensation (grouping patients with ascites and 
variceal bleeding): MiRNA-10a-5p generated an AUC of 0.63 (95% CI 0.53 - 0.72, p = 
0.012), miRNA-10b-5p generated an AUC of 0.61 (95% CI 0.51 to 0.70, p = 0.031), 
miRNA-22-3p generated an AUC of 0.62 (95% CI 0.53 - 0.72, p = 0.013), and miRNA-101-
3p generated an AUC of 0.73 (95% CI 0.65 - 0.82, p < 0.001) to distinguish patients with 
advanced decompensated cirrhosis. (Abbreviations: 95% CI, 95% confidence interval; 
AUC, area under the curve; ROC, receiver operating characteristics). 
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Stepwise logistic regression, including forward selection and backward elimination, was 
used to select a miRNA panel that could distinguish varices from cirrhosis. A panel 
comprising miRNA-10b-5p and miRNA-101-3p resulted an in AUC of 0.78 (95% CI 0.66 – 
0.90, p < 0.001) using the Youden’s index derived cut-point of 0.50. The varices miRNA 
panel reaches a sensitivity of 70%, specificity of 83%, PPV of 81%, NPV of 74% and 
overall accuracy of 77%. Discriminating ascites from cirrhosis, a panel consisting of 
miRNA-10a-5p and miRNA-146a-5p resulted in an AUC of 0.83 (95% CI 0.75 – 0.92, p < 
0.001) using an miRNA panel specific cut-point of 0.78, with a sensitivity of 63%, 
specificity of 87%, PPV of 90%, NPV of 54% and an overall accuracy of 71%. The miRNA 
panel for the identification of variceal bleeds compared to cirrhosis includes only miRNA-
10a-5p. Using the Youden’s index derived cut-point of 0.56 resulted in an AUC of 0.80 
(95% CI 0.65 – 0.95, p < 0.001) with a sensitivity of 50%, specificity of 97%, PPV 89%, 
NPV of 78% and overall accuracy of 80% (see Figure 6.4 and Table 6.6) 
 
Discriminating decompensated cirrhosis, grouping ascites and variceal bleed patients, 
from compensated cirrhosis patients, including cirrhosis and varices patients, resulted in a 
miRNA panel of miRNA-10a-5p, miRNA-146a-5p and miRNA-423-3p with an AUC of 0.78 
(95% CI 0.70 – 0.86, p < 0.001). The decompensation miRNA panel used a Youden’s 
specific cut-point of 0.59 deriving a sensitivity of 68%, specificity of 80%, PPV of 81%, 
NPV 67% and overall accuracy of 74% (see Figure 6.4 and Table 6.6). 
 
The most statistically significant differentially expressed miRNAs miRNA-10a-5p and 
miRNA-10b-5p were not combined together during the model selection process. It is 
suggested that this may be due to the high level of correlation between those two miRNAs. 
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Table 6.6. MiRNA panels to discriminate the spectrum of decompensated liver 
disease. 
Complication miRNA panel ROC curve performance 
Varices miRNA-10b-5p + 
miRNA-101-3p 
AUC of 0.78 
(95% CI 0.66 – 0.90) 
Ascites miRNA-10a-5p + 
miRNA-146a-5p 
AUC of 0.83 
(95% CI 0.75 – 0.92) 
Variceal Bleed miRNA-10a-5p AUC of 0.80 
(95% CI 0.65 – 0.95) 
Decompensated liver disease 
 
miRNA-10a-5p + 
miRNA-146a-5p + 
miRNA-423-3p 
AUC of 0.78 
(95% CI 0.70 – 0.86) 
MiRNA panels derived from stepwise logistic regression, using forward selection and 
backward elimination. All comparisons to cirrhotic patients, except the decompensated 
liver disease miRNA panel which combines ascites and variceal bleed patients compared 
to cirrhosis and varices patients. (Abbreviations: 95% CI, 95% confidence interval; AUC, 
area under the curve; ROC, receiver operating characteristics). 
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Figure 6.4. Performance of serum miRNA panels to discriminate the spectrum of 
decompensated liver disease. MiRNA panel ROC curve performance as follows: Varices 
miRNA panel (miRNA-10b-5p and miRNA-101-3p) with and AUC of 0.78 (95% CI 0.66 – 
0.90, p < 0.001) using an Youden’s index derived cut-point of 0.50; ascites miRNA panel 
(miRNA-10a-5p and miRNA-146a-5p) with an AUC of 0.83 (95% CI 0.75 – 0.92, p < 0.001) 
using an Youden’s index derived cut-point of 0.78; variceal bleed miRNA panel (miRNA-
10a-5p) with and AUC of 0.80 (95% CI 0.65 – 0.95, p < 0.001) using an Youden’s index 
derived cut-point of 0.56 and decompensation miRNA panel (miRNA-10a-5p, miRNA-
146a-5p and miRNA-423-3p) with and AUC of 0.78 (95% CI 0.70 – 0.86, p < 0.001) using 
an Youden’s index derived cut-point of 0.59. Blue line = Varices miRNA panel, Orange line 
= Ascites miRNA panel, Green line = Variceal bleed miRNA panel, Black line = 
Decompensation miRNA panel. (Abbreviations: 95% CI, 95% confidence interval; AUC, 
area under the curve; ROC, receiver operating characteristics). 
 
6.4.5 Cross-validation of miRNA panels 
 
To further assess the miRNA panels in discriminating the spectrum of decompensated 
liver disease k-fold cross validation (5-fold) analysis was performed. The cross validation 
performance of the varices miRNA panel, using the Youden’s index derived cut-point of 
0.50, resulted in an AUC of 0.79 (95% CI 0.65 – 0.92) with sensitivity of 72%, specificity of 
71%, PPV of 70%, NPV of 71% and overall accuracy of 67%. The ascites miRNA panel, 
using a Youden’s index derived cut-point of 0.78, resulted in an AUC of 0.84 (95% CI 0.75 
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– 0.92) with sensitivity of 63%, specificity of 82%, PPV of 87%, NPV of 53% and overall 
accuracy of 68%. Assessing the cross-validation performance of the variceal bleeding 
miRNA panel resulted in an AUC of 0.84 (95% CI 0.72 – 0.96) using the Youden’s index 
derived cut-point of 0.56. This analysis resulted in a sensitivity of 52%, specificity of 97%, 
PPV, 93%, NPV 79% and overall accuracy of 80% (see Figure 6.5) 
 
Performing cross-validation on the decompensated miRNA panel resulted in an AUC of 
0.77 (95% CI 0.69 – 0.85), with sensitivity of 66%, specificity of 75%, PPV of 76%, NPV of 
63% and overall accuracy of 70%. As previously described this miRNA panel used a 
Youden’s index derived cut-point of 0.59 (see Figure 6.5). 
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Figure 6.5. K-fold (5-fold) cross-validation ROC curve of serum miRNA panels to 
discriminate the spectrum of decompensated liver disease. (A) a miRNA panel 
(comprising miRNA-10b-5p and miRNA-101-3p) to distinguish patients with compensated 
cirrhosis with varices from those with compensated cirrhosis generated an AUC of 0.79 
(95% CI 0.65 – 0.92) following 5-fold cross-validation. (B) a miRNA panel (comprising 
miRNA-10a-5p and miRNA-146a-5p) to distinguish patients with ascites from those with 
cirrhosis alone AUC of 0.84 (95% CI 0.75 – 0.92) following 5-fold cross-validation. (C) a 
miRNA panel (comprising miRNA-10a-5p) to distinguish patients with variceal bleeds from 
those with cirrhosis alone generated an AUC of 0.84 (95% CI 0.72 – 0.96) following 5-fold 
cross-validation. (D) a miRNA panel (comprising miRNA-10a-5p, miRNA-146a-5p and 
miRNA-423-3p) to distinguish patients with decompensated cirrhosis (grouping ascites and 
variceal bleed) from those with compensated cirrhosis (with or without varices) alone 
generated AUC of 0.77 (95% CI 0.69 – 0.85) following 5-fold cross-validation. 
(Abbreviations: 95% CI, 95% confidence interval; AUC, area under the curve; miRNA, 
microRNA; ROC, receiver operating characteristics). 
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6.4.6 Performance of clinical markers to identify the spectrum of decompensated 
liver disease  
 
Within this study, the performance of established clinical markers was analysed to 
compare them with selected miRNA panels. A platelet count of < 150 (x109/L)2 was used to 
distinguish patients with varices, ascites and variceal bleeding, when compared with 
cirrhosis alone. Using the platelet count to diagnose varices, compared with cirrhosis 
alone, resulted in an AUC of 0.80 (95% CI 0.69 – 0.92, p < 0.001) with a sensitivity of 
73%, specificity of 70%, PPV of 71%, NPV of 72%, and overall accuracy of 72%. 
Employing the same comparison, the varices miRNA panel resulted in an AUC of 0.78 
(95% CI 0.66 – 0.90, p < 0.001). Combining both biomarkers using logistic regression 
analysis, (i.e. varices miRNA panel and platelet count < 150 (x109/L)2 improved the ROC 
curve performance with an AUC of 0.84 (95% CI 0.74 – 0.93, p < 0.001; see Figure 6.6A 
and Table 6.7).  
 
Assessing the diagnostic performance of a platelet count of < 150 (x109/L)2 to discriminate 
ascites from cirrhosis resulted in an AUC of 0.82 (95% CI 0.73 – 0.91, p < 0.001) with 
sensitivity of 73%, specificity of 70%, PPV of 83%, NPV of 57% and overall accuracy of 
72%. The ascites miRNA panel was marginally better than platelet count alone with an 
AUC of 0.82 (95% CI 0.73 - 0.91, p < 0.001). Combining the ascites miRNA panel and 
platelet count of < 150 (x109/L)2 to discriminate patients with ascites resulted in the best 
ROC curve performance with an AUC of 0.87 (95% CI 0.79 – 0.94, p < 0.001; see Figure 
6.6B and Table 6.7)  
 
Using the same criterion, a platelet count of < 150 (x109/L)2, to discriminate variceal 
bleeding from cirrhosis resulted in an AUC of 0.71 (95% CI 0.55 – 0.88, p = 0.010) with a 
sensitivity of 50%, specificity of 70%, PPV of 47%, NPV of 72%, and overall accuracy of 
63%. Employing the same comparison, the variceal bleeding miRNA panel resulted in an 
AUC of 0.80 (95% CI 0.65 – 0.95, p < 0.001). Combining the variceal bleeding miRNA 
panel and platelet count only resulted in a marginal improvement in ROC curve 
performance over the miRNA panel alone with an AUC of 0.81 (95% CI 0.67 – 0.96, p < 
0.001; see Figure 6.6C and Table 6.7). 
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Table 6.7. Performance overview of platelet count and miRNA panel to identify the 
spectrum of decompensated liver disease. 
Complication Platelet count Platelet count and  
miRNA panel 
Varices AUC of 0.80 
(95% CI 0.69 – 0.92) 
AUC of 0.84 
(95% CI 0.74 – 0.93) 
Ascites AUC of 0.82 
(95% CI 0.73 – 0.91) 
AUC of 0.87 
(95% CI 0.79 – 0.94) 
Variceal Bleed AUC  of 0.71 
(95% CI 0.55 – 0.88) 
AUC of 0.81 
(95% CI 0.67 – 0.96) 
ROC curve performance of platelet count < 150 (x109/L)2 to identify patients with varices, 
ascites and variceal bleeding alone and in combination with their respective miRNA 
panels. All comparisons were made with cirrhotic patients as the control group.  
(Abbreviations: 95% CI, 95% confidence interval; AUC, area under the curve; miRNA, 
microRNA; ROC, receiver operating characteristics). 
 
The performance of MELD score as a diagnostic tool to identify patients with cirrhosis-
related complications was also assessed and compared with the performance of the 
assembled miRNA panels. ROC curve analysis of the MELD score in this cohort resulted 
in an AUC of 0.92 (95% CI 0.86 – 0.98, p < 0.001) to distinguish patients with ascites 
compared to cirrhosis and an AUC of 0.92 (95% CI 0.84 – 1.00, p < 0.001) to distinguish 
patients with variceal bleeding compared to cirrhosis. ROC curve analysis was also 
performed to assess the performance of the MELD score in distinguishing patients with 
decompensated cirrhosis, grouping patients with ascites and patients with variceal 
bleeding compared to cirrhosis and varices, resulted in an AUC of 0.85 (95% CI 0.79 - 
0.91, p < 0.001). 
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Figure 6.6. ROC curves for identifying severity of clinical decompensation using 
platelet count alone or in combination with circulating miRNA panels. (A) In 
distinguishing patients with varices, the performance of platelet count (AUC = 0.80, 95% 
CI 0.69 – 0.92, p < 0.001) was enhanced in combination with the varices miRNA panel 
(AUC = 0.84, 95% CI 0.74 – 0.93, p < 0.001). (B) In distinguishing patients with ascites, 
the performance of platelet count (AUC = 0.82, 95% CI 0.73 – 0.91, p < 0.001) was 
enhanced in combination with the cirrhosis miRNA panel (AUC = 0.87, 95% CI 0.79 – 
0.94, p < 0.001). (C) Platelet count alone demonstrated the lowest diagnostic utility in the 
identification of patients with variceal bleeding compared to cirrhosis (AUC = 0.71, 95% CI 
0.55 – 0.88, p = 0.010). When used in combination with the variceal bleeding miRNA 
panel, there was no significant improvement in the miRNA panel’s ability to detect patients 
with variceal bleeding (AUC = 0.81, 95% CI 0.67 – 0.96, p < 0.001). In all cases, a 
diagnostic cut-off for platelet count of platelets < 150 (x109/L)2 was used to identify 
patients with the respective complication. (Abbreviations: 95% CI, 95% confidence interval; 
AUC, area under the curve; miRNA, microRNA; ROC, receiver operating characteristics). 
177 
 
To assess performance of the MELD score, cut-off values of MELD ˃ 12 and MELD ˃ 15 
were applied to distinguish patients with ascites and/or variceal bleeding. For the MELD 
score cut-off of 12, comparing patients with ascites to patients with cirrhosis, the 
performance characteristics were as follows: sensitivity 55%, specificity 93%, PPV 94%, 
NPV 51%, and overall accuracy 68%. For the MELD score cut-off of 12 and the same 
comparison, the performance characteristics were as follows: sensitivity 33%, specificity 
100%, PPV 100%, NPV 43%, and overall accuracy 56%. Combining the MELD score with 
the ascites miRNA panel did not improve the overall ROC curve performances with an 
AUC of 0.88 (95% CI 0.81 – 0.95, p < 0.001), for the MELD score cut-off of 12 (see Figure 
6.7A), and an AUC of 0.89 (95% CI 0.82 – 0.95, p < 0.001) for a MELD score cut-off of 15 
(see Figure 6.8A). 
 
Applying the MELD score cut-off value of 12 to identify patients with variceal bleeding, 
compared with cirrhosis, resulted in a sensitivity of 38%, specificity of 93%, PPV of 75%, 
NPV of 74%, and an overall accuracy of 74%. Using the MELD score cut-off of 15 and the 
same comparison resulted in a sensitivity of 25%, specificity of 100%, PPV of 100%, NPV 
of 71%, and an overall accuracy of 74%. Combining the MELD score with the variceal 
bleed miRNA panel resulted in AUCs of 0.82 (95% CI 0.68 – 0.95, p < 0.001) and 0.85 
(95% CI 0.72 – 0.97, p < 0.001) for MELD score cut-offs of 12 and 15 (see Figure 6.7B 
and Figure 6.8B), respectively.  
 
Applying the MELD score cut-off values to identify patients with clinical decompensation 
(i.e. grouping patients with ascites and patients with variceal bleeding), compared with 
compensated cirrhosis, resulted in a sensitivity of 51%, specificity of 90%, PPV of 87%, 
NPV of 59%, and an overall accuracy of 68% for the MELD score cut-off of 12, and a 
sensitivity of 32%, specificity of 98%, PPV of 96%, NPV of 53%, and an overall accuracy 
of 61% for the MELD score cut-off of 15. The combination of the decompensation miRNA 
panel and MELD score actually resulted in reduced performances of the ROC curves for 
MELD score, with AUCs of 0.83 (95% CI 0.76 – 0.90, p < 0.001) and 0.83 (95% CI 0.77- 
0.90, p < 0.001) for the cut-off values of 12 and 15 (see Figure 6.7C and Figure 6.8C), 
respectively.  
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Figure 6.7. ROC curves for identifying severity of clinical decompensation using 
MELD ≥12 alone or in combination with circulating miRNA panels. (A) In 
distinguishing patients with ascites, the performance of MELD AUC of 0.92 (95% CI 0.86 – 
0.98, p < 0.001) was decreased in combination with the ascites miRNA panel (AUC = 0.88, 
95% CI 0.81 – 0.95, p < 0.001). (B) In distinguishing patients with variceal bleeding, the 
performance of MELD AUC of 0.92 (95% CI 0.84 – 1.00, p < 0.001) was decreased in 
combination with the variceal bleed miRNA panel (AUC = 0.82, 95% CI 0.68 – 0.95, p < 
0.001) (C) MELD alone demonstrated the lowest diagnostic utility in the identification of 
patients decompensated cirrhosis (grouping ascites and variceal bleeding) compared to 
compensated cirrhosis (± varices) AUC of 0.85 (95% CI 0.79 - 0.91, p < 0.001). When 
used in combination with the decompensated miRNA panel, there was decrease in 
MELD’s ability to detect patients with decompensation (AUCs = 0.83, 95% CI 0.76 – 0.90, 
p < 0.001). In all cases, a diagnostic cut-off for MELD ≥ 12 was used to identify patients 
with the respective complication. (Abbreviations: 95% CI, 95% confidence interval; AUC, 
area under the curve; MELD, model for end-stage liver disease; miRNA, microRNA; ROC, 
receiver operating characteristics). 
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Figure 6.8. ROC curves for identifying severity of clinical decompensation using 
MELD ≥ 15 alone or in combination with circulating miRNA panels. (A) In 
distinguishing patients with ascites, the performance of MELD AUC of 0.92 (95% CI 0.86 – 
0.98, p < 0.001) was decreased in combination with the ascites miRNA panel (AUC = 0.89, 
95% CI 0.82 – 0.95, p < 0.001) (B) In distinguishing patients with variceal bleeding, the 
performance of MELD AUC of 0.92 (95% CI 0.84 – 1.00, p < 0.001) was decreased in 
combination with the variceal bleed miRNA panel (AUC = 0.85, 95% CI 0.72 – 0.97, p < 
0.001) (C) MELD alone demonstrated the lowest diagnostic utility in the identification of 
patients decompensated cirrhosis (grouping ascites and variceal bleeding) compared to 
compensated cirrhosis (± varices) AUC of 0.85 (95% CI 0.79 - 0.91, p < 0.001). When 
used in combination with the decompensated miRNA panel, there was decrease in 
MELD’s ability to detect patients with decompensation (AUC = 0.83, 95% CI 0.77- 0.90, p 
< 0.001) In all cases, a diagnostic cut-off for MELD ≥ 15 was used to identify patients with 
the respective complication. (Abbreviations: 95% CI, 95% confidence interval; AUC, area 
under the curve; MELD, model for end-stage liver disease; miRNA, microRNA; ROC, 
receiver operating characteristics). 
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6.4.7 Identification of novel miRNAs in varices 
 
To this point all miRNA examined have been previously identified and annotated, however, 
performing next generation sequencing also identified novel, as yet non-annotated 
circulating miRNAs in cirrhosis and varices. Strong variability identified in miRNA yield, as 
described in Section 6.4.2, affected the total number of libraries included in the 
subsequent analysis. Only samples with more than 10,000 reads mapped to known pre-
miRNAs were included, resulting in a reduced dataset of n = 11 serum samples. For the 
purpose of novel miRNA identification patients with varices (n = 2) and variceal bleeds (n 
=3) were grouped together and compared to cirrhotic patients (CC, n = 6).  
 
The expression levels of 4 non-previously described miRNAs were identified in both 
groups (n = 11): novel miRNA-AW1 (i.e., AW-1, Anna Weis-1) with a median of 388 reads 
(IQR 189 – 626; see Figure 5.5), novel miRNA-AW2 with a median of 348 reads (IQR 150 
– 511; see Figure 5.6), novel miRNA-AW3 with a median of 146 reads (IQR 79 – 197; see 
Figure 5.7) and novel miRNA-AW4 with a median of 77 reads (IQR 43 – 114; see Figure 
5.8). As these miRNAs were identified in the previous chapter, their detailed structure and 
sequence can be found in the respective figures in Chapter 5. Performing differential 
expression analysis comparing cirrhosis with all patients with varices (i.e. grouping varices 
with variceal bleeding) showed no significance. There was no significant differential 
expression of the 3 most abundant miRNAs: novel miRNA-AW1 (p = 0.818), novel miRNA-
AW2 (p = 0.053) and novel miRNA-AW3 (p = 0.055). In contrast, significant increased 
expression for was found for novel miRNA-AW4 (p = 0.028), when comparing cirrhosis and 
varices. 
 
6.5 Discussion 
 
Cirrhosis-related complications are associated with high morbidity and mortality rates and 
the onset of decompensated disease generally confers a poor prognosis. The diagnosis of 
varices relies on invasive gold standard investigations, endoscopy and HVPG, and non-
invasive and accurate diagnostic tests are needed. While ascites and variceal bleeding 
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can be easily diagnosed,71, 73 identifying patients at risk of these complications prior to their 
onset, could improve patient management and potentially decrease mortality. MiRNAs 
have been shown to have great potential as diagnostic biomarkers in a variety of disease 
states but, to date, have not been investigated as diagnostic markers of cirrhosis-related 
complications.211 Although this study focused on the identification of miRNA expression 
related to the actual presence of complications, these preliminary results represent a 
foundation upon which future studies could be developed.  
 
Serum samples of 136 patients were used to identify differentially expressed miRNAs 
across the spectrum of cirrhosis, including compensated cirrhosis (CC, n=30), 
compensated cirrhosis with varices (CV, n=30), cirrhosis with ascites (A, n=60), and 
cirrhosis with incident variceal bleeding (VB, n=16). To identify potential miRNA biomarker 
candidates, a subset of 60 samples was screened using small RNA NGS and the 10 most 
promising miRNA candidates were selected for further studies. An attempt to confirm the 
differential expression using qRT-PCR of 5 miRNA candidates in association with 
individual cirrhosis-related complications and clinical decompensation (ascites and/or 
variceal bleeding) was undertaken during the validation phase. The diagnostic 
performances of these miRNAs, alone or in combination as miRNA panels, were assessed 
to identify patients with different cirrhosis-related complications. Finally, the performances 
of diagnostic miRNA panels were compared with currently accepted indicators of disease 
severity to assess their clinical utility.  
 
6.5.1 MiRNA-10a-5p and miRNA-10b-5p 
 
In this study of decompensated cirrhosis, circulating miRNA-10a-5p was one of the most 
significant differentially expressed miRNAs, showing consistently increased expression in 
patients with decompensation compared with compensated cirrhosis patients. Differential 
expression of miRNA-10a-5p in liver disease has been described previously but results are 
mixed and the significance of these findings is unclear. Furthermore, much of what is 
already known about miRNA-10a-5p is in relation to HCC, which was not the primary focus 
of the current experiments. Increased expression of serum miRNA-10a-5p has been 
described in a CHB cohort with substantial histological features388 as well as a study of 
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patients with HCC.389 The latter study also described increased circulating miRNA-10a-5p 
levels in patients with chronic hepatitis compared with healthy control patients, however 
limited patient characteristics were provided.389 Increased tissue expression of miRNA-
10a-5p has also been reported in HCV-associated dysplastic nodules and HCV-associated 
HCC compared with non-tumorous surrounding tissue,315 whereas another study reported 
decreased tissue miRNA-10a-5p expression in HCC of mixed aetiologies.390 Increased 
hepatocyte expression of miRNA-10a-5p has also been reported in vitro, following 
sorafenib treatment and in sorafenib-resistant Huh7 and HepG2 cells.391 Other studies in 
HCC have suggested an inhibitory function of miRNA-10a-5p on HCC cell matrix adhesion 
through the targeting of EphA4, which regulates EMT and the β1 integrin pathway. In fact, 
inhibition of miRNA-10a-5p led to an increase of β integrin protein.392 Inhibition of miRNA-
10a-5p has been shown to upregulate E-cadherin and downregulate ICAM1,392 which are 
molecules involved in EMT and inflammatory signalling, respectively. Upstream in the 
gene expression cascade of miRNA-10a-5p is the long-non-coding tumour suppressor 
TUSC7, which is decreased in HCC, and lower levels of TUSC7 have been correlated to 
poorer overall survival.393 In fact, low tissue TUSC7 levels appear to correlate with lower 
E-cadherin levels and lower in vitro TUSC7 expression results in increased miRNA-10a-
5p, leading to a reduction in EphA4. Based on these results, it has been suggested that 
EMT in HCC may be promoted through a potential TUSC-7-miRNA-10a-5p-EphA4 axis.393 
Differential expression of miRNA-10a-5p has also been reported in other cancers. 
Circulating miRNA-10a-5p has been described in oesophageal squamous cell 
carcinoma,394 and disease risk stratification in pancreatic cancer identified a correlation 
between high risk groups and miRNA-10a-5p levels.395 MiRNA expression appears to be 
disease-specific as decreased miRNA-10a-5p expression has been conversely reported in 
the plasma of lung cancer patients.396 Although this study did not report any significant 
differential tissue expression of miRNA-10a-5p,396 several other studies have shown 
differential expression in tissue with increased expression in lung cancer, and metastatic 
lung cancer 397 and decreased expression in tissue samples of recurrent breast cancer.398, 
399  
 
In addition to the purported involvement of miRNA-10a-5p in cancer, potentially through 
the regulation of EMT, this miRNA has also been described in hypoxia400 and inflammatory 
diseases. In a study of inflammatory bowel disease, decreased miRNA-10a-5p was 
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reported in the inflamed mucosa of patients401 and decreased expression in the synovium 
of rheumatoid arthritis patients.402 In fact, it has been reported that miRNA-10a-5p 
regulates a pro-inflammatory phenotype in endothelial cells through direct binding of 
MAP3K7.403 
 
Similar to miRNA-10a-5p, miRNA-10b-5p demonstrated significantly increased expression 
in association with the cirrhosis-related complications investigated here. There are limited 
studies reporting differential expression of circulating miRNA-10b-5p in liver disease. One 
study described increased serum miRNA-10b-5p expression in chronic liver disease and a 
further increase in HCC, however the aetiology of liver disease in these patients was not 
reported.404 In HBV, increased tissue miRNA-10b-5p expression correlated with increased 
disease severity (by fibrosis stage).405 In biopsy-proven NAFLD, however, significant 
differential expression of miRNA-10b-5p in serum was not observed when compared to 
healthy control patients, although the trend was towards decreased expression. In that 
study, however, a negative correlation between serum miRNA-10b-5p levels and the 
presence of inflammation was observed.406 Increased miRNA-10b-5p expression in liver 
tissue has been described in HBV patients, where increased miRNA-10b-5p expression 
correlated with fibrosis stage.405 A similar pattern of expression has been seen in HCC 
tissue samples, compared with non-tumorous tissue405, 407-409 and increased tissue 
miRNA-10b-5p expression is correlated with metastatic disease and poorer overall 
survival.410 Increased miRNA-10b-5p levels have also been confirmed in vitro, comparing 
HCC with non-HCC cell lines.409, 411 There are limited data on the function of miRNA-10b-
5p, although functional studies in HepG2 cells suggest a potential oncogenic role of 
miRNA-10b-5p (with higher expression increasing cell viability and migration and 
decreased expression reducing colony formation).409 In fact, the transcription of the 
potential tumour suppressor HOXD10 has been described as a miRNA-10b-5p target, 
modulating the target genes RhoC, MMP-2 and MMP-9 which are linked with tumour 
invasion and metastasis.411 Inhibiting miRNA-10b-5p resulted in inhibition of the 
downstream targets of HOXD10 whereas in vivo studies (using a mouse model of HCC), 
demonstrated increased tumour size following the injection of a miRNA-10b-5p-expressing 
vector.411 Several other targets of miRNA-10b-5p in HCC have been described, such as 
members of the KLF4/KLF11/Smad7/Smad4 axis,412 which regulates EMT, and tumour 
suppressors CADM1410 and CADM2, which also has a potential role in inhibiting EMT.413 
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In line with HCC studies, increased miRNA-10b-5p expression has also been shown in the 
serum of patients with gastric cancer414 and melanoma.415 High expression levels of 
miRNA-10b-5p also appear to correlate with advanced melanoma stages, lymph node 
metastasis and shorter overall and disease-free survival.415 In assessing miRNA-10b-5p 
expression in other cancers, however, there is significant inter-study variation. For 
example, in gastric cancer one study reported increased miRNA-10b-5p expression in 
cancer tissue samples414 with high expression correlating with shorter overall survival,416 
whereas another study reported decreased miRNA-10b-5p expression in the majority of 
cancer tissue samples.417 A meta-analysis assessing the role of miRNA-10b-5p confirmed 
this variability, with conflicting reports of increased and decreased miRNA-10b-5p 
expression in studies of the same cancer.418 The meta-analysis concluded that higher 
miRNA-10b-5p expression in some cancers, such as lung, breast and gastric cancer, is 
associated with poorer overall survival.419 Increased miRNA-10b-5p has also been 
described in inflammatory disease, for example in T helper 17 cells of ankylosing 
spondylitis.420 This is of particular interest as T helper 17 cells have been suggested to 
contribute to hepatic inflammation.421 Supporting the link of miRNA-10b-5p and CLD is that 
the transcription of osteopontin, which has been implicated as a promoter of hepatic 
fibrosis, has also been identified as potential miRNA-10b-5p target.422 
 
The co-relationship of miRNA-10a-5p and miRNA-10b-5p has been previously been 
investigated, albeit in the setting of breast cancer.423 Although they are located on different 
chromosomes (miRNA-10a on chromosome 17 (17q21.32), miRNA-10b on chromosome 2 
(2q31.1)). Tan et al. suggested that miRNA-10a and miRNA-10b could target each other’s 
primary transcripts to repress expression of adjacent HOX genes.423 Both miRNAs are 
indeed located within the HOX gene cluster, miRNA-10a adjacent to HOXB4 and miRNA-
10b adjacent to HOXD4.390, 423 Both miRNAs and their host genes show eight significantly 
hypermethylated CpG sites in HCC tissues samples and statistically decreased miRNA-
10a-5p in HCC tissue expression is consistent with methylation of the host gene 
HOXB4.390 Overall, this provides evidence of a close relationship between miRNA-10a-5p 
and miRNA-10b-5p but only in the context of malignancy. Little is known of a co-
relationship between mi-RNA-10a-5p and mi-RNA-10b-5p in the context of cirrhosis and 
the occurrence of cirrhosis-related complications. The fact that serum levels of these 
miRNAs were consistently increased across the spectrum of decompensated cirrhosis 
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makes the findings of the current study novel and worthy of further studies to confirm their 
significance. 
 
In the current study, miRNA-10a-5p and miRNA-10b-5p were the most significant 
differentially expressed miRNAs with increased levels in cirrhosis- and portal hypertension-
related complications. Interestingly, another study has identified both miRNAs as highly 
abundant in epithelial cells and identified the hypertension-related gene TBX5 as a 
putative target gene of both miRNAs.424 Differential expression of both miRNAs has also 
been linked with angiogenesis, with loss of miRNA10a-5p and miRNA-10b-5p leading to 
impaired blood vessel outgrowth in a zebrafish model.425 These results are supported by 
the observation that miRNA-10b-5p overexpression in endothelial cells induces tube 
formation and angiogenesis through targeting of HOXD10, and the finding that heparin 
reduces miRNA-10b-5p expression in vitro.426 Of note, these findings have been confirmed 
in an independent study (using a breast cancer mouse model) that demonstrated 
suppression of miRNA-10b-5p in endothelial cells results in increased HOXD10 and 
inhibition of miRNA-10b-5p leads to significantly reduced numbers of tumour endothelial 
cells as well as phenotypic change in tumour vascularity.427 Although there are no studies 
assessing the role of miRNA-10a-5p and miRNA-10b-5p in portal hypertension, these 
earlier studies do suggest that these miRNAs might have a functional role in states of 
elevated intravascular pressure and angiogenesis. A putative role in vascular changes 
associated with the development of portal hypertension, however, remains speculative but 
warrants further investigation. 
 
6.5.2 MiRNA-22-3p 
 
In the current study, increased serum expression of miRNA-22-3p was seen in association 
with ascites and variceal bleeding but significantly increased expression was only seen 
across the overall spectrum of disease severity (by ANOVA analysis) rather than for 
individual group comparisons. MiRNA-22-3p has previously been reported in several 
studies of chronic liver disease. Reduced miRNA-22-3p expression was reported in the 
serum of cirrhotic HCV patients, compared with healthy controls, and also in patients with 
HCC patients, compared with CHC alone.428 There are also reports of an association 
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between miRNA-22-3p and chronic HBV infection.354 In non-viral aetiologies, such as 
paediatric CF liver disease, increased expression of circulating miRNA-22-3p has also 
been reported compared with CF controls without liver disease.312 In tissue samples, 
decreased miRNA-22-3p levels have been reported in HBV-related HCC, where it has also 
has been correlated with reduced disease-free survival.429 A meta-analysis of miRNA-22-
3p expression in HCC tissues confirmed that lower miRNA-22-3p tissue expression 
correlated with significantly poorer survival of HCC patients.430 One study investigating the 
effects of miRNA-22-3p in HCC cells showed decreased miRNA expression and inhibited 
proliferation and decreased tumour size and formation through the use of ectopic miRNA-
22-3p expression,429 suggesting a potential tumour suppressive role for miRNA-22-3p. 
Several functional targets for miRNA-22-3p have been described, such as HDAC4 (which 
is needed for cell proliferation429), CD147431 (a potential HCC prognostic marker432), 
galectin 9433, 434  and galectin 1.435 Interestingly, both galectins have been previously linked 
with angiogenesis436 as well as HCC development.437 In addition to a possible tumour 
suppressor role, increased liver tissue miRNA-22-3p has also been described in the study 
of other diseases. Using a mouse model of diabetes, miRNA-22-3p expression was linked 
to increased lipid accumulation in HepG2 cells.438 MiRNA-22-3p has also been linked to 
the Wnt signalling pathway, regulating the expression of gluconeogenic genes through 
targeting TCF7, and leading to an increased expression of enzymes of gluconeogenesis in 
HepG2 cells.438, 439 Interestingly, one study investigating miRNA expression in epithelial 
cells identified miRNA-22-3p as one of the most abundant miRNAs and postulated the 
hypertension-related gene encoding the adrenergic receptor A1B (ADRA1B) as a putative 
target.424 Supporting a potential link between miRNA-22-3p, hypertension and liver 
disease, a study using miRNA-22-3p antisense in a liver disease mouse model led to 
decreased portal pressure and decreased fibrosis.440 This study identified BMP7 as a 
miRNA-22-3p target440, which is also linked with the Wnt signalling pathway. 
 
6.5.3 MiRNA-27b-3p 
 
When comparing patients’ expression levels of circulating miRNA-27b-3p across different 
cirrhosis-related complications, this study identified a significant increase in the variceal 
bleed patient cohort. Although circulating miRNA-27b-3p has previously not been 
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described in variceal bleeding, it has been reported as being abundant in epithelial cells in 
a study investigating miRNAs in hypertension. More specifically miRNA-27b-3p has been 
shown to target the hypertension related endothelial-receptor A (EDNRA) as shown by 
anti-miRNA transfections into epithelial cells decreasing EDNRA mRNA levels. Other 
putative hypertension-related targets of miRNA-27b-3p include Golgi SNAP receptor 
complex member 2 (GOSR2) and plasma membrane calcium-transporting ATPase1 
(ATP2B1).424 Although more studies are required, this suggests that miRNA-27b-3p could 
be involved in the regulation of intravascular pressure and increased expression in 
patients with variceal bleeding could reflect a role in modulating portal hypertension.  
 
Other studies suggest that expression of miRNA-27b-3p is strongly linked to lipid 
metabolism. A study investigating liver miRNAs in mice identified miRNA-27b-3p as 
important regulatory miRNA in lipid metabolism, having the most predicted target genes 
within lipid metabolism when compared with other miRNAs.441 In fact, a high-fat diet in 
mice led to an increase in the expression of miRNA-27b-3p within the liver441, 442 and key 
lipid metabolism genes have been identified as potential mi-RNA-27-3p target genes, 
including ANGPTL3441 LDLR and LDLAP1442 Of note, miRNA-27b-3p changes do not 
appear to lead to changes in plasma and hepatic lipid levels.442  
 
A regulatory function of miRNA-27b-3p has also been suggested for HCV lifecycle, with 
increased miRNA-27b-3p induced through HCV replication and ectopic miRNA expression 
decreasing HCV RNA levels in vitro. Interestingly, with ectopic miRNA-27b-3p expression 
in hepatocytes in vitro, larger and more abundant lipid droplets were observed suggesting 
a link between HCV replication and the presence of steatosis.443 The same study also 
showed that the increase in lipid droplets was reversible using a PPARα agonist.443 A 
negative correlation between miRNA-27b-3p and PPARα mRNA levels has also been 
described in HCV core transgenic mice.444 Furthermore, an inverse correlation has also 
been described with PPARγ, with high miRNA-27b-3p levels identified alongside low 
PPARγ expression levels in a rat fibrosis model.445 PPARγ was also identified as 
functional target of miRNA-27b-3p446 and evidence of decreased PPARγ expression in a 
human hepatic stellate cell line446 suggests a potential link with fibrosis. In other models, 
such as a mouse model of liver injury investigating bone marrow derived macrophages, 
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miRNA-27b-3p expression was linked to the inhibition of macrophage activation in chronic 
liver injury through the 15d-PGJ2/PPARγ axis.447 Following these links between miRNA-
27b-3p and hepatic fibrosis further, there are also studies suggesting a link to cellular 
inflammatory responses with decreased miRNA-27b-3p levels following IFN-γ stimulation 
of liver epithelial cells.448 The current study only aimed to identify individual miRNAs in the 
circulation that were associated with the presence of different features of hepatic 
decompensation, and therefore cannot validate previous experimental data that seek to 
link pathophysiology and increased expression of individual miRNAs. It is nonetheless 
reassuring that other investigators are exploring the mechanisms behind progressive liver 
disease and expression levels of candidates identified in the current study (such as 
miRNA-27b-3p). Overall, there is growing evidence that miRNA-27b-3p may be involved in 
hepatic fibrosis, through lipid metabolism and inflammation, and potentially involved in the 
modulation of hypertension. With increased serum levels seen in combination with variceal 
bleeding, this miRNA represents an interesting target to pursue for future studies. 
 
Differential expression of miRNA-27b-3p has also been described in HCC, with increased 
expression seen in HCC tissue samples and HCC cell lines.449 Higher levels of miRNA-
27b-3p in tissue have also been correlated with shorter overall and disease-free 
survival.450 Increased miRNA-27b-3p was also observed in multidrug resistant HCC cells, 
449 and it has been suggested that miRNA-27b-3p can enhance drug response by 
activation of p53-dependant apoptosis and sensitise liver cancer cells to drug treatment, 
including Sorafenib.451  
 
6.5.4 MiRNA-101-3p 
 
Finally, this study also found circulating miRNA-101-3p to be significantly increased in the 
serum of patients with ascites, when compared with all other study groups. Post hoc 
comparison also showed a significant increase in expression compared to compensated 
cirrhosis patients with varices. To date there is no study that has identified differential 
expression of miRNA-101-3p in the setting of ascites complicating cirrhosis, although 
increased serum miRNA-101-3p expression has been reported in HBV related HCC.452 
Conversely, decreased miRNA-101-3p expression has been shown in HCC tissue 
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samples 452-455 and HCC cell lines.453, 455 Functional studies involving miRNA-101-3p in 
hepatoma cells showed that ectopic expression reduces colony formation in vitro and 
sensitises cancer cells to apoptosis.453 Mcl-1 has been described as a functional target of 
miRNA-101-3p,453 which has previously been shown to sensitize human cancer cells to 
apoptosis.456 MiRNA-101-3p has also been described to decrease proliferation in vitro 
through the functional target SOX9.455 Additionally, clinically higher miRNA-101-3p 
expression in HCC tissue samples also been correlated with increased overall survival.455 
A meta-analysis examining miRNA-101-3p expression in solid tumours concluded that 
lower miRNA-101-3p correlates with poorer overall survival.457 Decreased expression of 
miRNA-101-3p has been linked with increased expression of DNA dependant protein 
kinases, which are needed for renal carcinoma cell proliferation,458 and decreased miRNA-
101-3p expression has been reported in primary and metastatic breast cancer tissue 
compared with non-cancerous tissue.459 In gastric cancer, which also showed decreased 
miRNA-101-3p expression in gastric cancer tissue and cell lines, lower circulating miRNA-
101-3p were reported in gastric cancer patients compared with controls.460 In gastric 
cancer, Mcl-1 has also been identified as its functional target,460 which supports 
observations described in HCC. The existing data for miRNA-101-3p suggests it could 
have a tumour suppressive function, although its roles in other complications of cirrhosis, 
such as ascites, require further investigation.  
 
6.5.5 MiRNA in decompensated cirrhosis 
 
This study identified 5 significantly differentially expressed miRNAs across the spectrum of 
cirrhosis-related complications. Expression levels of miRNA-10a-5p and miRNA-10b-5p 
were significantly increased across all complications, suggesting these could be further 
studied as biomarkers of decompensation in cirrhosis. The same could be said of miRNA-
22-3p, which displayed significant differential expression across the group as a whole, 
although expression levels of this miRNA could not distinguish individual complications 
from one another. Expression of miRNA-27b-3p and miRNA-101-3p were significantly 
expressed in the cirrhosis-related complications of variceal bleeding and ascites, 
respectively. A review of the literature, however, found that these have predominantly 
been described in HCC (and other cancers) rather than clinical decompensation. There 
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are some data linking the currently identified candidates with inflammation (miRNA-10a-
5p, miRNA-10b-5p, miRNA-27b-3p), lipid metabolism (miRNA-22-3p and miRNA-27b-3p) 
and EMT regulation (miRNA-10a-5p and miRNA-10b-5p), all of which are recognised 
factors in cirrhosis and disease progression.  
 
MiRNA-10a-5p, miRNA-10b-5p and miRNA-22-3p have all been described in osteoporosis 
and decreased circulating miRNA-22-3p expression has been identified in patients with 
osteoporotic fractures.461 In that study, miRNA-22-3p was purported to negatively regulate 
osteogenesis through the inhibition of β-catenin in the Wnt signalling pathway and in vitro 
data also suggest that increased expression of miRNA-22-3p reduces osteogenesis 
leading to osteoporosis.462 While cirrhotic patients do have a higher prevalence of 
osteoporosis463 and have a higher risk of hip fractures compared with non-cirrhotic 
patients,464, 465  the potential mechanisms responsible for reduced bone health are of more 
relevance to the findings of the current study. Increased miRNA-10a-5p expression has 
also been shown to inhibit osteogenic differentiation in vitro, via its regulation of angiogenic 
activity by downregulating VEGF expression in endothelial cells. This study, like the study 
of miRNA-22-3p, identified β-catenin as a functional target of miRNA-10a-5p.466  It is 
perhaps unsurprising that differential expression of these miRNAs have also been 
described in other metabolic and inflammatory diseases, such as diabetes (miRNA-22-3p) 
or rheumatoid arthritis (miRNA-10a-5p). To explore whether the currently identified 
candidate miRNAs were simply reflecting the presence of other medical comorbidities, 
rather than cirrhosis-related complications, the patients’ medical records were re-
examined. The study cohorts were heterogeneous but there appeared to be no over-
representation of Type 2 diabetes mellitus, osteoporosis, inflammatory rheumatological 
conditions, or systemic hypertension in any of the cohorts. Although the quality of the data 
in the medical records was variable, a thorough review (including interrogation of patient 
medication lists and other medical services consulted) suggested that medical comorbidity 
was not a clinically-significant factor affecting these results.  
 
Despite these representing preliminary data only, it is proposed that differential miRNA 
expression identified in this study truly reflects differences in miRNA expression in 
association with the cirrhosis-related complications of varices, ascites and variceal 
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bleeding. The reasons in support of this proposition include the relatively large sample size 
and the overall heterogeneous nature of this study group (including different disease 
aetiologies and an unselected patient cohort with respect to medical comorbidities and 
medication use). It could be argued, therefore, that the miRNAs described here would not 
have reached statistical significance if dependent on other patient factors. It has to be 
recognised, however, that formally controlling for other patient factors could provide much 
cleaner data and potentially a longer list of candidates (by reducing the background “noise” 
associated with variations in individual patient miRNA expression levels) but this was 
beyond the scope of the current study. The current study represents one of the first 
investigations of miRNA expression levels in decompensated cirrhosis and clearly 
additional extensive studies are required to further explore the prognostic potential of 
these preliminary data.  
 
An important part of the current study was ROC curve analysis using stepwise logistic 
regression to identify possible diagnostic miRNA panels for the presence of cirrhosis-
related complications. The miRNA panel for varices (including miRNA10b-5p and miRNA-
101-3p) resulted in an AUC of 0.78, which suggests fair performance. When combined 
with platelet count (< 150 (x109/L)2), the diagnostic performance improved to an AUC of 
0.84. Although this preliminary result requires validation, this is very promising. Although it 
cannot replace the current gold standard endoscopy, it could be used to non-invasively 
identify patients at higher risk of varices and/or those for whom screening endoscopy is 
unnecessary. Performing endoscopies requires clinical resources, such as personnel or 
equipment, and pre-selecting patients with portal hypertension and a higher risk of varices 
could optimise the use of limited resources, thereby improving cost-efficiency and benefits 
to the health care system. Current guidelines recommend using non-invasive tools such as 
liver stiffness measurement > 20-25 kPa alone or in combination with platelet count or 
spleen size to identify patients with clinical significant portal hypertension.467 The Baveno 
VI consensus statement recommends using a liver stiffness measurement of < 20 kPa and 
platelet count above 150 (x109/L)2 to identify patients at very low risk of varices.76 While 
the Baveno VI criteria out-performed the microRNA panel, with a negative predictive value 
of 98%,77 access to liver stiffness measurement is limited to centres where the technology 
exists. Although the use of FibroScan as a routine assessment in our patient cohort was 
limited, future validation studies could provide prospective data on the benefits of 
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combining non-invasive assessments (i.e. Baveno VI criteria and microRNA panel) to 
further improve diagnostic performance.  
 
The ascites miRNA panel (miRNA-10a-5p and miRNA-146a-5p) resulted in an AUC of 
0.83 and its combination with the platelet count cut-off improved this further, with an AUC 
of 0.87. The very good diagnostic performance of this combination of non-invasive 
assessments need to be further validated but, again, is very promising. It must be 
remembered that these data are based on the identification of ascites using the gold 
standard of ultrasound imaging and the miRNA panel was retrospectively derived in a 
cohort where the presence of ascites was already known. To be truly useful, this would 
require prospective validation but another limitation is that ultrasound is currently 
performed on a 6-monthly basis for other reasons and it is unlikely that the development of 
a miRNA panel would avoid the need for regular surveillance ultrasound. As a prognostic 
factor in patients with cirrhosis, the diagnosis of ascites is significant and it is possible that 
this miRNA panel (± other miRNAs) could be developed to provide a novel non-invasive 
prognostic score. Obviously, this is speculative and the current results are very preliminary 
so one must be cautious not to over-interpret the clinical utility of these promising results. 
Using a non-invasive test to identify patients at risk of ascites, rather than simply 
diagnosing it once it is apparent, has appeal. This approach could provoke a change in 
patient management (i.e. stricter dietary controls, more stringent adherence to abstinence, 
earlier treatment of the underlying cause of liver disease) that prevents the appearance of 
that complication in the future. Once again, the current study sought to provide preliminary 
data on miRNAs that are associated with the presence of complications of cirrhosis, rather 
than any candidates that are predictive of the onset of complications, but this is the 
direction in which this research will travel if the current findings are validated. In fact, 
follow-up of the current cohort allowing identification of previously compensated patients 
who develop complications and a correlation with their individual miRNA expression profile 
represents the logical next step in this research.  
 
The ROC curve performance of the variceal bleeding miRNA ‘panel’ (miRNA-10a-5p) 
resulted in an AUC of 0.80. The combination of the miRNA panel with platelet count only 
marginally improved the diagnostic accuracy, with an AUC of 0.81. This might be due to 
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the poor performance of platelet count alone within the variceal bleeding study cohort, with 
an AUC of 0.71. The identification of non-invasive patient factors or biomarkers that could 
select patients at highest risk of a fatal cirrhosis-related complication, like variceal 
bleeding, remains an urgent clinical need. The performance of the currently described 
miRNA panel to identify patients with variceal bleeding is promising but, once again, this 
cohort was only identified after the occurrence of variceal bleeding. The true potential of 
any validated miRNA panel will be in its ability to prospectively identify patients who 
subsequently bleed and do so with a clinically-relevant window of opportunity within which 
to alter disease trajectory with preventative intervention/s. Currently the miRNA panel 
analysis included only a limited number of samples and clearly further validation studies in 
a larger cohort are needed first, before any possible predictive miRNA panel could be 
prospectively studied providing a clinically useful test. While one should not over-interpret 
potential of these results, it is tempting to speculate on where this research is heading on 
the basis of promising preliminary data. 
 
ROC curve performance was also assessed for the decompensated cirrhosis miRNA 
panel (miRNA-10a-5p, miRNA- 146a-5p and miRNA-423-3p). The decompensated miRNA 
panel grouped the complications ascites and variceal bleed together and compared them 
to compensated cirrhosis patients, including patients with varices. Of note, the miRNA 
panel included miRNA-423-3p, which did not reach statistical significance by itself, instead 
of other highly significant miRNAs (such as miRNA-10b-5p). The decompensation miRNA 
panel was developed after cross-validation and exclusion of some miRNAs is likely due to 
the strong correlation of expression levels between some of the miRNAs identified in this 
study, such as miRNA-10a-5p and miRNA-10b-5p. Performing ROC curve analysis with 
the decompensated miRNA panel resulted in an AUC of 0.78, which is fair-to-good. The 
MELD score is clinically used to stratify patients at increasing risk of mortality and a cut-off 
of 15 is currently used to distinguish patients for whom life-saving liver transplantation is 
indicated. To explore the clinical utility of miRNAs in distinguishing patients at highest risk 
of mortality, a MELD cut-off of 15 was tested independently and in combination with the 
miRNA panel for decompensated liver disease. A cut-off of 12 was also chosen arbitrarily 
as an identifier of patients who appear to be progressing towards consideration for 
cirrhosis. Performing ROC curve analysis for the MELD score (cut-offs 12 and 15) 
combined with the decompensated disease miRNA panel resulted in an AUC of 0.83, 
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which represents an improvement in the performance of the miRNA panel. The MELD 
score alone, however, resulted in an AUC of 0.85 and outperformed the miRNA panel 
(either alone or in combination with MELD score). In fact, the MELD score was able to 
distinguish patients with ascites (AUC of 0.92) and variceal bleeding (AUC of 0.92) with 
excellent accuracy. These very high diagnostic performances on ROC curve analysis were 
not improved when combined with the respective miRNA panel, with AUCs of 0.88 (MELD 
cut-off of 12) and 0.89 (MELD cut-off of 15) for ascites, and AUCs of 0.82 (MELD cut-off of 
12) and 0.85 (MELD cut-off of 15), for variceal bleeding. Overall, therefore, the 
performance of the decompensated cirrhosis miRNA panel was good, but held no 
advantages over routine clinical assessment to be clinical useful. Once again, the true 
clinical potential of any microRNA panel in decompensated cirrhosis rests in its ability to 
predict the onset of decompensation and the complications that are features of 
decompensated liver disease. Whether used alone or in combination with traditional 
markers of disease severity (such as thrombocytopenia or MELD Score), these preliminary 
results need to be prospectively validated in a larger patient cohort. 
 
There are some limitations to this study that need to be considered when evaluating the 
results. This study identified candidate miRNAs associated with different stages of 
decompensated cirrhosis and included 136 patients in total. To determine clinical utility a 
larger, external validation study cohort is needed to confirm results. The variceal bleeding 
cohort, in particular, was smaller compared to the other study groups with only 16 patients 
enrolled in this group. Another limitation of the study is that not all compensated cirrhosis 
control patients had an endoscopy performed, which is the gold standard diagnostic test to 
assess the presence of varices. While all of the varices sub-group had undergone 
endoscopy to confirm the presence of varices, only 43.3% of patients in the control cohort 
of compensated cirrhosis alone had undergone an endoscopic examination of the upper 
gastrointestinal tract leaving 56.7% patients who had not had a recent endoscopy. None of 
these patients had splenomegaly (or, by definition, ascites) and obviously none had a 
history of variceal bleeding. Furthermore, the median platelet count was very robust in this 
group with 199 (x109/L)2 (IQR 141.8 - 233.8), but the presence of varices in this group 
could not be definitively excluded. As such, in identifying microRNA candidates to 
accurately distinguish patients with varices, some potential candidates may have been 
missed or the significance of any differential expression under-represented. The protocol 
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also established patient cohorts based on the presence or absence of complications. The 
majority of variceal bleeding patients (12 of 16 patients; 75%) were enrolled within 3 
months of their bleeding episode. To explore the true potential of a diagnostic panel, it 
clearly would have been advantageous to assemble a cohort of patients who provided 
their serum samples prior to their episodes of variceal bleeding. Obviously, this poses 
some logistic issues that could not be overcome for the purposes of the current study. It is 
anticipated that follow-up of all enrolled patients with routine serum sample collection will 
allow incident variceal bleeding to be captured and the diagnostic potential of the variceal 
bleeding miRNA panel to be prospectively assessed as part of a subsequent study. 
 
Strong correlations were identified between the two most significantly differentially 
expressed miRNAs identified (miRNA-10a-5p and miRNA-10b-5p) in association with 
cirrhosis-related complications. Combining these miRNAs in one panel did not improve the 
diagnostic performance of the panel as they were frequently co-expressed. The benefit of 
a panel is that it potentially limits numbers of false positives and negatives through the 
inclusion of multiple miRNAs but this is not the case when 2 miRNAs have very similar 
expression profiles. As these individual miRNAs showed such significant differential 
expression, it would be interesting if each miRNA was able to contribute to future studies 
testing these panels in a larger, external validation cohort. Alternative diagnostic 
approaches, such as a decision tree, could also be considered in future studies to 
maximise the performance of miRNAs as clinically useful non-invasive biomarkers. For the 
purposes of the current study, the aims were limited to the identification of miRNA 
candidates but clearly, if these preliminary results are validated, their clinical application 
could be explored further.  
 
By performing sequencing and PCR validation, this study identified 5 highly significant 
miRNA candidates with differential expression in patients with different cirrhosis-related 
complications. Although miRNAs have been the focus of much interest in the non-invasive 
assessment of HCC and hepatic fibrosis, limited data is available in decompensated 
cirrhosis. Patients with decompensation often present unpredictably and this makes any 
study of a non-invasive diagnostic test somewhat difficult. In contrast, any assessment of 
hepatic fibrosis reflects a “snapshot” of disease in time and is suited to ad hoc sample 
collection, while surveillance of cirrhotic patients at regular intervals for the appearance of 
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a space-occupying lesion makes development of a diagnostic biomarker in cancer 
somewhat easier from a technical perspective. In establishing a cohort of patients 
representing the spectrum of disease in cirrhosis, and the banking of matched serum 
samples, this work definitely creates a valuable resource for future studies. By its very 
nature as a dynamic process, the study of patient cohorts whose disease changes with 
time provides an opportunity to re-evaluate larger data sets prospectively and potentially 
identify miRNA signatures of progressive disease and/or individual miRNA profiles 
associated with different disease trajectories. An additional advantage of studying miRNAs 
as biomarkers of disease is that these miRNA are presumably active participants in the 
pathophysiology of cirrhosis and its complications. It is beyond the scope of this work but 
the very identification of candidates is important as these, if validated, could be further 
explored to tell us how complications occur (i.e. the gene targets and the proteins 
generated).This is in contrast to other non-invasive biomarkers, which are usually either 
end-products of the disease state (i.e. fibrosis markers, AFP, thrombocytopenia), or true 
“bystanders” and cannot provide additional information about disease pathogenesis. The 
discovery of miRNA biomarkers could potentially be exploited with the development of new 
therapeutics that work on the miRNA targets or give us a clearer understanding of the 
pathways involved that could, in turn, generate new findings that lead to better drug 
development. 
 
In the current study of cirrhosis decompensation, the same four potentially novel, 
previously undescribed miRNAs were identified when assessing cirrhosis versus early 
HCC in Chapter 5. These were also abundantly expressed in cirrhosis when compared to 
varices (grouped with variceal bleeds). Among those 4 miRNAs, only novel miRNA-AW4 
had a significantly increased expression in varices, when compared with cirrhosis, 
suggesting this miRNA may be an interesting miRNA candidate for the diagnosis of 
varices. This study encountered similar difficulties as in the HCC analysis with overall low 
sequencing performance. MiRNA analysis was therefore performed in a smaller subset of 
samples, which means that any newly-identified miRNAs would need to be validated using 
qRT-PCR before any further conclusions can be drawn. This step would be followed by 
databank deposition and replication of the data in an independent study cohort.  
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In conclusion, this study has identified several miRNAs whose expression profile is 
associated with cirrhosis-related complications, with miRNA-10a-5p and miRNA-10b-5p 
showing the most significant differential expression followed by miRNA-22-3p, miRNA-
27b-3p and miRNA-101-3p. While the current study only provides preliminary data of such 
associations, these miRNAs represent interesting targets for further investigation as non-
invasive biomarkers of disease severity and trajectory in future studies. The development 
of miRNA panels associated with varices, ascites and variceal bleeding was also 
undertaken and these panels were tested for diagnostic accuracy, with generally good 
ROC curve performance. While these findings are novel and require further validation 
studies, this work highlights the clinical potential of the miRNA panels identified. In 
particular, the combination of a miRNA panel and thrombocytopenia (platelet count < 150 
(x109/L)2) shows promising diagnostic potential for non-invasively distinguishing patients 
with and without varices. Future studies validating these promising results are planned and 
it is hoped that further work will build upon these findings to realise the clinical potential of 
miRNA assessment in the management of patients with cirrhosis and its complications.  
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CHAPTER 7                                                                 
General discussion….….. 
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Globally, chronic liver disease of multiple aetiologies continues to place an enormous 
burden on the healthcare system and is associated with unacceptable morbidity and 
mortality. The diagnosis of chronic liver disease is important as early identification can 
enable earlier intervention prior to the onset of cirrhosis (i.e. when fibrosis regression is still 
possible). Perhaps as important is an accurate diagnosis of cirrhosis, as cirrhotic patients 
represent the population at risk of cirrhosis-related complications (e.g. variceal bleeding, 
ascites, and HCC). Unfortunately the development of any of these complications is usually 
associated with a very poor short- to medium-term prognosis. Cirrhosis-related 
complications are also associated with a high level of patient morbidity and are a 
significant drain on healthcare resources.  
 
The early identification of cirrhosis-related complications, or ideally the identification of 
those at imminent risk of such complications, is of critical importance to effective patient 
management via early intervention. It is an unfortunate fact in medicine that most 
complications are only diagnosed after they appear, and therefore after the onset of 
morbidity and potentially irreversible impact on disease trajectory. Identification of varices, 
for example, relies on endoscopy (to directly diagnose them) or HVPG measurement (to 
indirectly diagnose clinically significant PHT), both of which are invasive procedures with 
limited accessibility. The release of the Baveno VI criteria to identify patients at extremely 
low risk of significant gastro-oesophageal varices represents a successful application of a 
non-invasive technology (e.g. LSM) to individualised care and preventative medicine. It is, 
however, limited by the need for technology and expertise to perform the necessary 
assessment, as well as by the fact that it merely identifies patients at low risk (who would 
not have come to significant harm) rather than those at high risk of clinically significant 
varices (whose level of care has not been directly improved). Nevertheless, the Baveno VI 
consensus statement represents a step forward in the use of non-invasive tools in CLD. 
 
In cirrhosis, some complications do not require the development of new technologies or 
biomarkers to detect them. With ascites, for example, the gold standard test is routinely 
performed on a 6-monthly basis as part of accepted surveillance for HCC. It could be 
argued that no other developed biomarker or imaging tool will be as effective in the 
detection of ascites. Furthermore, mild-to-moderate ascites can be diagnosed on physical 
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examination – meaning no further testing is needed – and even modest weight gain, which 
can be detected by the patient or a carer prior to any medical assessment, is sometimes 
sufficient to suggest the presence of ascites and be satisfactorily treated prior to the onset 
of any significant morbidity. Nevertheless, for a number of reasons that will be outlined 
below, it is reasonable to pursue the development of non-invasive methods to identify 
patients with, or at risk of, cirrhosis-related complications.    
 
One of the most worrisome complications of cirrhosis remains the development of HCC, 
which is a cancer with an increasing incidence and mortality rate in many countries 
(including Australia). In the setting of cirrhosis, most HCC in known patients occurs via the 
use of 6-monthly ultrasound as routine surveillance. If a lesion is identified, follow-up 
dynamic imaging is generally required to make a diagnosis before intervention can be 
undertaken. This confirmatory imaging, however, is not always conclusive which often 
leads to repeat imaging (typically after 3-6 months) until interval growth and clearer 
characteristics can confirm the lesion to be malignant. This approach has 2 major 
drawbacks: first, imaging or recall may be suboptimal leading to undesirable delays in 
making a diagnosis; and, second, delaying possible intervention in the event of a proven 
malignancy can be extremely distressing for the patient. Ideally, in combination with 
routine imaging, a complementary test would be undertaken to significantly improve the 
sensitivity, specificity and effectiveness of surveillance investigations. Unfortunately, the 
only currently-accepted tumour marker, AFP, performs sub-optimally and is especially 
poor in the diagnosis of early disease. This is especially problematic when it is appreciated 
that curative treatment in HCC is only available for “early stage” disease, with 
recommended interventions in more advanced disease being effectively palliative. Ideally, 
the necessary diagnostic tools should exist to reliably diagnose pre-malignant lesions, 
such as high-grade-dysplastic nodules, or early/small HCC, as delayed diagnosis of early 
HCCs can lead to delayed treatment and reduce survival. 
 
MiRNAs are small non-coding RNAs that regulate post-transcriptional events. They can 
also be involved in the development and progression of disease due to their downstream 
effects on cellular processes and protein-coding genes. A better understanding of miRNAs 
and their roles in diseases could afford a better understanding of the factors affecting 
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progression of the disease itself. Disease-specific miRNA expression profiles have been 
reported, especially in cancer, and miRNAs are increasingly being investigated for their 
therapeutic potential. Additionally, miRNAs are released into the circulation and are 
directly measurable in body fluids. It is not surprising, therefore, that there has been an 
enormous surge in scientific interest in miRNAs and a concerted effort to investigate the 
potential for circulating miRNAs to be employed as non-invasive biomarkers in CLD, and in 
cirrhosis and HCC in particular. 
 
Based upon the literature to date and to further explore this potential, it was hypothesised 
that i) circulating miRNAs exhibit differential expression across the spectrum of CLD, ii) 
miRNA expression profiles are associated with different disease stages and could be 
quantified in peripheral blood as a mean of diagnosis, iii) a combination of miRNA 
candidates could outperform, or be used to improve the performance of, currently 
accepted non-invasive biomarkers to improve diagnostic performance and iv) that miRNAs 
differentially expressed during the development of HCC are involved in the regulation of 
hepatocyte gene expression that could play key roles in hepatic carcinogenesis. To 
address these hypotheses, a series of experiments was undertaken using blood samples 
from patients with differing severities of CLD (including compensated cirrhosis, 
decompensated cirrhosis of different types, and cirrhosis complicated by HCC). On the 
basis of the results of those experiments, a number of in vitro experiments were also 
undertaken to investigate the functional impact of differential expression of specific miRNA 
candidates. While a number of significant findings were made – and have been discussed 
in detail in the preceding chapters – a number of obstacles were also encountered. It is 
therefore the purpose of this discussion to not only look forward to where the positive 
findings take this research but also to examine with circumspection what lessons have 
been learnt from negative results, with a view to providing a firm foundation upon which 
other investigators can build in the future.  
 
Although miRNAs can be expressed specifically in one cell type, they are more commonly 
expressed across multiple cell types with altering expression levels.205 MiRNAs also have 
a strong cellular context with the same miRNAs (e.g. miRNA 125b) functioning as both 
tumour suppressor and/or oncogene. In such cases, the miRNA functional role is 
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determined by the cellular environment.206 As this variation in miRNA function has been 
described in miRNAs detected at the tissue level, it is unsurprising that it has also been 
described in circulating miRNAs. Furthermore, circulating miRNAs derived from blood 
samples embody a very complex read-out. As most miRNAs are ubiquitously expressed 
across different cell types, the origin of individual miRNAs in serum cannot be easily 
determined. It is plausible that the use of miRNA panels (i.e. combinations of miRNAs that 
are each independently differentially-expressed in association with a particular disease 
phenotype) could be more specific to a certain disease but this remains speculative.  
 
This thesis demonstrated that the expression of circulating miRNA-151a-5p is reduced in 
HCV patients with cirrhosis and HCC compared with cirrhosis alone. Upon review of the 
literature, this result is at odds with previous reports in HCC, where increased levels of 
miRNA-151a-5p were observed in the tissue of patients with HCC.122, 330 Although counter-
intuitive, this result is in fact somewhat reassuring as this observation of inversely-related 
expression of miRNAs in tissue versus serum is very common across many studies 
quantifying circulating miRNAs in the setting of malignancy. It does, however, highlight the 
biological challenges involved with research in cell-free miRNAs. To date, no clear 
rationale has been advanced as to why the levels of a circulating miRNA, thought to be 
specific to a particular disease, are increased while the purported source of miRNA (i.e. 
the tissue of interest) exhibits decreased levels of expression. One explanation may be 
that circulating miRNA expression profiles are not determined by the disease itself (i.e. 
activity at the tissue level) but their levels are secondarily affected by the disease (or 
perhaps tissue-based miRNA expression) or are just coincidentally differentially-
expressed. The fact that this is a common finding across multiple organs makes the latter 
unlikely. The former explanation could be related to how miRNAs are released into 
circulation. MiRNAs can be released either through active secretion in EVs or in a non-
selective manner through apoptosis. If a specific miRNA is released via apoptosis, then it 
could be expected that circulating miRNA expression would generally increase with 
disease progression and increased apoptosis. If, on the other hand, the source of 
circulating miRNAs are actively released EVs, then increased expression in that context 
could represent a means of communication between diseased cells and other cells 
(including cells of the immune response). In fact, one study has reported an active transfer 
of miRNAs from macrophages into HCC cells, with miRNAs decreasing proliferation of the 
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targeted HCC cell. The findings suggest that miRNAs from immune cells are delivered 
through intercellular transfer to HCC cells as a defence mechanism.468 This argument 
lends support to the hypothesis that increased peripheral levels of miRNAs are part of the 
specific response to diseased cells. While this is an attractive hypothesis, it clearly 
requires dedicated studies of the biogenesis and regulation of miRNAs that are well 
beyond the scope of this thesis. 
 
As mentioned previously, one of the major issues affecting studies of peripheral miRNA 
levels in association with disease phenotypes is that the precise source of those circulating 
miRNAs cannot be determined. This issue also affects other blood-based biomarkers of 
disease and is a common criticism of fibrosis biomarker panels when used in patients with 
CLD in addition to a number of other chronic inflammatory or fibrotic conditions. In addition 
to biological challenges and advantages of miRNA expression studies, such as cellular 
context or disease specific miRNA expression profiles, there are important methodological 
challenges that need to be addressed. 
 
In HCC, miRNAs have been the subject of great interest and many circulating miRNA 
candidates have been proposed. The quality of these studies varies greatly and many 
promising candidates fail to be reproduced or validated. Such discrepancies were 
observed in the current study as well. For example, this study’s finding of decreased 
circulating miRNA-151a-p in cirrhotic patients with HCC (compared with cirrhosis alone) is 
in contrast to another study in plasma which reported increased expression of miRNA-
151a-5p in viral hepatitis-related HCC.329 Such inter-study variation has been previously 
reported by others as well,339, 340 and has been a major limitation to the development of 
miRNAs as diagnostic biomarkers.  
 
Over the years, comparing findings of miRNA studies using serum and plasma samples 
has been problematic. Here, there are two confounding issues that need to be 
approached: pre-analytical variation and data normalisation. Pre-analytical variation starts 
with the sampling of a serum or plasma specimen. It is crucial that cellular components are 
removed from these samples as erythrocytes, platelets or leucocytes can release their 
miRNA contents into the fluid if not handled and processed adequately. This has been 
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shown to alter miRNA expression profiles, such as increased miRNA-16 expression levels 
in haemolysed samples.229, 379 An additional sampling error that can alter miRNA contents 
is caused by sample storage. Although miRNAs have been shown to be very robust and 
can resist degradation temporarily, samples kept at room temperature for more than 24 
hours show decreased miRNA expression levels due to degradation. This problem can be 
avoided with immediate sample processing and freezing as the miRNA content is stable 
when frozen.229 Here small sample aliquots are recommended, especially for biobanks, as 
repeated freeze-thaw cycles also leads to miRNA degradation.469 In this thesis, a stringent 
protocol for sample processing was established, consisting of immediate centrifugation, 
haemolysis assessment, sample aliquoting and storage within 12 hours of sample 
collection. For future studies, it would be prudent to ensure that all correct laboratory 
processes are similarly in place to avoid such issues. 
 
It has been shown that circulating miRNAs are expressed with very low abundance, 
especially when compared to tissue expression,229 which introduces a further layer of 
technical complexity. Utilised miRNA isolation methods should be carefully selected as the 
mode of isolation can influence subsequent results. Originally, miRNA studies started with 
guanidinium thiocyanate based isolations, also known as TRIzol®, which usually result in 
low RNA purity. Also, these isolations contain phenol, which can be carried over into the 
RNA sample causing contamination. Phenol-free isolation methods provide higher RNA 
purity and overcome these limitations. They do so, however, at the expense of lower RNA 
yields.470 Quantification of circulating miRNAs is also challenging as low concentrations fall 
below the limit of detection of most spectrophotometers, especially for phenol-free isolation 
methods. Although these technical challenges could temper one’s enthusiasm for further 
exploration of the potential of circulating miRNAs, these are only the preliminary steps in 
the development of miRNA as clinically useful biomarkers and are not considered 
insurmountable. 
 
One aspect of this thesis that proved a major obstacle, however, was the issue of how to 
manage the abundant data that were obtained. Data normalisation is critical to minimise 
data variation that obscures or overestimates meaningful biological changes. This 
becomes even more important in samples with low abundance, such as with circulating 
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miRNAs in body fluids.229 Quantitative gene expression analysis commonly requires 
ubiquitously expressed genes that function as endogenous references and identification of 
an appropriate reference RNA is critical to accurate analysis of the data. Strategies to 
identify reference miRNAs in previous studies have been reviewed and validated,471 
however the majority of these studies focussed on tissue samples. The absence of a 
suitable endogenous reference poses a singular challenge to studies of circulating miRNA 
as no universal endogenous housekeeper has yet been identified. It has been proposed 
that the expression of some miRNAs, such as miRNA-16, increases with haemolysis and 
therefore are unsuitable for use as a reference miRNA.229 While synthetic spiked-in 
miRNAs have been investigated as normalising references, this approach really only 
accounts for technical variation rather than biological variation within the individual 
samples and therefore is not suitable for normalisation.229 The currently-accepted 
approach appears to be identification and investigation of the most ubiquitously and stably 
expressed miRNA within a sample set using bioinformatics tools, such as NormFinder256, 
although these references need to be defined specifically to the investigated dataset. For 
the purposes of this thesis, large datasets were used to screen for miRNA candidates, 
using either microarray or NGS, to facilitate use of a global normalisation approach (i.e. 
quantile normalisation or normalisation based on library size and composition). With 
careful application, this also provided a suitable dataset for the identification of disease 
specific reference miRNAs, identified through NormFinder and distance metrics.  
 
Analysing larger datasets, such as microarray or next-generation sequencing datasets, 
provides an advantage whereby alternative normalisation methods can be used, even in 
the absence of suitable reference miRNA. These normalisation strategies include quantile 
normalisation, median absolute deviation scaling normalisation, variance stabilizing 
normalization, mean-centring restricted normalisation, and concordance correlation 
restricted normalisation or global mean expression normalisation. The normalisation 
performance of these methods has been assessed elsewhere,279, 472-476 although 
assessing normalisation efficiency in the investigated dataset before proceeding with 
analysis is highly recommended. Using a global normalisation approach also provides the 
opportunity to screen for differential expressed miRNAs and identify stable ubiquitously 
expressed reference miRNA specific to the sample set investigated.  
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When investigating miRNAs as diagnostic tools, all of these biological and technical issues 
need to be considered. The biological difficulties one encounters with circulating miRNA 
studies will largely depend on whether the miRNA expression profile has a high specificity 
for the disease phenotype and is highly reproducible. In such cases, the origin and 
function of these miRNAs is of interest but arguably not needed for the miRNA (or panel of 
miRNAs) to have acceptable diagnostic accuracy. The technical challenges confronting 
circulating miRNA studies, however, could limit the likelihood that miRNAs will realise their 
potential as non-invasive biomarkers. It is important to note that, even if samples are 
processed promptly, haemolysis can still occur in clinical samples and, during the 
biomarker discovery phase, haemolysis can cause problems. An element of vigilance is 
required to ensure that differentially-expressed miRNAs that are identified (and the 
endogenous reference miRNA selected) are actually specific to the disease and not 
altered due to haemolysis. If the reference miRNA is independent of haemolysis and the 
identified miRNA is disease-specific then haemolysis should not present any barriers to 
the clinical application of a specific identified miRNAs being developed as a biomarker. 
Normalisation of circulating miRNA, however, remains a substantial issue and is arguably 
the most limiting factor for miRNAs as biomarkers. This reflects a constant effort to 
develop new and improved methods of normalisation. Regrettably, investigators typically 
return to the principles of a disease specific endogenous miRNA or variations of 
exogenous miRNA normalisation approaches. One study, for example, suggested the use 
of the geometric mean of three exogenous Caenorhabditis elegans (spike-in) miRNAs,477 
which unfortunately does not address the issue that an exogenous control does not 
account for endogenous variations.  
 
Although a range of technical limitations need to be addressed, overall, circulating miRNAs 
hold great promise as potential non-invasive biomarkers. Until these issues are settled, it 
is proposed that standardised procedures for biomarker discovery studies, especially 
circulating miRNAs, be developed. Furthermore, as a relatively new area of scientific 
research, documentation of scientific methods used in miRNA studies is generally sub-
optimal and substantially more methodological detail is needed to increase reproducibility 
of miRNA results. In the future, alternative platforms could be used to overcome difficulties 
with data normalisation.  
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It is generally accepted that qRT-PCR is the validation gold standard – hence its use in the 
current thesis – as it provides relative quantification of miRNAs. Importantly, qRT-PCR is 
already used in scientific and clinical laboratories and, as such, the technique would be 
easily adaptable for miRNA diagnostics in clinical medicine. The technology is scalable as 
multiplex reactions are commonly used in clinical medicine, arguably making the use of 
miRNAs cost-effective (compared with other diagnostic imaging alternatives and 
interventions). The next generation of diagnostic tools, such as digital PCR, are currently 
being established in diagnostic laboratories. Digital PCR has already been successfully 
applied to miRNA studies and provides absolute quantification, potentially overcoming the 
need for an endogenous reference.478 Alternatively, studies using novel platforms, such as 
NanoString (NanoString Technologies, Seattle, Washington, United States), can now 
measure miRNAs and mRNAs on a molecular level within one sample. One study using 
this technique also showed that it can detect miRNAs in serum samples,479 opening the 
possibilities of using other RNAs within the same sample as a reference. 
 
MiRNAs regulate post-transcriptional events and cellular processes. Altered miRNA 
expression has therefore been implicated in the development of various chronic and 
malignant diseases, including HCC. The functional role of miRNA has also understandably 
led to increased investigations into the therapeutic potential of miRNAs. The identification 
of differential miRNA expression is usually followed by downstream investigation, exploring 
the functional impact of these miRNAs, and identifying miRNA-mRNA interactions relies 
strongly on bioinformatics and functional assays.480 To apply a more global approach and 
to identify the entire spectrum of miRNA-mRNA interactions, the current thesis used a pull-
down assay and next generation sequencing to identify miRNA targets of miRNA-151a-5p 
and miRNA-486-5p, both miRNAs that were identified as differentially-expressed in serum 
samples of HCV patients with HCC. Identifying miRNA targets alone, however, can 
provide insufficient information about ensuing interactions and the subsequent impact on 
physiological and pathological processes. It does, however, provide a foundation for 
further, more in-depth investigations. Unfortunately, with increased understanding of how 
miRNAs alter post-transcriptional events it becomes increasingly obvious that downstream 
interactions are much more complex than previously imagined.  
 
208 
 
By way of example, the extent by which translation can be repressed varies strongly 
between miRNA targets and can be affected by processes such as mutations altering the 
miRNA binding site accessibility.189 Investigating potential mRNA targets using qRT-PCR 
(used in this study), western blot or luciferase reporter assay, provides a preliminary 
understanding of the functional role of miRNAs, however, to assess the complexity behind 
miRNA function in vivo studies are really needed. In fact, miRNAs do have great potential 
to function as systemic therapeutics, and there are studies providing detailed 
characterisation of miRNAs and their targets. For example, treatment with miRNA-7 can 
regulate the growth arrest specific 6 (GAS6) and tyrosine kinase TYRO3 axis and can 
overcome Sorafenib resistance of HCC in vitro and in vivo.228 Importantly, in vivo delivery 
of miRNAs using lipid nanoparticles has been reported.481 This example shows that 
miRNA do have potential as therapeutic and, more importantly, delivery in vivo is possible 
suggesting a potential translation into the clinic. Clearly more studies are needed before 
miRNA therapeutics reach clinical trials, yet there is great potential as shown by the latest 
miRNA-7 studies. The miRNAs identified in the current study are also promising, 
especially miRNA-486-5p and its potential effects on the ERK5 pathway, but the 
complexity illustrated above should encourage us to proceed diligently and respectfully. 
The data presented in the current thesis are interesting and the identified candidates do 
represent the next logical focus for investigations but there is clearly a long way to go on 
this journey. 
 
Notwithstanding these words of caution, the very characteristics of miRNAs make them 
attractive candidates with a strong potential as non-invasive biomarkers. Indeed, this 
thesis identified several miRNAs that are differentially expressed across the spectrum of 
CLD, cirrhosis and HCC. As a pilot study of miRNA expression profiling, there is much to 
be optimistic about and some promising findings upon which to build. A strength of the 
study was the ability for individually identified miRNAs, as well as combinations as miRNA 
panels, to distinguish patients with more advanced disease and complications of cirrhosis. 
The miRNA panel for HCC (miRNA-122-5p + miRNA-142-3p + miRNA-486-5p) was 
excellent (AUC=0.94) and the miRNA panel for ascites (miRNA-10a-5p + miRNA-146a-5p) 
performed very well (AUCs=0.83) in this small cohort study. This was followed by the 
miRNA panels for cirrhosis (miRNA-122-5p + miRNA-409-3p), varices (miRNA-10b-5p + 
miRNA-101-3p), variceal bleed (miRNA-10a-5p) and the decompensated cirrhosis miRNA 
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panel (miRNA-10a-5p + miRNA-146a-5p + miRNA-423-3p) with AUCs ranging between 
0.78 - 0.80. When combining these miRNA panels with other biomarkers currently 
available in clinical use, (e.g. in combination with AFP, FIB-4, MELD scores or platelets 
count) some improvement in diagnostic performance was observed but it was not 
substantial. Nevertheless, these findings and the work invested in obtaining these results 
should provide a good platform from which to advance. One interesting finding was the 
fact that the MELD score outperformed the miRNA panel across the spectrum of cirrhosis 
and decompensation and its performance was not enhanced by combining it with the 
miRNA panels. The MELD Score is clearly a well-known measure of disease severity but 
is not currently formally used as a biomarker to predict (or exclude) the onset of specific 
complications. Whether the MELD Score performs as well in a larger external cohort 
remains to be seen. 
 
The miRNA identified with potential to diagnose early HCCs (miRNA-451a) did not perform 
satisfactorily and currently has limited clinical potential. This was the sole miRNA identified 
as other selected candidates lacked statistical significance. The current study cohort, 
however, was unique as it included only early HCC and even patients with a suspicious 
lesion but no formal diagnosis. This is clearly a patient group of great clinical interest as a 
reliable, specific biomarker would encourage earlier intervention. In terms of the study 
design, however, there were some limitations with fewer patients with indeterminate 
lesions ultimately being diagnosed with HCC (which accords with the natural history of 
lesions detected on surveillance imaging). Furthermore, all of the cancers detected were 
early HCC. Based upon earlier discussions of a potential relationship between miRNA 
expression levels in established malignancy and the peripheral circulation, it is difficult to 
comprehend how already low levels of circulating miRNA should be significantly altered in 
very early HCC. It could be argued that results were also limited by restricting analysis to 
only 5 miRNAs for validation and selecting more target miRNAs for validation might deliver 
more promising results. 
 
Finally, some technical aspects of the study itself merit attention. To truly assess the 
diagnostic potential of the miRNA panel, validation in a prospective study cohort is 
needed. In addition, validation in an extended and independent study cohort would be 
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beneficial to assess the robustness of the miRNA panel. To address this issue, internal k-
fold cross-validation was used to evaluate miRNA panels, which is a sound statistical 
approach to identify outliers and assess robustness, and while this approach 
demonstrated the validity of the miRNA panels, it is ultimately inferior to use of an actual 
validation cohort. Additionally, to validate the diagnostic potential, larger numbers are 
needed to improve confidence in the sample size but also to ensure that truly significantly 
differentially-expressed miRNAs are not excluded. Other issues that need to be addressed 
in future validation experiments include clinical aspects such as the lack of biopsy tissue to 
confirm fibrosis staging and the inconsistent use of FibroScan (which could have yielded 
additional information to improve the accuracy of any non-invasive biomarker). 
Additionally, all HCC patients would ideally have a histological specimen available, (i.e. 
following resection or biopsy) to assure that these patients have been allocated correctly, 
although this was not the practice of the clinicians involved. Furthermore, long-term follow-
up (> 2 years) of “benign” lesions would be undertaken to ensure that these were not 
indolent tumours. The lack of tissue specimens also means that expression levels of 
selected serum miRNAs could not be compared with tissue expression levels, which 
needs to be addressed in future studies. Finally, this study had access to available patient 
data regarding comorbidities and medication use but the quality of the data, given the 
retrospective nature of the cohort allocations, was inconsistent and some important patient 
factors may have been missing. Obviously, a well-characterised, prospectively-enrolled 
patient cohort would provide cleaner data to more confidently assess the diagnostic 
potential of the miRNAs identified. 
 
Overall, it is fair to say that the miRNA panels identified in this study showed promising 
(albeit preliminary) results and do encourage further exploration of their diagnostic 
potential as biomarkers in cirrhosis and HCC. However, a word of caution here is that all 
patients included in this thesis were retrospectively selected and characterised by known 
features of their disease. As such, the purpose of this thesis was to determine miRNA 
expression profiles in association with known fibrosis stages or complications. It is 
therefore too early to be considering clinical application of individual miRNAs or panels of 
miRNAs as predictive of complications or diagnostic biomarkers. Indeed, in many ways, 
the lessons learnt in exploring the roles of miRNAs mirrors the successes and failures of 
molecular profiling in HCC – with much promise but many pitfalls that have stifled clinical 
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application to date. Nevertheless, with what has been learnt throughout this thesis together 
with emerging literature in this field, it seems reasonable to be confident that miRNAs will 
become a useful diagnostic and prognostic tool in the future. 
 
Recent modalities or tests are also aimed at predicting patient mortality, for example by 
using an methacetin breath test,482 or by modifying well-established tests (e.g. Na-MELD 
Score).483 New approaches for predicting deterioration in cirrhosis patients have also been 
proposed, such as a genomic test using a 186 gene signature combined with bilirubin and 
platelet count,484 however these have not been established for clinical use. This highlights, 
however, the increased interest in identifying new and better diagnostics and in addressing 
the need to identify patients at risk of disease progression. As previously discussed, the 
Baveno VI criteria represents the most recent implementation of non-invasive tests to 
identify varices. Other studies follow the same principle, assessing the potential of LSM to 
identify disease progression. For example, one study is investigating the performance of 
shear wave elastography to identify HVPG with a non-invasive method.485 It would be 
interesting to assess a combination of Baveno VI criteria and miRNA panels to continue to 
improve their diagnostic potential and identify patients with clinically-significant varices.  
 
In conclusion, this thesis aimed to identify circulating miRNA expression signatures across 
the stages of CLD, cirrhosis and HCC, by combining selected miRNAs into diagnostic 
panels and to assess their diagnostic performance alone or in combination with currently 
used clinical biomarkers (AFP, MELD, platelet count). This is driven by the need for better 
diagnostic tests to identify patients at risk of cirrhosis-related complications, including 
HCC, with the expectation that earlier diagnosis could lead to earlier treatment and 
reduced patient morbidity and mortality. This thesis has identified several potential 
diagnostic miRNA panels alone or in combination with platelet count (varices and ascites 
miRNA panel only) with promising diagnostic performances. Although this study could only 
establish purported associations, it is reasonable to suggest that this work represents a 
foundation for future studies. In terms of future studies, validation of assembled miRNA 
panels in an external validation cohort is indicated (and ideally in a prospective study 
cohort). Future studies would need to be carefully planned, based on the technical issues 
encountered in this and other studies, to ensure that the highest quality data are obtained. 
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Formal LSM in all patients could also be undertaken as a complementary non-invasive tool 
to test whether combinations of different approaches have advantages. Finally, luciferase 
assays would need to be performed to investigate the putative targets of validated 
differentially-expressed miRNAs. 
 
This thesis identified potential diagnostic biomarkers for stratifying cirrhosis and HCC 
which, in the future, can also be investigated for their downstream function – increasing 
the knowledge of molecular mechanisms behind disease progression in cirrhosis. 
Secondly, this thesis aimed to investigate potential downstream targets of HCC associated 
miRNAs identified in the first part of the study, to identify involvement of miRNAs in HCC 
pathogenesis. This is in the setting of the functional involvement of miRNA in disease 
pathogenesis and their potential application as therapeutics. This thesis identified 
hundreds of putative miRNA-mRNA interactions of the selected miRNAs-151a-5p and 
miRNA-486-5p and identified, using a bioinformatics approach, key carcinogenic pathways 
that could potentially are regulated by these miRNAs. A pilot functional study showed 
potential involvement of miRNA-486-5p in the ERK5 pathway contributing to HCC 
pathogenesis. Although, there are several limitations in this study, such as transient 
transfection methods utilised and limited functional studies performed, the miRNAs 
investigated have the potential to be functionally involved in HCC pathogenesis. Future 
functional studies using stable transfection and in vivo experiments could further explore 
the roles of miRNA-151a-5p and miRNA-486-5p in HCC.  
 
Research into the roles of miRNAs as biomarkers in CLD is at a preliminary stage, Overall 
this thesis sheds light on differential miRNA expression across the entire course of CLD, 
from the onset of cirrhosis to HCC development, provides potential miRNA candidates that 
can be investigated further for their diagnostic and prognostic potential, and creates a solid 
foundation for functional studies of miRNA-151a-5p and miRNA-486-5p in HCC 
pathogenesis. 
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